Phase II study of pembrolizumab in combination with binimetinib and 
bevacizumab in patients with refractory colorectal cancer  
 
Principal Investigator:  Christopher H. Lieu, MD 
 
[STUDY_ID_REMOVED]  
 
December 30, 2021 
   
 
Page 1 of 106   Phase  II study  of pembrolizumab  in combination  
with binimetinib  and bevacizumab  in patients with 
refractory colorectal cancer  
 
 
COMIRB  / Protocol  Number:  17-0466  
 
Principal Investigator:   
Christopher  H. Lieu,  MD 
 
Coordinating  Center:   
University  of Colorado  
Medical  Monitor:  University  of Colorado  
IND Sponsor:  Christopher  H. Lieu,  MD 
IND Number:  138244  
Funded  by: Merck  & Co, Inc., Pfizer , Inc. 
Version  Date:  December 30 , 202 1 
PROTOCOL  # 17-0466  
PI: Christopher  H. Lieu,  MD 
Version  Date:  12.30 .2021  
 
 
 
 
 
 
    
Page 2 of 106   
 
 
This is an investigator -initiated  study.  The Principal  Investigator  (PI), Christopher  H. Lieu,  
MD, is conducting  the study  and acting  as the sponsor.  As the sponsor -investigator,  both the 
legal/ethical  obligations  of a PI and those  of a sponsor  will be followed.  
 
The trial will be carried  out in accordance  with Good  Clinical  Practice  (GCP)  as required  by 
applicable  United  States  (US)  laws and applications,  including  but not limited  to United  States  
(US)  Code  of Federal  Regulations  (CFR)  applicable  to clinical  studies  (45 CFR  Part 46, 21 CFR 
Part 50, 21 CFR Part 56, 21 CFR  Part 312, and/or 21 CFR  Part 812). 
 
The PI will assure that  no changes  to the protocol  will take place without  documented  approval  
from  the Institutional  Review  Board  (IRB).  All personnel  involved  in the conduct  of this study  
have completed  Human  Subjects  Protection  Training.  
 
I agree  to ensure  that all staff members  involved  in the conduct  of this study  are informed  about  
their obligations  in meeting  the above commitments.  
 
 
 
Sponsor -Lead Principal Investigator:  Christopher  H. Lieu, MD   
 
 
 
Signed:    Date:      
STATEMENT  OF COMPLIANCE  
PROTOCOL  # 17-0466  
PI: Christopher  H. Lieu,  MD 
Version  Date:  12.30 .2021  
 
 
 
 
 
 
    
Page 3 of 106   
 
 
 
ACRONYM  DESCRIPTION  
IIT Investigator -Initiated  Trial  
ALP Alkaline  phosphatase  
BID Bis in die or Twice  a day 
CEA  Carcinoembryonic  antigen  
Cl Clearance  
Cmax  Maximum  concentration  
Cmin  Minimum  concentration  
CR Complete  response  
CRC  Colorectal  cancer  
cSCC  cutaneous squamous cell carcinoma  
CT Computed  tomography  
Ctrough  Target  trough  concentration  
Cyp Cytochrome  P 450 
DLT  Dose  limiting  toxicity  
DOR  Duration  of response  
EC Ethics  committee  
ECHO  Echocardiogram  
ECOG  Eastern  Cooperative  Oncology  Group 
eCRF  electronic  Case Report  Form 
EDC  Electronic  data capture  
ERK  Extracellular  signal  regulated  kinase  
FFPE  Formalin -fixed,  paraffin -embedded  
FOLFIRI  Leucovorin  plus Fluorouracil  plus irinotecan  
GEJ Gastroesophageal junction  
HBcAb  Hepatitis  B core antibody  
HbsAg  Hepatitis  B surface  antigen  
HBV  Hepatitis  B virus  
HCC  Hepatocelluclar C arcinoma  
HCV  Hepatitis  C virus  
HIPAA  Health  insurance  portability  and Accountability  Act 
HNSCC  Head and Neck Squamous Cell Carcinoma  
HNSTD  Highest  non-severely  Toxic  Dose  
HR Hazard  Ratio  
IARC  International  Agency  for Research  on Cancer  
ICH International  conference  on Harmonization  
IMP Investigational  medicinal  product  
IND Investigational  new drug 
IRB Institutional  Review  Board  
Iv Intravenous  
LIST  OF ABBREVIATIONS  
PROTOCOL  # 17-0466  
PI: Christopher  H. Lieu,  MD 
Version  Date:  12.30 .2021  
 
 
 
 
 
 
    
Page 4 of 106   
ACRONYM  DESCRIPTION  
LVEF  Left ventricular  ejection  fraction  
mAb  Monoclonal  antibody  
MAPK  Mitogen -activated  protein  kinase  
mCRC  Metastatic  colorectal  cancer  
MHC  Major  histocompatibility  complex  
MRI  Magnetic  resonance  imaging  
MSI Microsatellite  
MSI-H Microsatellite instability -high 
MTD  Maximum -tolerated  dose 
MUGA  Multigated  acquisition  
NCI CTCAE  National  Cancer  Institute  Common  Terminology  Criteria  for Adverse  Events  
NGS  Next  generation  Sequencing  
NOEL  No observed  Effect  level  
NSCLC  Non-small  cell Lung  cancer  
OHRP  Office  for Human  Research  Protections  
ORR  Overall  response  rate 
OS Overall  survival  
PBPK  Physiologically -based PK  
PCR  Polymerase  chain  reaction  
PD-1 Programmed  death -1 
PD-L1 Programmed  death  ligand -1 
PFS Progression  free survival  
PMCBCL  Primary Mediastinal Large B -cell Lymphoma  
PO Per Os 
PR Partial  response  
Q2w  Every  2 weeks  
Q3w  Every  3 weeks  
QD Once  per day 
RCC  Renal Cell Carcinoma  
RECIST  Response  Evaluation  Criteria  in Solid  Tumors  
SCLC  Small Cell Lung Cancer  
SD Stable  disease  
TIL Tumor -infiltrating  lymphocyte  
TMB -H Tumor Mutation Burden -High  
TNF -α Tumor  necrosis  factor -α 
TSH  Thyroid -stimulating  hormone  
UAP  Unanticipated  Problems  
UC Urotheliel Carcinoma  
ULN  Upper  limit  of normal  
VEGF  Vascular  endothelial  growth  factor  
PROTOCOL  # 17-0466  
PI: Christopher  H. Lieu,  MD 
Version  Date:  12.30 .2021  
 
 
 
 
 
 
    
Page 5 of 106   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
- Change  in pre-and post-treatment  levels  of PD-L1 and 
phosphorylated  ERK expression  by IHC.  
- Patterns  of change  in mRNA expression  in a panel  of 
immune  related  genes  in tumor  tissues  prior  to treatment  
PROTOCOL  SUMMARY  / SYNOPSIS  
Protocol  Title:  Phase II  study  of pembrolizumab  in combination  with binimetinib  
and bevacizumab  in patients  with refractory colorectal  cancer  
Objectives:  • Primary  Objective:  
To determine  the effect  of pembrolizumab,  binimetinib,  and 
bevacizumab  on response rate using RECIST  v1.1 in patients  
with colorectal  cancer  who have progressed  on at least  two 
lines  of standard  therapy  
 
• Secondary  Objectives:  
1. To determine  the progression -free survival  (PFS)  of 
combination  therapy  with pembrolizumab,  binimetinib,  
and bevacizumab  
2. To determine  the effect  of combination  therapy  with 
pembrolizumab,  binimetinib,  and bevacizumab  on 
overall  survival  
3. To evaluate  safety  and tolerability  of combination  
therapy  
 
• Exploratory  Objectives : 
1. Evaluate  relationship  between  PD-L1 tumor  expression  
and mismatch  repair  status  and efficacy  of 
pembrolizumab,  binimetinib  and bevacizumab.  
2. To assess  change  in PD-L1 and phosphorylated  ERK 
expression  in pre-and post-treatment  tumor  tissue.  
3. To compare  the response  rate determined  according  to 
RECIST  v1.1 to that identified  by Immune  Related  
Response  Criteria  (irRC).  
Endpoint:  • Primary  Endpoint:  
Objective Response rate (ORR  per RECIST  V1.1)  
 
• Secondary  Endpoints:  
Progression  Free Survival  (PFS)  
Overall  Survival  (OS) 
Safety  and Tolerability  
 
• Tertiary/  exploratory:  
- Response rate according  to pre-treatment  PD-L1 tumor  
expression  by IHC 
 
PROTOCOL  # 17-0466  
PI: Christopher  H. Lieu,  MD 
Version  Date:  12.30 .2021  
 
 
 
 
 
 
    
Page 6 of 106   
after  binimetinib  alone,  and after binimetinib,  
pembrolizumab  and bevacizumab.  
- Compare the response  rate determined  according  to 
RECIST  v1.1 to that identified  by Immune  Related  Response  
Criteria  (irRC).  
 
Population:   
• Gender  Male  and Female  
• Age  18 years  
• Demographic  group  refractory  metastatic  colorectal  cancer  
• General  health  status  ECOG  0-1 
 
Phase:  II 
Number of 
Participating  Sites  
enrolling  subjects:   
 
1 
Description  of Study  
Agent:  Pembrolizumab  200 mg IV Q3weeks  
Binimetinib  45 mg PO BID continuous  
Bevacizumab  7.5 mg IV Q3weeks  
Study  Duration:  Approximately  12 months  
PROTOCOL  # 17-0466  
PI: Christopher  H. Lieu,  MD 
Version  Date:  12.30 .2021  
 
 
 
 
 
 
    
Page 7 of 106   
 
 
 
 
 
 
SCHEMATIC  OF STUDY  DESIGN  
PROTOCOL  # 17-0466  
PI: Christopher  H. Lieu,  MD 
Version  Date:  12.30 .2021  
 
 
 
 
 
 
    
Page 8 of 106   
TABLE OF CONTENTS  
STATEMENT  OF COMPLIANCE  ................................ ................................ ................................ ................................ .2 
LIST  OF ABBREVIATIONS  ................................ ................................ ................................ ................................ .......... 3 
PROTOCOL  SUMMARY  / SYNOPSIS  ................................ ................................ ................................ ......................... 5 
• PRIMARY  OBJECTIVE : ................................ ................................ ................................ ................................ ...........  5 
• SECONDARY  OBJECTIVES : ................................ ................................ ................................ ................................ .... 5 
• EXPLORATORY  OBJECTIVES : ................................ ................................ ................................ ................................ . 5 
• PRIMARY  ENDPOINT : ................................ ................................ ................................ ................................ ............  5 
SCHEMATIC  OF STUDY  DESIGN  ................................ ................................ ................................ ............................... 7 
1 PARTICIPATING  SITES  ................................ ................................ ................................ ................................ ..... 12 
2  INTRODUCTION:  BACKGROUND  INFORMATION  & SCIENTIFIC RATIONALE  ................................ ...............  12 
2.1 BACKGROUND INFORMATION  ................................ ................................ ................................ ................................ .......  12 
BACKGROUND ON BINIMETINIB  ................................ ................................ ................................ ..............................  15 
SUMMARY OF  NON-CLINICAL TRIALS  WITH BINIMETINIB  ................................ ................................ ................................ ...........  15 
SUMMARY OF  CLINICAL TRIALS WITH BINIMETINIB  ................................ ................................ ................................ ..................  15 
HEALTHY  SUBJECTS  ................................ ................................ ................................ ................................ ..........................  15 
ADVANCED CANCER  PATIENTS – MONOTHERAPY  ................................ ................................ ................................ ....................  16 
ADVANCED CANCER  PATIENTS – COMBINATION THERAPY  ................................ ................................ ................................ .........  16 
CLINICAL PHARMACOKINETICS  OF BINIMETINIB  ................................ ................................ ................................ ......................  16 
BACKGROUND  ON PEMBROLIZUMAB  ................................ ................................ ................................ .......................  16 
SUMMARY OF  NONCLINICAL TRIALS  ................................ ................................ ................................ ................................ ..... 17 
SUMM ARY OF  CLINICAL TRIALS ................................ ................................ ................................ ................................ ............  17 
PHARMACOKINETICS  OF PEMBROLIZUMAB  ................................ ................................ ................................ ...........................  18 
BACKGROUND  ON BEVACIZUMAB  ................................ ................................ ................................ ............................  18 
2.2 RATIONALE  ................................ ................................ ................................ ................................ ...............................  19 
2.3 POTENTIAL RISKS AND BENEFITS  ................................ ................................ ................................ ................................ ... 19 
2.3.1  IMPORTANT  IDENTIFIED/  POTENTIAL  RISKS  ................................ ................................ ......................  20 
2.3.2  KNOWN  POTENTIAL  BENEFITS ................................ ................................ ................................ ...............  22 
3 OBJECTIVES AND PURPOSE  ................................ ................................ ................................ ...........................  23 
PRIMARY  OBJECTIVE:  ................................ ................................ ................................ ................................ ................  23 
SECONDARY  OBJECTIVES:  ................................ ................................ ................................ ................................ .........  23 
EXPLORATORY  OBJECTIVES:  ................................ ................................ ................................ ................................ ...... 23 
4 STUDY  DESIGN  AND  ENDPOINTS  ................................ ................................ ................................ .................  23 
4.1 DESCRIPTION OF THE STUDY DESIGN  ................................ ................................ ................................ .............................  23 
STAGE 1: SAFETY RUN-IN ................................ ................................ ................................ ................................ ..................  24 
STAGE 2: DOSE EXPANSION  ................................ ................................ ................................ ................................ ...............  25 
4.2 STUDY ENDPOINTS  ................................ ................................ ................................ ................................ .....................  26 
4.2.1  PRIMARY  ENDPOINT  ................................ ................................ ................................ ................................ . 26 
4.2.2   SECONDARY  ENDPOINTS  ................................ ................................ ................................ ............................  26 
4.2.3   EXPLORATORY  ENDPOINTS  ................................ ................................ ................................ ......................  26 
5.1 SUBJECT INCLUSION CRITERIA  ................................ ................................ ................................ ................................ .......  27 
5.2 SUBJECT EXCLUSION CRITERIA  ................................ ................................ ................................ ................................ ...... 28 
5.3 SUBJECT WITHDRAWAL OR TERMINATION  ................................ ................................ ................................ ......................  31 
5.3.1  REASONS  FOR  WITHDRAWAL  OR TERMINATION  ................................ ................................ ................  31 
PROTOCOL  # 17-0466  
PI: Christopher  H. Lieu,  MD 
Version  Date:  12.30 .2021  
 
 
 
 
 
 
    
Page 9 of 106  5.3.2   HANDLING  OF SUBJECT  WITHDRAWALS  OR TERMINATION ................................ ................................ . 32 
5.4 PREMATURE TERMINATION OR SUSPENSION OF STUDY (STUDY STOPPING RULES) ................................ ................................ .. 32 
6 STUDY AGENTS ................................ ................................ ................................ ................................ ..............  32 
6.1 STUDY AGENT (S) AND CONTROL DESCRIPTION  ................................ ................................ ................................ ................  32 
6.1.1   PEMBROLIZUMAB  (KEYTRUDA)  ................................ ................................ ................................ ..................  33 
6.1.2   BINIMETINIB  ................................ ................................ ................................ ................................ ...............  35 
6.1.3   BEVACIZUMAB  (BEVACIZUMAB -AWWB  ALSO  ALLOWED)  ................................ ................................ ...... 36 
6.2 STUDY AGENT ACCOUNTABILITY PROCEDURES  ................................ ................................ ................................ .................  38 
7 STUDY  PROCEDURES  AND  SCHEDULE  ................................ ................................ ................................ ..........  38 
7.1 STUDY PROCEDURES /EVALUATIONS  ................................ ................................ ................................ ..............................  38 
7.2 LABORATORY PROCEDURES /EVALUATIONS  ................................ ................................ ................................ .....................  38 
7.2.1   CLINICAL  LABORATORY  EVALUATIONS  (RESEARCH  PROCEDURES)  ................................ .....................  39 
7.2.2  OTHER  ASSAYS  OR PROCEDURES  (RESEARCH)  ................................ ................................ .....................  40 
7.2.3   SPECIMEN  PREPARATION,  HANDLING,  AND  STORAGE  ................................ ................................ ........  40 
7.2.4   SPECIMEN  SHIPMENT  ................................ ................................ ................................ ...............................  41 
7.3 STUDY SCHEDULE  ................................ ................................ ................................ ................................ ......................  41 
7.3.1   SCREENING  ................................ ................................ ................................ ................................ .................  41 
7.3.2   ENROLLMENT/BASELINE  ................................ ................................ ................................ .............................  44 
7.3.3  TREATMENT  PERIOD  ................................ ................................ ................................ ................................ . 44 
7.3.4   FINAL  STUDY  VISIT/EARLY  TERMINATION  VISIT  ................................ ................................ ..................  47 
7.3.5   SURVIVAL FOLLOW -UP ................................ ................................ ................................ ...............................  47 
7.3.6   UNSCHEDULED  VISIT  ................................ ................................ ................................ ................................ . 47 
7.3.7  SCHEDULE  OF EVENTS  ................................ ................................ ................................ ................................  48 
TABLE  1. SCHEDULE OF EVENTS  ................................ ................................ ................................ ................................  48 
TABLE 2. SCHEDULE OF BIOMARKERS FOR EXPANSION COHORT  ................................ ................................ .............  50 
7.4 JUSTIFICATION FOR SENSITIVE PROCEDURES  ................................ ................................ ................................ ....................  50 
7.5 CONCOMITANT MEDICATIONS , TREATMENTS , AND PROCEDURES  ................................ ................................ ........................  50 
7.6 PROHIBITED MEDICATIONS , TREATMENTS , AND PROCEDURES  ................................ ................................ ............................  50 
7.7 PROPHYLACTIC MEDICATIONS , TREATMENTS , AND PROCEDURES  ................................ ................................ ........................  51 
7.8 RESCUE MEDICATIONS , TREATMENTS , AND PROCEDURES  ................................ ................................ ................................ .. 52 
7.9 SUBJECT ACCESS TO STUDY AGENT AT STUDY CLOSURE  ................................ ................................ ................................ ..... 52 
8 ASSESSMENT  OF SAFETY  ................................ ................................ ................................ ...............................  53 
8.1 SPECIFICATIONS OF SAFETY PARAMETERS  ................................ ................................ ................................ .......................  53 
8.1.1  DEFINITION  OF ADVERSE  EVENTS  (AE) ................................ ................................ ................................ ... 53 
8.1.2  DEFINITION  OF SERIOUS  ADVERSE  EVENTS  (SAE) ................................ ................................ .................  53 
8.1.3   DEFINITION  OF UNANTICIPATED  PROBLEMS  (UAP)  ................................ ................................ ..............  54 
8.2 CLASSIFICATIONS OF AN ADVERSE EVENT  ................................ ................................ ................................ ........................  54 
8.2.1    SEVERITY  OF EVENT  ................................ ................................ ................................ ................................ ... 54 
8.2.2   RELATIONSHIP  TO STUDY  AGENTS ................................ ................................ ................................ ..........  54 
8.2.3   EXPECTED  ADVERSE  EVENTS  ................................ ................................ ................................ ....................  55 
8.3 TIME PERIOD AND FREQUENCY FOR EVENT ASSESSMENT AND FOLLOW -UP ................................ ................................ ...........  55 
8.4 REPORTING PROCEDURES  ................................ ................................ ................................ ................................ ............  56 
8.4.1  ADVERSE  EVENT  REPORTING ................................ ................................ ................................ ...................  56 
8.4.2  SERIOUS  ADVERSE  EVENT  REPORTING  ................................ ................................ ................................ ...... 60 
8.4.3   UNANTICIPATED  PROBLEM  REPORTING  ................................ ................................ ................................  62 
8.4.4  EVENTS  OF SPECIAL  INTEREST  ................................ ................................ ................................ .................  62 
8.4.5   REPORTING  OF PREGNANCY  ................................ ................................ ................................ ...................  62 
8.5 STUDY HALTING RULES ................................ ................................ ................................ ................................ ...............  63 
9 STUDY  OVERSIGHT  AND  CLINICAL  MONITORING  ................................ ................................ .......................  64 
STUDY  OVERSIGHT  ................................ ................................ ................................ ................................ ...........................  64 
PROTOCOL  # 17-0466  
PI: Christopher  H. Lieu,  MD 
Version  Date:  12.30 .2021  
 
 
 
 
 
 
    
Page 10 of 106  QUALITY CONTROL AND  QUALITY  ASSURANCE  ................................ ................................ ................................ .......................  65 
10 STATISTICAL  CONSIDERATIONS  ................................ ................................ ................................ ....................  65 
10.1  STATISTICAL AND ANALYTICAL PLANS ................................ ................................ ................................ ...........................  65 
10.2  STATISTICAL HYPOTHESES  ................................ ................................ ................................ ................................ ..........  65 
10.3  ANALYSIS DATASETS  ................................ ................................ ................................ ................................ .................  66 
10.4  DESCRIPTION OF STATISTICAL METHODS  ................................ ................................ ................................ ......................  66 
10.4.1  General Approach  ................................ ................................ ................................ ................................ . 66 
10.4.2  Analysis of the Primary Effi cacy Endpoint(s) ................................ ................................ .........................  66 
10.4.3  Analyses of the Secondary Endpoints(s)  ................................ ................................ ...............................  67 
10.4.4  Safety Analyses  ................................ ................................ ................................ ................................ ..... 67 
10.4.5  Adherence and Retention Analyses  ................................ ................................ ................................ ...... 67 
10.4.6  Baseline Descriptive Statistics  ................................ ................................ ................................ ...............  67 
10.4.7  Planned Interim Analyses  ................................ ................................ ................................ .....................  67 
10.4.8  Additional Sub -Group Analyses ................................ ................................ ................................ .............  68 
10.4.9  Multiple Comparison/Multiplicity  ................................ ................................ ................................ .........  68 
10.4.10  Tabulation of Individual Response Da ta ................................ ................................ ...............................  68 
10.4.11  Exploratory Analyses  ................................ ................................ ................................ ............................  68 
10.5 SAMPLE SIZE ................................ ................................ ................................ ................................ .....................  68 
10.6 MEASURES TO MINIMIZE BIAS ................................ ................................ ................................ ..............................  68 
11 QUALITY  ASSURANCE  AND  QUALITY  CONTROL  ................................ ................................ .........................  68 
12 ETHICS/PROTECTION  OF HUMAN  SUBJECTS  ................................ ................................ ................................  69 
12.1 ETHICAL STANDARD  ................................ ................................ ................................ ................................ ............  69 
12.2 INSTITUTIONAL REVIEW BOARD  ................................ ................................ ................................ .............................  69 
12.3 INFORMED CONSENT PROCESS  ................................ ................................ ................................ ..............................  69 
12.3.1  Consent/As sent and Other Informational Documents Provided to Subjects  ................................ ........  70 
12.3.2  Consent Procedures and Documentation  ................................ ................................ .............................  70 
12.4  PARTICIPANT AND DATA CONFIDENTIALITY  ................................ ................................ ................................ ...................  70 
12.4.1  Research Use of Stored Human Samples, Specimen, and Data  ................................ ............................  71 
12.5 FUTURE USE OF STORED SPECIMENS  ................................ ................................ ................................ ......................  71 
13 DATA  HANDLING  AND  RECORD  KEEPING  ................................ ................................ ................................ ... 71 
13.1 DATA COLLECTION AND MANAGEMENT RESPONSIBILITIES  ................................ ................................ ..........................  71 
13.2  STUDY RECORDS RETENTION  ................................ ................................ ................................ ................................ ...... 73 
13.3 PROTOCOL DEVIATIONS  ................................ ................................ ................................ ................................ .......  73 
13.4 PUBLICATION AND DATA SHARING POLICY  ................................ ................................ ................................ ...............  74 
14 STUDY  ADMINISTRATION  ................................ ................................ ................................ ...............................  74 
15 CONFLICT  OF INTEREST  POLICY  ................................ ................................ ................................ .....................  74 
16 LITERATURE  REFERENCES  ................................ ................................ ................................ ................................  75 
17 APPENDICES  ................................ ................................ ................................ ................................ ....................  77 
APPENDIX 1 ................................ ................................ ................................ ................................ ................................ ... 77 
Table  3. Guidelines  for the Management  of Pembrolizumab - and Binimetinib -Associated  Hepatotoxicity  ............  77 
Table  4. Guidelines  for the Management  of Pembrolizumab - and Binimetinib -Associated  Hepatotoxicity  (cont.)  78 
Table  5. Guidelines  for the Management  of Pembrolizumab - and Binimetinib -Associated  Pulmonary  Events
 ................................ ................................ ................................ ................................ ................................ ...............  79 
Table  6. Guidelines  for the Management  of Pembrolizumab - and Binimetinib  -Associated  Rash  ...........................  81 
Table  7. Guidelines  for the Management  of Grade  3 or Higher  Elevations  in CPK and Rhabdomyolysis  ................  83 
Table  8. Guidelines  for the Management  of Pembrolizumab - and Binimetinib -Associated  Ocular  Toxicity  ...........  85 
Table  9. Guidelines  for the Management  of Gastrointestinal  Toxicity  ................................ ................................ ..... 88 
GASTROINTESTINAL  TOXICITY  ................................ ................................ ................................ ................................ ..............  89 
GUIDANCE  ................................ ................................ ................................ ................................ ................................ ..... 89 
PROTOCOL  # 17-0466  
PI: Christopher  H. Lieu,  MD 
Version  Date:  12.30 .2021  
 
 
 
 
 
 
    
Page 11 of 106  Table  10. Guidelines  for the Management  of Reduction  in Left Ventricular  Ejection  Fraction  ................................  93 
Table  10. Guidelines  for the Management  of Reduction  in Left Ventricular  Ejection  Fraction  (cont.)  ......................  94 
Table  11. Guidelines  for the Management  of Hypertension  ................................ ................................ .......................  95 
Table  12. Guidelines  for the Management  of Hemorrhage  ................................ ................................ ......................  96 
Table  13. Guidelines  for Management  of Venous  Thromboembolic  Events  ................................ .............................  97 
Table  14. Guidelines  for the Management  of Arterial  Thromboembolic  Events  ................................ ......................  98 
Table  15. Guidelines  for the Management  of Proteinuria  ................................ ................................ ........................  99 
Table  16. Guidelines  for the Management  of Fistula  ................................ ................................ .............................  100 
Table  17. Guidelines  for the Management  of Wound  Dehiscence  ................................ ................................ .........  100 
Table  18. Guidelines  for the Management  of Posterior  Reversible  Encephalopathy  Syndrome/Reversible  Posterior  
Leukoencephalopathy  Syndrome  ................................ ................................ ................................ ........................  101 
Table  19. Management  Guidelines  for Guillain -Barre  ................................ ................................ ...........................  101 
Table  20. Management  Guidelines  for infusion -related  reactions  ................................ ................................ ..........  103 
Table  21. Guidelines  for the Management  of Unspecified  Related  Adverse  Events  Grade  3 or Higher  Other  than  
Laboratory  Abnormalities  ................................ ................................ ................................ ................................ ..... 105 
Table  22. Guidelines  for Grade  3 and Higher  Unspecified  Laboratory  Abnormality  Adverse  Events  ....................  106 
 
  
PROTOCOL  # 17-0466  
PI: Christopher  H. Lieu,  MD 
Version  Date:  12.30 .2021  
 
 
 
 
 
 
    
Page 12 of 106   
 
 
University  of Colorado  is the participating  site in this study.  A complete  and current  listing  of 
investigators,  research  personnel,  research  facilities  and other  study  centers  (if applicable)  
participating  in this study  will be maintained  throughout  the duration  of this study  on applicable  
study  required  forms  such as an FDA  Form  1572 , the COMIRB  Research  Personnel  Form , 
and/or a UCCC  Protocol Contact  List, incorporated  herein  by reference.  
 
 
 
 
 
2.1 Background Information  
 
Colorectal  cancer (CRC)  is among  the top four causes  of cancer  in the United  States,  and the 
SEER  database  estimates  that 8% of all cancer  deaths  were secondary  to colorectal  cancer in 
2016.  Late stage colorectal  cancer  has a very low 5-year survival  rate, and unfortunately,  20% 
of patients  have metastatic  CRC (mCRC)  at the time of diagnosis  [1]. Approximately  55-60% 
of patients  with mCRC  will have a rat sarcoma  virus  (RAS)  proto -oncogene  mutation.  RAS  
mutation  may comprise  of activating  mutations  in KRAS  (exon 2, 3,  4), NRAS  (exon 2, 3, 4)  
or infrequently  in HRAS  [2]. RAS  mutations  are an important negative  predictive  and 
prognostic  biomarker  because they correlate with worse  outcomes  and resistance  to anti- 
EGFR  therapies.  BRAF  mutations  are yet another  negative  prognostic  marker for mCRC.  
Although  ongoing  research  advances  have resulted  in some  improved  therapies  for advanced  
CRC in the  last decade,  it continues  to be  associated  with poor survival  [3, 4]. There  is a very 
clear  unmet  need  for effective  therapies  for patients  with advanced  CRC.  
 
The initial  standard  of care for treatment  of mCRC,  irrespective  of RAS  status,  is systemic  5- 
FU based  chemotherapy.   Anti-VEGF  therapies  are usually  used in combination  with 5-FU 
based  chemotherapy  and/or alone.  Median  survival  for untreated  patients  with mCRC  is less 
than a year while  median  overall  survival  (OS) with standard  of care therapy  is approximately  
30 months. Patients  with RAS -wild type tumors  have the option of  being  treated  with anti- 
epidermal  growth  factor  receptor  monoclonal  antibodies  such as cetuximab.  An insight  into 
cancer cell  biology  is integral  to developing  new targeted  therapies.  Sustained  proliferative  
signaling  such as the MAPK (Mitogen  Activated  Protein  Kinase)  signaling cascade,  
angiogenesis  and evasion  of immune  destruction  are some  of the critical  hallmarks  of tumor  
growth  [5]. Understanding  these  processes  is critical  and are described  below in further  detail.  
 
MAPK  Signaling Pathway  
 
The mitogen  activated  protein  kinase  signaling  cascade is a key intracellular  signaling  network  
that transduces  multiple  proliferative  and differentiating  signals  from  the extracellular  
environment  to the nucleus  of the cells to activate  cellular growth  and differentiation.  The 
MAPK pathway  has also been  implicated  in the  regulation  of the tumor  immune micro - 
1 PARTICIPATING  SITES  
2  INTRODUCTION:  BACKGROUND  INFORMATION  & SCIENTIFIC 
RATIONALE  
PROTOCOL  # 17-0466  
PI: Christopher  H. Lieu,  MD 
Version  Date:  12.30 .2021  
 
 
 
 
 
 
    
Page 13 of 106   
environment.  MEK inhibition  takes  advantage  of blocking  the signaling  cascade  as well as 
altering  the immunogenicity.  
 
The MAPK  signaling  cascade is activated  by upstream  stimuli  through  activated  cell 
membrane  tyrosine  kinase receptors.  This in turn leads  to a series  of phosphorylation  events  
and protein  interactions  involving  RAS -RAF -MEK -ERK,  which  ultimately  results  in tumor  
cell proliferation,  invasion,  migration,  angiogenesis  and metastases.  RAS  and RAF  muta tions  
activate  the MAPK signaling  pathway  through  MEK  which  has made MEK a highly  sought  
after target  in cancer  drug development.  MEK  inhibition  alone  or in combination  is already  
FDA approved  for melanoma [2]. 
 
In addition  to blocking  the signaling  cascade,  there is growing  evidence  to suggest  that the 
MAPK pathway  influences  TIL populations  and expression  of PD-L1. Kakavand  et al showed  
that there  was a significant increase in CD4,  CD8  and PD-1 lymphocytes  in patients  treated  
with combination  therapy  of BRAF  and MEK inhibitors  [6]. Triple  negative  breast  cancers  
were shown  to be  associated  with improved  prognosis  if TILs were noted  in residual  disease  
post treatment with neoadjuvant  chemotherapy.  Genetic or transcription  alterations  that 
resulted  in activation  of the RAS -MAPK  signaling  pathway  correlated  with lower  TILs.  
Breast  cancer  mouse  models  showed  enhanced  anti-cancer  immune  response with  combined  
MEK and PD-L1/PD -1 inhibition  [7]. Lui et al also showed  that a MEK  inhibitor alone  or in 
combination  with PD-1 inhibitor in vivo  led to increased  CD4  and CD8  TILs.  Their study  also 
indicated  improved  efficacy  with concurrent  MEK  and PD-1 inhibition or  sequential MEK  
inhibition followed  by PD-1 inhibition compared  to PD-1 followed  by MEK  inhibition  [8]. 
 
The Programmed T -cell Death Ligand Pathway  
 
Cancer  development  is a multistep  multifactorial  process.  Evasion  of immune detection  and 
destruction  has been proposed  as one of the emerging  hallmarks  of cancer development.  The 
theory  of immune  surveillance  suggests  that the immune system  constantly  monitors  cells in 
the body  and eliminates  the majority  of nascent  cancer  cells.  People  who have suppressed  or 
defective  immune  systems  such as HIV or transplant  patients  who are pharmacologically  
immune  suppressed  have  a higher  incidence of certain  types  of cancer [5]. However,  healthy  
immunocompetent individuals  are also  known  to develop  cancer.  Tumors  have shown  the 
ability  to create and  maintain  an immunosuppressive  microenvironment  that promotes  their 
survival  and growth  [5, 9]. Programmed  Death -Ligand  1(PD -L1/B7 -H1/CD274)  is expressed  
by many  cancer cells.  PD-L1 and PD-L2 are ligands to PD-1, a cell surface  receptor  that 
belongs  to the  immunoglobulain  superfamily.  Binding  of PD-L1 to PD-1 receptors  on T cells 
results  in suppression  of T-cell migration,  proliferation  and function.  The cancer  cell 
effectively  prevents  T cell mediated  destruction  by promoting  the PD-L1-PD-1 axis (Figure  
1)[9-14]. This understanding  has led to the  development  of immune  checkpoint  inhibitors  such 
as pembrolizumab.  
PROTOCOL  # 17-0466  
PI: Christopher  H. Lieu,  MD 
Version  Date:  12.30 .2021  
 
 
 
 
 
 
    
Page 14 of 106   
 
 
Figure  1. PD-1 mediated  T-cell activation  (A), exhaustion  (B) and blockade  (C). (A) APC or tumor  cell mediated  T- 
cell activation  results  in PD-1 expression.  (B) PD-L1 binds  to PD-1 and “turns  off” the T-cell. (C) PD-L1-PD-1 
blockade  results  in persistent  activation  of the T-cell which  then  continues  to maintain  its effector  functions.  
APC,  Antigen  presenting  cell; IFN-, Interferon  gamma;  MHC,  major  histocompatibility  complex;  PD-1, 
Programmed  death -1; PD-L1, programmed  death  ligand  1; TCR,  T-cell receptor[11]  
 
The Angiogenesis  Signaling Pathway  
 
The hypothesis  that angiogenesis,  the formation  of new blood  vessels,  is crucial  to tumor  
growth  is supported  by a large body  of scientific data.  In the adult,  angiogenesis  
(a continuous  process  during  embryogenesis)  is turned  on only transiently  as part of 
physiological  processes.  During  tumor  progression,  an “angiogenic  switch” is almost  always  
activated,  which  leads  to continuous  production  of new vessels  that sustain  expanding  
neoplastic growths  [5]. Recognition  that angiogenesis  is crucial  to tumor  growth  has led to 
the identification  of a large number  of angiogenic growth  factors,  including  VEGF,  which  is 
responsible  for stimulating  new blood vessel  formation.  
 
Angiogenesis  is the  rate-limiting  step for tumor  proliferation  and thus a  target  for antitumor  
therapy.  In addition,  VEGF  has been  involved  in the  inhibition of  the immune cell function  by 
tumors  [16, 17]. VEGF  leads  to a functional  defect  of the dendritic  cells,  which  are potent  
antigen -presenting  cells critical  to regulation  of the adaptive  immune  response.  VEGF  binds to  
CD34 -positive  cells (through  VEGFR1/Flt -1) and inhibits the  activation  of the transcription   

PROTOCOL  # 17-0466  
PI: Christopher  H. Lieu,  MD 
Version  Date:  12.30 .2021  
 
 
 
 
 
 
    
Page 15 of 106   
factor  NF-kB, which  leads  to a defect  in the  functional maturation  of the dendritic cells  [17, 
18]. The defects  in the  dendritic cell  function  are a major  component  of tumor immune  escape  
and influence  vascular endothelial  and hematopoietic  progenitors  that allow  tumor  immune  
escape.  
 
Bevacizumab  is a recombinant humanized  IgG1  mAb  that binds  VEGF  and neutralizes  the 
biological  activity  of VEGF  by preventing  the interaction  of VEGF  with its receptors.  
Bevacizumab  is a commercially  available  medication  (Avastin®) that has a broad  
development  program  as it has been  evaluated  and shown  efficacy  across  several  tumor types,  
including  CRC. Bevacizumab  is approved  for the treatment  of mCRC.  
 
Background on Binimetinib  
 
Binimetinib  (MEK162/ARRY -438162)  is an orally  bioavailable,  small  molecule selective and 
potent  mitogen -activated  protein  kinase  (MEK)  1 and MEK 2 inhibitor.  It is currently  being  
investigated  as a single  agent  and in combination  with other  chemotherapeutic  and targeted  
agents  in patients  with advanced  or metastatic  solid  tumors.  
 
Summary of  non-clinical trials  with binimetinib  
CRC  xenograft  tumors  in mice  showed  dose and time dependent  inhibition  of ERK  
phosphorylation  and tumor growth  following  administration  of binimetinib.  Similar  efficacy  
was observed  in other  xenograft models  of NSCLC,  pancreatic cancer,  ovarian  cancer,  
fibrosarcoma  and melanoma.  The primary  metabolic  pathways  were glucoronidation,  N- 
demethylation  and cleavage  of N-O bond.  Both  fecal  and urinary  excretion  of binimetinib  
were observed.  
 
Toxicity  studies  were conducted  in rats and monkeys.  The most commonly  occurring  
toxicities  in rats were  skin inflammation  and tissue mineralization  of multiple  organs.  The 
HNSTD (highest  non-severely  toxic  dose)  for binimetinib  based  on 28 -day monkey  toxicity  
studies  was 3 mg/kg.  The 9 month repeat  dosing  study  in monkeys  showed  GI inflammation  
and associated  secondary  changes  in blood  work  and NOEL  was identified  as 2 mg/kg.  
 
Summary of  clinical trials with binimetinib  
As of  January  2017,  a total of 2750 healthy  adult subjects  and patients  have received  at 
least 1 dose  of binimetinib,  either as a single agent  or in combination  with targeted  inhibitors  
of PKC,  CDK4/6,  PI3K,  RAF,  EGFR  or IGF-1R or with the standard  chemotherapy  agent  
paclitaxel.  These  patients  constitute  the binimetinib  safety  population,  which  includes  229 
healthy  subjects, 164 patients  with rheumatoid  arthritis,  17 patients  with hepatic  dysfunction,  
6 patient  with renal  dysfunction  and 2334  patients  with advanced  cancer.  
 
Healthy  subjects  
220 healthy  subjects received  at least a single  dose of binimetinib  across  11 studies.  In the 
ARRY -162-0602  study,  the most frequently  reported  AE were  diarrhea,  headache,  rash and 
acne.  The CMEK162X2108  study  reported  a total of 14 AE with 3 of those  AE being  grade 3. 
The side effect  profile was very similar to the  ARRY -162-0602  study  except  for increased   
 
PROTOCOL  # 17-0466  
PI: Christopher  H. Lieu,  MD 
Version  Date:  12.30 .2021  
 
 
 
 
 
 
    
Page 16 of 106   
ALT,  AST and GGT.  Some other  studies  reported  decreased  neutrophil  count  and pre- 
syncope.  None of these studies  in healthy  subjects reported  SAE  or deaths.  
 
Advanced cancer  patients  – monotherapy  
2159 advanced  cancer  patients  received  at least 1 dose  of binimetinib  in 20  clinical  studies  
either as a single agent  or in combination.  The recommended  single agent  dose of binimetinib  
has been evaluated  in two phase I studies  (ARRAY -162-111 and CMEK162X1101)  and 
multiple  other  phase II and III trials  and has been determined  to be  45 mg  BID.  
 
Advanced cancer  patients – combination therapy  
Binimetinib  has been administered  in combination  with RAF  inhibitors  (encorafenib  or 
RAF265),  PI3KC/AKT  pathway  inhibitors  (BEZ235,  buparlisib,  BYL719),  PKC -selective  
inhibitor  sotrastaurin,  CDK4/6  inhibitor  LEE011,  IGF-1R monoclonal  inhibitor  ganitumab,  
EGFR  inhibitor panitum umab,  and standard  chemotherapy  agent paclitaxel  in 1275 patients  
across  13 studies.  The RP2D of binimetinib  in combination  studies  is 45  mg BID.  
 
Clinical Pharmacokinetics  of Binimetinib  
Clinical  studies  have assessed  the pharmacokinetics  of binimetinib  in healthy  subjects  to 
determine  the absolute  bioavailability  and food effect.  The food effect  study  
(CMEK162A2103)  showed  that food delayed  but did not affect  the amount  of absorption  of 
binimetinib  into the systemic  circulation.  Therefore,  patients  are not required  to fast when  
taking  binimetinib.  The Clinical  study  ARRY -162-0602  in healthy  subjects identified  a 
median  t1/2 of binimetinib  for all doses  was 7.11 h and the median  Tmax  was 1 h post dose.  
The ADME  of a single oral dose of 45 mg of 14C-binimetinib  was investigated  in healthy  
males  in the  CMEK162A2102.  The metabolism  of binimetinib  is primarily  through  direct  
glucorinidation  and estimated  to be  approximately  61.2%.  62.3%  of binimetinib  is eliminated  
in the  feces  while  the rest is eliminated  in the  urine.  There  is an ongoing  study  
(CMEK162A2104)  investigating  the PK of binimetinib  in patients  with hepatic  impairment.  
Preliminary  data indicates  that there  are no significant  PK changes  in patients  with mild 
hepatic  impairment.  
 
Background  on Pembrolizumab  
 
Pembrolizumab  (KEYTRUDA,  MK-3475)  is an intravenous,  potent  and highly  selective  
humanized  monoclonal  antibody  of the immunoglobulin  G4 (IgG4)/kappa  isotype  designed  to 
directly  block  the interaction between  PD-1 and its ligands,  PD-L1 and PD-L2. 
Pembrolizumab is currently approved for use in advanced or unresectable melanoma, non -
small cell lung cancer (NSCLC),head and neck squamous cell cancer (HNSCC),  classical 
Hodgkin’s Ly mphoma, primary mediastinal large B -cell lymphoma (PMBCL), urothelial 
carcinoma (UC), microsatellite instability -high (MSI -H) tumors, gastric and gastroesophageal 
junction (GEJ) adenocarcinoma, cervical cancer, hepatocellular carcinoma (HCC), Merkel cell 
carcinoma (MCC), and advanced renal cell carcinoma (RCC) . [15]
PROTOCOL  # 17-0466  
PI: Christopher  H. Lieu,  MD 
Version  Date:  12.30 .2021  
 
 
 
 
 
 
    
Page 17 of 106   
Summary of  nonclinical trials  
Pembrolizumab  has been  shown  to enhance  T-lymphocyte  immune  responses  in cultured  
blood cells from  healthy  subjects,  cancer  patients  and cynomolgus  monkeys.  In vivo,  
pembrolizumab  was shown  to enhance  human  T-cell response  to staphylococcus  Enterotoxin  
B. It was also shown  to potentiate  antigen -specific  recall  response to the  tetanus  toxoid  
antigen.  
 
Pembrolizumab  binds  to human  and cynomolgus  monkey  PD-1 with comparable  affinity  and 
blocks  the binding  of PD-1 to PD-L1 and PD-L2 with comparable  potency.  Pembrolizumab  
did not bind to mouse,  dog or rat blood PD-1. These studies  have provided  the rationale for  
cynomolgus  macaque as  the relevant  species  for preclinical  development.  Due to lack of 
cross  reactivity  of pembrolizumab with PD-1 from  rodents,  an anti-mouse  PD-1 antibody  was 
generated  for use in in-vivo studies  in syngeneic  mouse  tumor  models.  PD-1 blockage  
demonstrated  anti-tumor  efficacy  in each of these  syngeneic  tumor  models.  Anti-PD-1 therapy  
was also shown  to enhance  efficacy  and regression  rates of chemotherapeutic agents  such as 
5-FU in-vivo.  The use of pembrolizumab  in combination  regimens  that included  
dexamethasone  was also assessed.  Results  showed  no impact  on efficacy  of anti-PD-1 
treatment.  
 
Toxicology  of pembrolizumab  was studied  in 1-month  and 6-month  repeat dose chronic  
nonclinical  toxicity  studies.  Pembrolizumab  was well tolerated  at all dose levels.  There were  
no test article  related  concerning  findings.  PD-L1 signaling  blockade has  been noted  in murine  
models  of allogeneic  pregnancy.  Treatment  with anti-PD-L1 mAb  resulted  in increased  rates 
of abortion.  There  is good  evidence  to suggest  the PD-1/PD -L1 blockade is important  in feto- 
maternal  tolerance.  Therefore,  data suggests  that PD-1/PD -L1 blockade will  result  in increased  
risk of abortion  and /or still births.  
 
Immunogenicity  of pembrolizumab was also evaluated  as part of the toxicity  studies.  Anti- 
pembrolizumab  antibodies  were  detectable  but no  related  toxicities  were  observed.  
 
Summary of  clinical trials  
The efficacy  of pembrolizumab  has been studied  in multiple  cancers. Currently , pembrolizumab 
is FDA  approved for  use in melanoma,  NSCLC, SCLC, HNSCC ,  classical Hodgkin’s 
Lymphoma , PMBCL, UC, MSI -H cancer , gastric and GEJ  adenocarcinoma, cervical cancer, 
HCC, MCC, RCC , endometrial carcinoma, TMB -H cancer, cSCC, and MSI -H CRC.  
 
In melanoma,  pembrolizumab  has been studied  in the phase I setting,  in ipilimumab  and 
BRAF  inhibitor  refractory  BRAF –mutant  advanced  melanoma (KEYNOTE -002) and 
ipilimumab -naïve  unresectable  or metastatic  melanoma (KEYNOTE -006, Phase  III, 
randomized  to IPI vs Pembrolizumab).  The KEYNOTE -002 study  showed  a statistically  
significant improvement in PFS with a suggestion  of benefit  in OS. The KEYNOTE -006 
showed  benefits  in OS and PFS.  The data from  these  studies  led to the approval  of 
pembrolizumab  for patients  with unresectable  or metastatic  melanoma.  
 
In NSCLC,  two clinical  studies  – KEYNOTE -001 and KEYNOTE -010. KEYNOTE -001 was 
an open  label,  phase 1 trial while KEYNOTE -010 was a randomized  phase  2/3 trial of 
7pembrolizumab  vs docetaxel  in PD-L1 positive,  platinum  refractory  NSCLC.  The 
PROTOCOL  # 17-0466  
PI: Christopher  H. Lieu,  MD 
Version  Date:  12.30 .2021  
 
 
 
 
 
 
    
Page 18 of 106   
KEYNOTE -010 trial demonstrated  clinically  significant  improvement  in OS and PFS.  The 
patients  with a PD-L1 tumor  proportion  score (TPS)   50% had the greatest  benefit.  
KEYNOTE -012, a phase 1b trial included  cohorts  of patients  who progressed  following  
cetuximab  and platinum  therapy  and subjects  who progresses  following  platinum  therapy  
without  cetuximab.  16% of patients  experienced  tumor response to pembrolizu mab and the 
duration  of response was  higher  than that seen with standard  of care treatments.  
 
Pharmacokinetics  of Pembrolizumab  
PK has been  obtained  from  various  pembrolizumab  trials  including  advanced  melanoma,  
NSCLC,  HNSCC,  urothelial  carcinoma,  and MSI-H tumors.  Pembrolizumab  is administered  
IV and is a 100%  bioavailable.  PK analysis  from  studies  confirm  that pembrolizumab  has a 
low systemic  clearance  and a limited  volume of distribution.  Pembrolizumab  is eliminated  via 
catabolism  with minimal  renal  excretion.  Hence,  food and drug-drug interactions  are not 
expected  to affect  pembrolizumab  exposure.  The systemic  clearance  of pembrolizumab  is 0.22  
L/day  and the t1/2 is estimated  to be  ~ 22 days.  Steady  state of the drug is achieved  after ~ 18 
weeks  of ongoing  therapy.  
 
Pembrolizumab  exposure  occurs  in a dose-dependent  manner  with clearance being  
independent  of time or concentration.  PK studies  have  indicated  that the fixed  dosing  of 200 
mg provides  the same adequate  level  of exposure  to drug as body  weight  based dosing.  
Population PK analysis shows that both fixed dosing and weight -based dosing provides similar 
control of PK variability with considerable overlap in the distribution of exposures, supporting 
suitability of 200 mg Q3W. Additionally, pharmacology da ta shows full target saturation in 
both systemic circulation (inferred from physiologically -based PK [PBPK] analysis) at 200 mg 
Q3W.  
 
Studies  have shown  no significant difference  in clearance  of pembrolizumab  between  patients  
with normal  renal  function  vs mild to  moderate  renal  impairment.  Pembrolizumab  has not been  
studied  in the  setting  of severe (GFR  <30 and  15 ml/min/1.73  m2) renal impairment.  
Similarly,  no important  differences  have been  observed  in clearance  of pembrolizumab  in 
patients  with mild hepatic  impairment.  However,  pembrolizumab  has not been studied  in 
moderate  to severe  hepatic impairment.  
 
Background  on Bevacizumab  
 
Bevacizumab  has been studied  in more  than 96,500  patients  in Phase  I−IV clinical  trials  in 
multiple  tumor  types since  the beginning  of it clinical  development.  More  than 
2 million patients  have  been treated  with bevacizumab  as a marketed  product  worldwide.  
 
The pharmacokinetics  of bevacizumab  are characterized  by a slow  CL, long half-life, and a 
volume  of distribution  consistent  with limited  extravascular  distribution.  
A comprehensive  population  PK analysis  of the pooled  data demonstrated  that CL was 
consistent  across  all studies  and tumor  types  and that overall  inter-indivi dual variability  in CL 
was approximately  33%. Post-hoc estimates  of bevacizumab  PK parameters  from  various  
tumor  types  show  that the pharmacokinetics  of bevacizumab  were accurately  estimated  across  
tumor  types  and a number of the covariates  evaluated  explain  the observed  PK variability.  
Albumin  levels, body  weight,  and sex were found  to be  significant  covariates  that explained  
PROTOCOL  # 17-0466  
PI: Christopher  H. Lieu,  MD 
Version  Date:  12.30 .2021  
 
 
 
 
 
 
    
Page 19 of 106  some  of the inter-individual  variability.  
 
The results  from  drug-drug interaction  PK studies  showed  that there were no interactions  
between  bevacizumab  and the anti-cancer  agents  tested.  Co-administration  of bevacizumab  
with other  anti-cancer agents  resulted  in similar  values  of CL and the volume of central  
compartment  for bevacizumab  was not affected  by dosing  with other anti-cancer  agents.  
 
See the Bevacizumab  Investigator’s  Brochure  for details  on nonclinical  and clinical  studies.  
 
2.2 Rationale  
 
There  is an unmet  need  for treatment  options  for patients  with refractory  metastatic  CRC.  
Patients  are currently  offered  chemotherapy  which provides  a limited  duration  of disease  
control  and results  in multiple toxicities  that impact  quality  of life. This study  proposes  
combination  therapy  with three  agents  that are known  to target  three key aspects  of 
metastatic  CRC cell biology - immune  evasion,  proliferative  signaling  and angiogenesis  [5]. 
Clinical  and non-clinical  data suggests  that inhibition  of MEK,  PD-1 and angiogenesis  
should  result  in additive  anti-tumor  activity.  
 
This study  requires  a tumor biopsy  pre- and post- treatment.  Since the advent  of the targeted  
therapy  era it has become clear that a better  understanding  of the intimate  biological  
mechanisms  that tailor  the cancer cell  phenotype  would  be translated  into a  better chance of 
disease  control.  However,  this has been  a difficult task due to the  complex  interaction  
between  the tumor  cell, tumor  stroma,  immune response,  and angiogenesis.  The animal  
models  do not appropriately  represent  these  intricate  interactions , especially  for the immune  
system.  
 
Therefore,  tumor  biopsies  during  the clinical  study  at different  time-points  present  the 
best opportunity  to increase  understanding  of the anti−tumor immune  response  as well as 
to identify  biomarkers  predictive of response and resistance.  
 
2.3 Potential Risks and Benefits  
 
Despite  recent  advances,  mCRC is commonly  an incurable disease and  patients  
eventually  succumb  to the  disease.  There has  been ongoing  research  to fulfill  this unmet  
need.  
 
Combination  therapy  with multiple  targeted  agents  is one  of the possible research  strategies.  
Clinical  and non-clinical  data suggest  potential  enhancement  in anti-tumor  activity  with 
combining  MEK,  PD-1 and angiogenesis  inhibitors.  Every  drug has its own set of side-
effects,  and the risk in combining  multiple  agents  is an increase  in number and  intensity  of 
adverse  events.  The potential  risks  and benefits  of this combination  therapy  are listed  below.  
 
 
 
 
 
 
 
PROTOCOL  # 17-0466  
PI: Christopher  H. Lieu,  MD 
Version  Date:  12.30 .2021  
 
 
 
 
 
 
    
Page 20 of 106   
 
 
Pembrolizumab  
 
Pembrolizumab is generally well tolerated and demonstrates a favorable safety profile in  
comparison to chemotherapy. Pembrolizumab is an immunomodulatory agent, and based on  
this mechanism of action, immune - mediated AEs ar e of primary concern. The important  
identified risks for pembrolizumab monotherapy are primarily of an immune -mediated  
nature  and included the following in the last IB (Edition 20): pneumonitis; colitis; hepatitis;  
nephritis; endocrinopathies that include hypophysitis (including hypopituitarism and  
 
secondary adrenal insufficiency), thyroid disorder (hypothyroidism, hyperthyroidism and  
thyroiditis), and Type I diabetes mellitus; uveitis; myositis; Guillain -Barré syndrome;  
pancr eatitis; myocarditis; myasthenic syndrome /myasthenia gravis (including exacerbation); 
myelitis ; encephalitis; sarcoidosis; severe skin  reactions including SJS and TEN, some with fatal 
outcome; and solid organ transplant  rejection following pembrolizumab tr eatment in donor organ 
recipients (risk applicable  primarily to postmarketing setting only, as such patients are currently 
excluded from Merck -sponsored  clinical studies with pembrolizumab).   
 
Immune -mediated ARs, including severe and fatal cases, have occ urred in patients receiving  
pembrolizumab. Immune -mediated ARs can occur after discontinuation of treatment.  
Immune -mediated ARs affecting more than one body system can occur simultaneously. In  
clinical studies, most immune -mediated ARs were reversible and managed with interruptions  
of pembrolizumab, administration of corticosteroids, and/or supportive care.  
 
The safety profile for pembrolizumab also includes 2 important potential risks – ie, increased  
risk of severe complications (such as ear ly severe GVHD and veno -occlusive disease) of  
allogeneic transplant in patients with hematologic malignancies who have previously been  
treated with PD -1 inhibitors; and GVHD after pembrolizumab administration in patients with  
a history of allogeneic HSCT.  
 
Safety  data from the  sponsor’s  reference  safety  dataset  includes  data from  KEYNOTE -001, 
KEYNOTE -002, KEYNOTE -006 and KEYNOTE -010 (n = 2799).  97.4%  of patients  in this  
dataset  experienced  1 or more  AE. 73.7%  of patients  experienced  adverse events  which  were  
thought  to be  drug related  by the investigator . The percentage of participants in the safety 
data set who experienced SAEs was lower. 37.2% of participants experienced 1 or more 
SAEs; 11.9% of participants discontinued due to an AE; and 10.1% of subjects  experienced  
a drug- related  SAE  as determined by the investigator.   
 
Most frequently  reported  (5%) AE in decreasing  order of frequency  thought to be  drug 
related  were fatigue,  pruritus,  rash,  diarrhea,  nausea,  arthralgia,  decreased  appetite,  asthenia,   
hypothyroidism,  vitiligo  and myalgias.  Of this  the 5 most frequently  reported  AE that are 
considered  drug-related  are fatigue (24.2%),  pruritus  (16.7%),  rash (13.8%),  diarrhea  (12.3%)  
and nausea (10.9%).  
 
 
 
2.3.1  IMPORTANT  IDENTIFIED/  POTENTIAL  RISKS  
PROTOCOL  # 17-0466  
PI: Christopher  H. Lieu,  MD 
Version  Date:  12.30 .2021  
 
 
 
 
 
 
    
Page 21 of 106   
Most frequently  reported  drug related  SAEs  (0.2%)  in decreasing  order of frequency  were  
pneumonitis,  colitis,  diarrhea,  pyrexia,  autoimmune  hepatitis,  pneumonia,  adrenal  insufficiency,  
hyponatremia,  dyspnea,  hyperthyroidism , nausea , acute kidney injury, confusional state, 
hypophysitis, hypopituitarism, hypothyroidism, and vomiting . The 5 most commonly  reported  
SAE  that are considered  drug-related  are pneumonitis  (1.6%),  colitis  (0.9%),  diarrhea  (0.6%),  
pyrexia (0.4%)  and autoimmune  hepatitis  (0.3%).  
 
Adverse events  of special  interest  in patients  treated  with pembrolizumab  include  
hypothyroidism,  hyperthyroidism,  pneumonitis,  infusion  reactions,  colitis,  severe skin 
reactions,  adrenal  insufficiency,  hepatitis,  hypophysitis,  thyroiditis,  uveiti s, myositis,  nephritis, 
pancreatitis,  T1DM,  Guilla in-Barre  syndrome , myasthenic  syndrome , sarcoidosis, encephalitis.  
 
Binimetinib  
Across  all oncologic  studies,  the majority  of AEs were reversible and grade  1 or 2 in severity.  
These  adverse events  include ocular events  (retinal, vascular  and other eye),  dermatologic  
events  (rash  and other),  edema,  myopathy/rhabdomyolysis  (including  CK elevation),  HTN,  
liver issues,  fatigue/asthenia,  pneumonitis,  hemorrhage,  thrombotic  and embolic events.  
CMEK162X2201  reported  24% of patients  had Grade 3 or 4 elevations  in blood  CK. All other  
AE have been  grade 1 or 2. Reproductive  toxicity  and QT prolongation  are included  in the  
toxicity  profile  for Binimetinib  but this  information  comes  from nonclinical  data. 
 
Bevacizumab  
The most  serious  adverse  events  identified  in clinical  trials  with bevacizumab  have  been  
gastrointestinal  perforations,  hemorrhage (including  tumor -associated  bleeding  and pulmonary  
hemorrhage/hemoptysis),  which  is more  common  in NSCLC  patients,  and arterial  
thromboembolic  events.  Other  adverse  events  observed  in patients  treated  with bevacizumab  
include fistulae,  wound -healing  complications,  hypertension,  arterial  and venous  
thromboe mbolism,  and proteinuria.  In addition,  congestive  heart  failure was  observed  rarely.  
Analyses  of the clinical  safety  data suggest  that the occurrence of hypertension  and proteinuria  
with bevacizumab  is likely  to be  dose dependent.  
 
The most  frequently  observed  adverse  events  in patients  who received  bevacizumab  have  been  
hypertension,  fatigue  or asthenia,  diarrhea,  and abdominal  pain.  Increased  rates of severe  
neutropenia,  febrile  neutropenia,  or infection  with severe  neutropenia  (including  some  
fatalities)  have been  observed  in patients  treated  with some  myelotoxic  chemotherapy  regimens  
plus bevacizumab  in comparison  to chemotherapy  alone.  There have been  rare reports  in the 
post-marketing  setting  of the development  of signs  and symptoms  that are consistent  with 
posterior  reversible encephalopathy  syndrome in bevacizumab -treated  
patients.  Very  rare cases  of hypertensive encephalopathy  have  also been reported,  some  of 
which  were  fatal.  
 
 
 
 
 
 
 
PROTOCOL  # 17-0466  
PI: Christopher  H. Lieu,  MD 
Version  Date:  12.30 .2021  
 
 
 
 
 
 
    
Page 22 of 106   
 
 
The study  regimen  combines  three  agents  that target  three  relevant  features  of cancer  cell 
biology,  the so-called  hallmarks  of cancer:  proliferative  signaling,  angiogenesis,  and immune  
evasion[5].  Furthermore,  the nonclinical  and clinical  data suggest  that the inhibition  of MEK,  
PD-L1, and the neo-angiogenesis  should  lead to a more  than additive  anti-tumor activity.  
 
Nonclinical  data show  a negative  association  between  MEK  activity  and active  antigen  
presentation  (MHC -I and II expression)  that appears  to be coupled  to simultaneous  PD-L1 
expression.  These  findings  link the MAPK  pathway  activation  to the tumor  immune -evasion.  
Consistently,  MEK inhibition  results  in an increased  number of tumor -infiltrating  CD8-positive  
T lymphocytes  and PD-L1 and MHC  expression  [7, 19]. These  effects  are responsible  for the 
enhanced  anti-tumor  immune  response  observed  with the combination  of MEK  with PD-L1/PD - 
1 inhibitors  [7]. The Phase  I Study  KEYNOTE -022 presented  at ASCO  2016  which  combined  
pembrolizumab  with MAPK  pathway  inhibition  (BRAF -I and MEK -I) in advanced  melanoma  
patients  showed  a 60% ORR  (n = 15)[20].  In the Phase  Ib Study  GP28363,  another  MEK -I - 
cobimetinib  was administered  with pembrolizumab  (immune  checkpoint  inhibitor)  and it has  
shown  promising  results  in patients  with refractory  CRC  (ORR  of 17.4%)  (in-house  data 
generated  at the University  of Colorado).  VEGF  plays  an important  role in immune  tolerance  
in the tumor  microenvironment  through  inhibition  of dendritic  cell differentiation  and 
maturation  [17, 21, 22]. Dendritic  cells are a relevant  component  of the immune  response  that 
links  the adaptive  and innate  immune  systems  through  the antigen  presentation  function.  In 
patients  with CRC,  the inhibition  of VEGF  with bevacizumab  increases  the peripheral  B and T 
cell compartments,  decreases  the Treg  compartment, and enhances  the functional  maturation  of 
dendritic  cells [17, 22, 23]. As a result  of these  effects,  bevacizumab  increases  CD8 -positive  T 
cell accumulation  in tumors  in both nonclinical  and clinical  biopsies  (in-house  mouse  data;  
Phase  Ib biopsy  data with  bevacizumab  and pembrolizumab).  
 
Based  on the potential  benefit  of the study  regimen,  the availability  of standard  therapy  in case 
the disease  progresses  and the well-defined  and tolerable  profile  of each agent,  the Sponsor  
believes  that in this study  the potential benefits  outweigh  its risks.  
 
The risks to subjects  are reasonable  in relation  to the anticipated  benefits  to subjects  and/or  
society,  and in relation  to the importance  of the knowledge  that may reasonably  be expected  to 
result,  thereby  falling  in favor  of performing  the study:  
 
• To Subject:  benefit  of possible short  term and sustained  disease  response  
resulting  in improvement  in both quantity  and quality  of life. 
• To Society:  The knowledge  gained  in terms  of toxicity  and efficacy  will 
guide  treatment for other patients  with mCRC.  
• Justify  the importance  of the knowledge  gained:  The knowledge  gained  in 
terms  of toxicity  and efficacy  will help determine  direction  future  research  
in the  area of mCRC.  
 
 
 
 
2.3.2  KNOWN  POTENTIAL  BENEFITS  
PROTOCOL  # 17-0466  
PI: Christopher  H. Lieu,  MD 
Version  Date:  12.30 .2021  
 
 
 
 
 
 
    
Page 23 of 106   
 
Primary  objective:  
1. To determine  the effect  of pembrolizumab,  binimetinib,  and bevacizumab  on 
response  rate in this patient  population  using  RECIST  v1.1.  
 
Secondary  objectives:  
1. To determine  the progression  free survival  (PFS)  of combination  therapy  with 
pembrolizumab,  binimetinib,  and bevacizumab  in patients  with advanced  CRC  
refractory  to at least two standard  lines of therapy.  
2. To determine  the effect  of pembrolizumab,  binimetinib,  and bevacizumab  on overall  
survival  in this patient  population.  
3. To evaluate  the safety  and tolerability  of pembrolizumab,  binimetinib,  and 
bevacizumab.  
 
Exploratory  Objectives:  
1. To evaluate  the relationship  between  PD-L1 tumor  expression  and mismatch  
repair  (MSS  v MSI)  status  and efficacy  of pembrolizumab,  binimetinib,  and 
bevacizumab.  
 
2. To assess  for change  in PD-L1 and phosphorylated  ERK  expression  in pre- and 
post- treatment  tumor tissue.  
3. To compare  the response  rate determined  according  to RECIST  v1.1 to that 
identified  by Immune  Related  Response Criteria  (irRC).  
 
 
 
 
4.1 Description of the Study Design  
 
This is an open -label,  single -center,  single -arm phase II  clinical  trial evaluating  the combination  
of pembrolizumab,  binimetinib,  and bevacizumab  in patients  with metastatic  colorectal  
adenocarcinoma  refractory  to at least two standard  lines of therapy.  All patients  in the 
expansion cohorts will require  a tumor  biopsy  prior  to treatment  and again  prior  to cycle  1, 
day 1 (binimetinib  run-in cohort)  or prior to cycle  2, day 1 (in patients  not receiving  the 
binimetinib  run-in). 
 
There are  2 stages to this study:  
1. Stage 1: safety  run-in (n = 10) 
2. Stage  2: Dose  expansion * (n = 64) with two cohorts  – Cohort  A (n = 32) and Cohort  B (n 
= 32) 
* Up to 3 2 participants may be enrolled into each cohort to account for attrition and screen fails.  
However, only 20 total participants are needed per cohort to meet the study objectives.  
 
 
3 OBJECTIVES AND PURPOSE  
4 STUDY  DESIGN  AND  ENDPOINTS  
PROTOCOL  # 17-0466  
PI: Christopher  H. Lieu,  MD 
Version  Date:  12.30 .2021  
 
 
 
 
 
 
    
Page 24 of 106   
Stage 1:  Safety run-in 
 
Rationale:  
Pembrolizumab,  binimetinib  and bevacizumab  have been assessed  in clinical  trials  as 
monotherapy.  Combination  therapy  of PD-1 inhibition  with MEK  inhibition  has also been  
studied  in the phase  I setting.  There  is an ongoing  phase  I trial of a PD-L1 inhibitor,  MEK -I and 
bevacizumab  but the toxicity  data from  this trial is not yet available . We are unaware  of any 
studies  that have  combined  pembrolizumab,  binimetinib  and bevacizumab  previously.  
Therefore,  the safety  run-in is a measure  to mitigate  the toxicity  risk posed  by combining  these  
three  agents.  
  
Design:  
Ten patients  will be accrued  to stage  1 and treated  with standard  doses  of pembrolizumab,  
binimetinib  and bevacizumab.  If the standard  doses  are not tolerable  and 2 or more  patients  
experience  a DLT,  then patients  would  be enrolled  in dose level  -1 which  would  comprise  of 
standard  doses  of pembrolizumab  and bevacizumab  but binimetinib  would  be at a dose lower  
of 30 mg PO BID.  If 2 or more  patients  experience  a DLT  at dose level  -1, then patients  will be 
enrolled  in dose  level  -2 which  will comp rise of standard  doses  of pembrolizumab  and 
bevacizumab  but a lower  dose of binimetinib  at 15 mg BID.  Upon  determination  of the safety  
and tolerability  of the treatment  regimen,  the study  will proceed  to stage  2. 
 
If any of the following  situations  occur,  then further  enrollment  and study  treatments  will be 
halted  immediately  until a thorough  investigation  and safety  analysis  has been conducted  
(DLT):  
o If any patient  experiences  death  due to an adverse  event  that is assessed  as related  to 
study  treatment  (by investigator  and/or  Sponsor),  it will lead to temporary  hold of study  
pending  review  by study  team.  
o Approximately  3 or more of the 10 patients  meet  individual  stopping  rules.  
 
The following  are treatment  stopping  rules  for an  individual  patient  and for the safety  run-in 
phase  of the study.  If any of the following  situations  of potentially  overlapping  toxicities occur  
and are assessed  as related  to study  treatment  by the investigator,  the study  treatment  will be 
halted  immediately  for the individual  patient,  and a thorough  investigation  and safety  
analysis  will be conducted:  
 
• Grade ≥ 3 hypertension  (defined  as ≥ 180 mmHg  systolic or ≥ 110  mmHg  diastolic  
blood pressure) refractory  to optimal  anti-hypertensive  management  for > 14 
consecutive days 
• Grade ≥ 3 hemorrhage (symptoms  and transfusion  of packed  RBCs  indicated)  
• Grade ≥ 3 pneumonitis  (symptomatic,  interfering  with activities  of daily  living;  
oxygen  indicated)  
• Recurrent  Grade 2 pneumonitis  (symptomatic;  medical  intervention  indicated;  limiting  
instrumental  ADL)  
• Grade ≥ 3 left ventricular  dysfunction  (symptomatic  congestive  heart  failure  
responsive  to intervention)  
• Grade ≥ 3 colitis  or diarrhea  not responsive  to anti-diarrheal  agents  (increase of ≥ 7 
stools per day over baseline; incontinence;  IV fluids  for ≥ 24 hours; hospitalization)  
PROTOCOL  # 17-0466  
PI: Christopher  H. Lieu,  MD 
Version  Date:  12.30 .2021  
 
 
 
 
 
 
    
Page 25 of 106  • ALT or AST  > 5 × ULN  in combination  with total bilirubin  > 2 × ULN  
• Grade ≥ 3 retinopathy  or retinal  vein occlusion.  
 
Once  10 patients  have  been enrolled  into the  study,  further  accrual  to the  study  will be 
temporarily  halted  while  the study  team  reviews  the totality  of clinical  data to determine  safety  
and tolerability  of the regimen.  Only  after the regimen  has been  determined  to be safe and 
tolerable  as detailed  above  can the dose expansion  phase  be initiated.  The safety  review  should  
contain  data from  patients  who have been receiving  the regimen  for a minimum  of one cycle of 
treatment.  
 
Stage 2: Dose expansion  
 
Rationale:  
Binimetinib  is administered  with a 7-day run-in in Cohort  A to explore  the hypothesis  that MEK  
inhibition  will increase  the tumor  immunogenicity,  thereby  enhancing  the effect  of immune  
checkpoint  inhibition  with pembrolizumab.  Two cohorts,  one with all agents  administered  
simultaneously  and the other  with a 7-day run-in of binimetinib  have  been  initiated  to determine  
if there  is any difference  in biomarker  expression  and clinical  efficacy  between  the two dosing  
strategies.  The two cohorts  are not comparators  but two divisions  of a single -arm study.  
 
Design:  
All enrolled  patients,  post-safety  run-in (if no DLT  in the  safety  lead-in) will be assigned  to one 
of two treatment  arms  – Cohorts  A or B. Patients  must  have   biopsiable disease in order to be  
eligible  for study  enrollment , and a pre -treatment biopsy will be done after the patient is 
randomized to a treatment arm  but prior to initiating treatment . A second  on-treatment  biopsy  
will also be done provided  tumor  is accessible and there is no  foreseeable  harm  to the  patient  
due to the  biopsy.  
All patients in the expansion cohort will have two biopsies while participating on this clinical 
trial. The first pre -treatment biopsy will be collected prior to treatment initiation but after 
randomization  onto the study . The second on -treatment biopsy will occur following enrollment 
and the  timepoint will be dependent upon the Cohort  to which  the patient is randomized . The on -
treatment biopsies will occur during one of the following timepoints:  
• Cohort A: Following the 7 -day Binimetinib run -in period and prior to C1D1.  
• Cohort B: Following co mpletion of Cycle 1 and prior to C2D1.  
To summarize, all patients in the expansion cohort will be required to submit two biopsies 
while participating on this clinical trial. The first pre -treatment biopsy will be performed on all 
patients after randomizat ion onto the study , but prior to treatment initiation. . The second on -
treatment biopsy will be completed following enrollment and the timepoint will be dependent 
on the subject’s randomization cohort (see above).  
 
In Cohort  A, up to  32 patients  will be treated  with a 7-day run-in of binimetinib  starting  day 
-7 of cycle  1 only.  Tumor  biopsy  will be performed  prior  to initiation  of treatment,  and again  
prior to  cycle  1 day +1. Pembrolizumab  and bevacizumab  will then be added  to binimetinib  on 
cycle  1 day +1. Cycle  1 will end on day 21. Patients  will start treatment  with 
pembrolizumab,  binimetinib,  and bevacizumab  on day  1 of all subsequent  cycles.  
 
PROTOCOL  # 17-0466  
PI: Christopher  H. Lieu,  MD 
Version  Date:  12.30 .2021  
 
 
 
 
 
 
    
Page 26 of 106  In Cohort  B, up to  32 patients  will initiate  pembrolizumab,  bevacizumab,  and binimetinib  
together  on day 1 of all cycles  including  cycle  1. These  patients  will undergo  biopsy  prior  to 
treatment  and again  at day 21 of  cycle 1. 
 
Patients  in the safety  run-in phase  and in the dose expansion  phase  will continue  to receive  study  
therapy  until disease  progression  according  to RECIST  v1.1,  unacceptable  toxicity,  death,  
patient  or physician  decision  to withdraw,  pregnancy  or maximum  upper  limit  of 
pembrolizumab  therapy  (35 cycles),  whichever  occurs  first. A rising  carcinoembryonic  antigen  
(CEA)  level  alone  is not considered  disease  progression.  Patients  are allowed  to receive  study  
treatment  beyond  disease  progression  if certain  conditions  are met (Please  see Section  6.1.1).  
Tumor  tissues  will be assessed  for mismatch  repair  status  at baseline,  PD-L1 expression,  and 
phosphorylated  ERK  expression  in pre- and post-treatment  specimens . In addition,  mRNA  
expression  of a panel  of immune  markers  will also be assessed  in both pre- and post-treatment  
tissues.  
 
All patients  will undergo  imaging  of the chest,  abdomen,  and pelvis  after every  three  cycles  for 
evaluation  of response according  to RECIST  v1.1.   
 
The study  will end when  all patients  enrolled  have  been  followed  until death,  have withdrawn  
consent,  have been  lost to follow -up, or the Sponsor  decides  to end the trial, whichever  occurs  
first. The time from  first patient  in until end of follow -up as described  above  is expected  to take 
approximately  12 months.  
 
4.2 Study Endpoints  
 
 
1. Response rate based  on CT imaging,  defined  as complete or partial  response 
according  to RECIST  v1.1 
 
 
1. Progression  free survival,  defined  as the time from  enrollment  to the first observation  
of progressive disease or death  from  any cause  
2. Overall  survival,  defined  as the time from  enrollment  to death  from  any cause  
3. Grade  1, 2, 3, 4 toxicities  associated  with pembrolizumab,  bevacizumab,  and 
binimetinib  as defined  by CTCAE  v4 
 
 
1. Response  rate according  to mismatch  repair  status  and pre-treatment  PD-L1 
tumor  expression  by IHC.  
2. Change  in pre- and post-treatment  levels  of PD-L1 and phosphorylated  ERK  
expression  by IHC.  
3. Pattern  of change  in mRNA  expression  in a panel  of immune  related  genes  in tumor  
tissues  prior  to treatment,  after binimetinib  alone,  and after binimetinib,  pembrolizumab,  
and bevacizumab.  
4. Compare  the response rate determined  according  to RECIST  v1.1 to that identified  
by Immune Related  Response Criteria (irRC).  
 
4.2.1  PRIMARY  ENDPOINT  
4.2.2   SECONDARY  ENDPOINTS  
4.2.3   EXPLORATORY  ENDPOINTS  
PROTOCOL  # 17-0466  
PI: Christopher  H. Lieu,  MD 
Version  Date:  12.30 .2021  
 
 
 
 
 
 
    
Page 27 of 106   
 
 
 
5.1 Subject Inclusion Criteria  
 
In order  to be eligible  to participate  in this study,  an individual  must  meet  all of the following  
criteria:  
1. Provision  to sign and date the consent  form.  
2. Age ≥ 18 years.  
3. Able  to comply  with the study  protocol,  in the  investigator’s  judgment.  
4. Patient  must  state willingness  to undergo  pre- and post-treatment  biopsies.  According  to 
the investigator’s  judgement,  the planned  biopsies  should  not expose  the patient  to 
substantially  increased  risk of complications.  
5. Patient must have biopsiable disease.  
6. Eastern  Cooperative Oncology  Group  (ECOG)  performance status  of 0 or 1. 
 
7. Histologically  confirmed  unresectable  metastatic  colorectal  adenocarcinoma.  
8. Progression  or intolerance on at least two prior  lines of therapy  for unresectable  
metastatic  colorectal  adenocarcinoma.  
o Administration  of bevacizumab  previously  does not impact  study  inclusion.  
9. Measurable  disease,  according  to RECIST  v1.1.  Note that  lesions  intended  to be 
biopsied  should not be  target  lesions.  Lesions situated in a previously irradiated 
area are considered measureable if progression has been demonstrated in such 
lesions.  
10. Adequate  hematologic  and end organ  function,  defined  by the following  laboratory  
results  obtained  within  14 days prior to first dose of study  drug treatment:  
o WBC  ≥ 2.5 and ≤ 15.0 × 109/L 
o ANC  ≥ 1.5 ×  109/L 
o Platelet  count  ≥ 100 ×  109/L 
o Hemoglobin  ≥ 9 g/dL without  transfusion  in the  previous  week  
o Albumin  ≥ 2.5 g/dL 
o Serum  bilirubin  ≤ 1.5  x the upper  limit  of normal  (ULN);  patients  with known  
Gilbert’s  disease  may have  a bilirubin  ≤ 3.0 ×ULN  
o INR and PTT ≤ 1.5 ×  ULN;  amylase  and lipase ≤ 1.5 ×  ULN  
o AST,  ALT,  and alkaline  phosphatase (ALP)  ≤ 3 × ULN  with the following  
exceptions:  
▪ Patients  with documented  liver metastases:  AST  and/or ALT  ≤ 5 ×ULN  
▪ Patients  with documented  liver or bone  metastases:  ALP ≤ 5×ULN  
o Creatinine clearance  ≥ 50 mL/min  
11. For women  of childbearing  potential, defined as a woman  who is post-menarcheal,  has 
not reached  a postmenopausal  state (≥ 12 continuous  months  of amenorrhea  with no 
identified  cause other  than menopause),  and has not undergone  surgical  sterilization  
(removal  of ovaries  and/or uterus) :  
o Acknowledgment that she is not currently breastfeeding and agreement  to 
remain  abstinent  (refrain  from  heterosexual  intercourse)  or agreement to  use 
contraceptive methods , as defined:  
▪ Remain abstinent; t he reliability  of sexual  abstinence  should be  
5 STUDY  ENROLLMENT  AND  WITHDRAWAL  
PROTOCOL  # 17-0466  
PI: Christopher  H. Lieu,  MD 
Version  Date:  12.30 .2021  
 
 
 
 
 
 
    
Page 28 of 106  evaluated  in relation  to the  duration  of the clinical  trial and the preferred  
and usual  lifestyle  of the patient.  Periodic abstinence (e.g.,  calendar,  
ovulation,  symptothermal,  or postovulation  methods)  and withdrawal  are 
not acceptable  methods  of contraception.  
▪ Contraceptive method s that result in a failure rate of < 1% per year 
during  the treatment  period  and for at least 180 days after the last study  
treatment.  Examples  of contraceptive  methods  with a failure  rate of < 
1% per year include bilateral  tubal  ligation,  male  sterilization,  hormonal  
contraceptives  that inhibit  ovulation,  hormone -releasing  intrauterine  
devices  and copper  intrauterine  devices.   
12. For men:  agreement  to remain  abstinent (refrain  from  heterosexual  intercourse)  or 
agreement to use contraceptive  methods , and to refrain  from  donating  sperm , as defined :  
o With female  partners  of childbearing  potential , pregnant  female partners,  or 
breastfeeding partner s men must : 
▪ Remain  abstinent ; the reliability  of sexual abstinence  should  be 
evaluated  in relation  to the duration  of the clinical  trial and the 
preferred  and usual  lifestyle  of the  patient.  Periodic  abstinence (e.g.,  
calendar,  ovulation,  symptothermal,  or postovulation  methods)  and 
withdrawal  are not acceptable  methods  of contraception ; or 
▪ Contraceptive methods; use a male condom plus partner use of a 
contraceptive method with a failure rate of <1% per year when having 
penile -vaginal intercourse with a woman of childbearing potential  who 
is not currently pregnant. Agreement must occur during  the treatment  
period  and for at least 180 days after the last dose of study  treatment. 
Men must  refrain  from  donating  sperm  during  this same period.  
 
5.2 Subject Exclusion Criteria  
 
An individual  who meets  any of the following  criteria  will be excluded  from  participation  
in this study:  
1. Cancer -related  exclusion  criteria:  
o Patients  with known  MSI-high status  or unknown  MSI status  are not 
eligible  for study  entry.  
o Patients  with known  BRAF  V600E mutations  are not eligible  for the study.  
o Surgical  procedure (surgical  resection,  wound  revision  or any other major  
surgery)  or significant traumatic  injury  within  60 days prior to enrollment,  
or anticipation  of need for major  surgical  procedure  during  the course of 
the study.  Minor  surgical  procedure  within  7 days (including  placement  of 
a vascular access  device)  of study  Cycle 1 Day 1. 
1. Study -related  biopsies  are NOT considered  surgical  
procedures  under  the exclusion  criteria  
o Untreated  CNS  metastases.  Treatment  of brain  metastases,  either by surgical  
or radiation  techniques,  must  have  been  completed  at least 4 weeks  prior  to 
initiation  of study  treatment.  
o Treatment  with any investigational  agent  or approved  therapy  within  21 
days (Cycle  1 Day  1). 
o Malignancies  other  than CRC within  3 years  prior  to Cycle  1 Day  1 with the 
PROTOCOL  # 17-0466  
PI: Christopher  H. Lieu,  MD 
Version  Date:  12.30 .2021  
 
 
 
 
 
 
    
Page 29 of 106  exception  of those  with a negligible  risk of metastasis  or death  (e.g.,  expected  
5-year overall  survival  > 90%)  treated  with expected  curative outcome (such  
as adequately  treated  carcinoma  in situ of  the cervix,  basal  or squamous  cell 
skin cancer,  localized  prostate  cancer treated  surgically  with curative  intent,  
ductal  carcinoma  in situ  treated  surgically  with curative  intent).  
o Prior  radiation  therapy  within 14 days prior  to study  Cycle 1 Day 1 and/or  
persistence  of radiation -related  adverse effects.  However,  palliative radiation  
therapy  (as long as it does not involve  target  lesions)  is permitted  on the  
study.  
o Prior  allogeneic  bone  marrow transplantation  or solid  organ  transplant  
for another  malignancy  in the  past. 
o Spinal  cord compression  not definitively  treated  with surgery  and/or radiation.  
o Uncontrolled  pleural  effusion,  pericardial  effusion,  or ascites  
requiring  recurrent  drainage  procedures.  
o Uncontrolled  tumor  related  pain.  Patients  who require  narcotic  pain 
medication  during  screening  should  be on a stable  dose regimen  prior  to 
Cycle  1 Day  1. 
2. Exclusion criteria  related  to study  medication:  
o Current  or recent  (within  10 days of study  enrollment)  use of acetylsalicylic  acid 
(> 325 mg/day),  clopidogrel  (> 75 mg/day)  or current  or recent  (within  10 days 
of first dose of bevacizumab) use of therapeutic oral or parenteral  anticoagulants  
or thrombolytic  agents  for therapeutic purpose.  Note:  The use of full-dose oral or 
parenteral  anticoagulants  is permitted  as long as the INR or aPTT  is within  
therapeutic  limits  (according  to the  medical  standard  of the enrolling  institution) 
and the patient  has been on a stable  dose of anticoagulants  for at least 2 weeks  at 
the time of Cycle  1 Day 1. Prophylactic use of anticoagulants  is allowed.  
o History  of severe allergic,  anaphylactic,  or other  hypersensitivity  reactions  to 
chimeric or humanized  antibodies  or fusion  proteins.  
o Known  hypersensitivity  or allergy  to biopharmaceuticals  produced  in Chinese  
hamster  ovary  cells,  any components  of Binimetinib,  Pembrolizumab,  or 
bevacizumab  formulations  or any premedications.  
o Prior  treatment  with CD137  agonists  or immune  checkpoint blockade  therapies,  
anti-PD-1, anti-PD L1, anti-PD-L2 or MAPK  pathway  inhibitors  (eg; BRAF,  
MEK,  ERK  inhibitors).  
o Has a diagnosis  of immunodeficiency  or is receiving  systemic  steroid  therapy  
or any other form  of immunosuppressive  therapy  within  7 days prior  to 
randomization.  
 
3. Exclusion criteria  based on autoimmune  conditions:  
o History  of autoimmune disease  including  but not  limited  to myasthenia  gravis,  
myositis,  autoimmune  hepatitis,  systemic  lupus  erythematosus,  rheumatoid  
arthritis,  inflammatory  bowel disease,  vascular  thrombosis  associated  with 
antiphospholipid  syndrome,  Wegener’s  granulomatosis,  Sjögren’s  syndrome,  
Guillain -Barre syndrome,  multiple  sclerosis,  vasculitis,  or glomerulonephritis.  
o History  of non-infectious  pneumonitis /interstitial lung disease  that required  
steroids  or has current  pneumonitis /interstitial lung disease . 
o Has an autoimmune  disease that  has required  systemic treatment  in the past 2 
years  with use of disease modifying  agents,  corticosteroids,  or 
immunosuppressive  drugs.  Replacement  therapy  (eg; thyroxine,  insulin,  
PROTOCOL  # 17-0466  
PI: Christopher  H. Lieu,  MD 
Version  Date:  12.30 .2021  
 
 
 
 
 
 
    
Page 30 of 106  physiologic corticosteroid  replacement therapy  for adrenal  or pituitary  
insufficiency)  is not considered  a form  of systemic  treatment.  
4. Exclusion criteria  based on organ  function  or medical history:  
o History  of clinically  significant  cardiac  or pulmonary  dysfunction  including  the 
following:  
1. Inadequately  controlled  hypertension  (that is defined  as systolic  
blood pressure  > 140 mmHg  and/or  diastolic  blood  pressure > 90 
mmHg  that is treated  or untreated).  
2. History  of myocardial  infarction  within  6 months  prior  to first 
dose of study  drug in Cycle.  
3. Prior history  of hypertensive crisis  or hypertensive  
encephalopathy.  
4. History  of idiopathic  pulmonary  fibrosis,  organizing  pneumonia  
(e.g.,  bronchiolitis  obliterans),  drug-induced  pneumonitis,  
idiopathic  pneumonitis,  evidence  of active  pneumonitis  on 
screening  chest  CT scan or non-infectious  pneumonitis  requiring  
steroids.  
o Significant  vascular  disease (e.g.,  aortic  aneurysm  requiring  surgical  repair  or 
recent  arterial  thrombosis)  within  6 months of  Cycle 1 Day  1. 
o History  of stroke or transient  ischemic  attack  within  6 months  prior  to Cycle  1 
Day 1. 
o Serious  non-healing  wound,  active ulcer or untreated  bone  fracture.  
o History  of abdominal  fistula  or gastrointestinal perforation  within  6 months  
prior to Cycle  1 Day 1. 
o History  of hemoptysis  (≥one teaspoon  of bright  red blood per episode),  or any 
other  serious  hemorrhage  or at risk of bleeding  (gastrointestinal  history  of 
bleeds,  gastrointestinal  ulcers,  etc.).  INR>  1.5 and aPTT  > 1.5 ×  ULN  within  14 
days prior to Cycle  1 Day  1. History  or evidence of inherited  bleeding  diathesis  
or significant  coagulopa thy at risk of bleeding.  
o Life expectancy  of < 12 weeks.  
o Any previous venous  thromboembolism≥  Grade  3. 
o Proteinuria  at screening  as demonstrated  by urine dipstick  ≥ 2+ and 24-hour.  
proteinuria > 1.0 g. 
o Left ventricular  ejection  fraction  (LVEF)  below  institutional  lower  limit  of 
normal.  
o Uncontrolled  serious  medical  or psychiatric  illness.  
o Pregnant  or lactating,  or intending  to become pregnant  during  the study.  
Women  who are not post-menopausal  (≥ 12 continuous  months  of amenorrhea  
with no identified  cause  other  than menopause)  or surgically  sterile  must  have a 
negative serum  pregnancy  test within  14 days prior  to Cycle  1 Day 1. 
5. Ocular  exclusion  criteria:  
o History  or evidence  of retinal  pathology  on ophthalmologic  examination  that is 
considered  a risk factor  for neurosensory  retinal  detachment/central serous  
chorioretinopathy,  retinal  vein occlusion  or neovascular  macular  degeneration.  
o Patients  will be excluded  if they have  the following  risk factors  for retinal  vein 
occlusion:  Uncontr olled  glaucoma with intraocular  pressure  ≥21 mmHg.  Serum  
cholesterol  ≥ Grade  2. Hypertriglyceridemia  ≥ Grade  2. Hyperglycemia  (fasting) 
≥ Grade  2 
PROTOCOL  # 17-0466  
PI: Christopher  H. Lieu,  MD 
Version  Date:  12.30 .2021  
 
 
 
 
 
 
    
Page 31 of 106  6. Exclusion criteria  based on infectious  diseases:  
o Active  infection  requiring  IV antibiotics  at screening.  
o Patients  with active  hepatitis  B (chronic or acute;  defined  as having  a positive  
hepatitis  B surface antigen  [HBsAg]  test at screening).  Patients  with past 
hepatitis  B virus  (HBV)  infection  or resolved  HBV infection  (defined  as the 
presence of hepatitis  B core antibody  [anti-HBc]  and absence  of HBsAg)  are 
eligible.  HBV DNA  test must be  performed  in these patients  prior  to Cycle  1 
Day 1. 
o Patients  with active  hepatitis  C. Patients  positive  for hepatitis  C virus  (HCV)  
antibody  are eligible  only if polymerase  chain  reaction  (PCR)  is negative  for 
HCV  RNA.  
o Known  HIV infection.  
o Influenza  vaccination  should  be given  during  influenza season.  Patients  must  
not receive  live, attenuated  influenza  vaccine  (e.g.,  FluMist®)  within  4 weeks  
prior to Cycle  1 Day 1 or at any time during  the study  and for at least 5 months  
after the last dose of study  drug.  
 
5.3 Subject Withdrawal or Termination  
 
 
Subjects  are free to withdraw  from  participation  in the study  at any time upon  request.  In 
addition,  the investigator  has the right  to withdraw  a patient  from  the study  at any time.  Reasons  
for withdrawal  from  the study  may include,  but are not limited  to, the  following:  
 
o Patient  withdrawal  of consent  at any time 
o Any medical  condition  that the Sponsor -Investigator  determines  may jeopardize  
the patient’s  safety  if he or she continues  in the  study.  
o Sponsor -Investigator  determines  it is in the  best interest  of the patient  
o Patient  non-compliance  
Patients  must  discontinue  study  treatment  if they experience  any of the following:  
o Disease  progression  (Patients  are allowed  to receive  study  treatment  beyond  
disease  progression  if certain  conditions  are met (Please  see Section 6.1.1)).  
o Symptomatic  deterioration  attributed  to disease  progression  as determined  by the 
investigator  after integrated  assessment  of radiographic  data,  biopsy  results,  and clinical  
status  
o Intolerable  toxicity  related to any  study  drug 
o Any medical  condition  that may jeopardize  the patient’s  safety  if he or she 
continues  study  treatment  
o Use of another non−protocol anti-cancer  therapy  
o Pregnancy  
 
Patients  must provide written  consent  to acknowledge  deferring  any standard  treatment  options  
that may exist  in favor  of continuing  study  treatment  at the time of initial  progression  (section  
7.3.1).  
 
5.3.1  REASONS  FOR  WITHDRAWAL  OR TERMINATION  
PROTOCOL  # 17-0466  
PI: Christopher  H. Lieu,  MD 
Version  Date:  12.30 .2021  
 
 
 
 
 
 
    
Page 32 of 106   
 
Every  effort  should be  made to obtain  information  on patients  who withdraw  from  the study.  
The primary  reason  for withdrawal  from the study  or study  drug discontinuation should be  
documented  on the appropriate eCRF.  However,  patients  will not be  followed  for any reason  
after consent  has been  withdrawn.  Patients  enrolled  in Stage  1 (safety  run-in) who withdraw  
consent  before completing  the first cycle for reasons  other  than adverse  events  will be 
replaced.  Patients  who withdraw  from Stage  2 of the study  will not be replaced.  
 
5.4 Premature Termination or Suspension of Study (Study Stopping Rules)  
 
The Sponsor -Investigator  has the right to terminate  this study  at any time.  Reasons  for 
terminating  the study  may include,  but are not limited  to, the following:  
o The incidence  or severity  of adverse  events  in this or other  studies  indicates  a 
potential  health  hazard  to patients.  
o Patient  enrollment  is unsatisfactory.  
 
The Sponsor -Investigator  will notify  Merck  and Pfizer  if they decide  to discontinue  the 
study.  Reasons  for discontinuing  the study  may include,  but are not limited  to, the  following:  
o Excessively  slow  recruitment  
o Poor  protocol  adherence  
o Inaccurate  or incomplete  data recording  
o Non-compliance  with the International  Conference  on Harmonisation  (ICH)  
guideline  for Good  Clinical Practice  
o No study  activity  (i.e., all patients  have completed  the study  and all obligations  
have  been  fulfilled)  
 
 
 
 
6.1 Study Agent(s) and Control Description  
 
The study  agents  for this study  are pembrolizumab,  binimetinib  and bevacizumab.  
Pembrolizumab  and binimetinib  packaging  will be overseen  by MERCK and Pfizer  clinical  
trial supplies  department  respectively  and will bear a label  with identification  required  by 
local  law. The packaging  and labeling  of the study  drugs  will be in accordance with  the 
manufacturer’s  standards  and local  regulations.  Local  packaging  and labeling  requirements  
may differ in some  countries.  
 
Upon  delivery  of the investigational  products  to the site,  site personnel  should  check  for 
damage and verify  proper  identity,  quality,  integrity  of seals and temperature  conditions.  Site 
personnel  should report  any deviations  or product  complaints  to the  study  monitor  and/or  
MERCK/ Pfizer  (depending  on drug) upon discovery.  
 
Pembrolizumab,  binimetinib  and bevacizumab  will be stored  at the clinical  site under the 
required  storage conditions  as indicated  on the  study  drug labels.  
 
5.3.2   HANDLING  OF SUBJECT  WITHDRAWALS  OR TERMINATION  
6 STUDY AGENTS 
PROTOCOL  # 17-0466  
PI: Christopher  H. Lieu,  MD 
Version  Date:  12.30 .2021  
 
 
 
 
 
 
    
Page 33 of 106   
 
A C Q U I S ITION 
Merck  & Co, Inc. will provide Pembrolizumab  from  commercial  supply.  
 
F ORM  U L ATI ON, APP  E ARA  NCE,  P A CKA  G I NG, A ND LAB  E LIN G 
Two drug product  (DP)  dosage  forms  are available  for pembrolizumab:  a white  to off-white  
lyophilized  powder,  50 mg/vial,  and a liquid,  100 mg/vial,  both in Type  I glass  vials 
intended  for single use only.  
 
KEYTRUDA  for injection  is a sterile,  preservative -free, white  to off-white  lyophilized  
powder  in single -use vials.  Each  vial is reconstituted  and diluted  for intravenous  infusion.  
Each  2 mL of reconstituted  solution  contains  50 mg of pembrolizumab  and is formulated  in 
histidine  (3.1 mg), polysorbate  80 (0.4 mg), and sucrose  (140 mg). May contain  
hydrochloric acid/sodium  hydroxide  to adjust  pH to 5.5. 
 
KEYTRUDA  injection  is a sterile,  preservative -free, clear  to slightly  opalescent,  colorless  
to slightly  yellow  solution  that requires  dilution  for intravenous  infusion.  Each  vial contains  
100 mg of pembrolizumab  in 4 mL of solution.  Each  1 mL of solution  contains  25 mg of 
pembrolizumab  and is formulated  in: L-histidine  (1.55  mg), polysorbate  80 (0.2 mg), 
sucrose  (70 mg), and Water for  Injection,  USP.  
 
P ROD  UCT  STO  RAG  E A N D STA  B I LIT Y 
KEYTRUDA  for injection  (lyophilized  powder):  carton  containing  one 50 mg single -use 
vial (NDC  00063029 -02). 
 
Store  vials under  refrigeration  at 2°C to 8°C (36°F  to 46°F).  
 
KEYTRUDA  injection  (solution):  carton  containing  one 100 mg/4  mL (25 mg/mL),  single - 
use vial (NDC  0006 -3026 -02) 
 
Store  vials under  refrigeration  at 2°C to 8°C (36°F  to 46°F)  in original  carton  to protect  from  
light.  Do not freeze.  Do not shake.  
 
Store  the reconstituted  and diluted  solution  from the KEYTRUDA  50 mg  vial either:  
 
At room  temperature  for no more  than 6 hours  from  the time of reconstitution.  This includes  
room  temperature  storage  of reconstituted  vials,  storage  of the infusion  solution  in the IV 
bag, and the duration  of infusion.  
 
Under  refrigeration  at 2°C to 8°C (36°F  to 46°F)  for no more  than 96 hours  from  the time 
of reconstitution.  If refrigerated,  allow  the diluted  solution  to come  to room  temperature  
prior to administration.   
 
The solution must be discarded after 6 hours at room temperature or 96 hours under 
refrigeration.  
 
Store  the diluted  solution  from  the KEYTRUDA  100 mg/4  mL vial either:  
6.1.1   PEMBROLIZUMAB  (KEYTRUDA)  
PROTOCOL  # 17-0466  
PI: Christopher  H. Lieu,  MD 
Version  Date:  12.30 .2021  
 
 
 
 
 
 
    
Page 34 of 106   
At room  temperature  for no more  than 6 hours  from  the time of dilution.  This includes  room  
temperature  storage  of the infusion  solution in  the IV bag, and the duration  of infusion.  
 
Under  refrigeration  at 2°C to 8°C (36°F  to 46°F)  for no more  than 96 hours  from  the time 
of dilution.  If refrigerated,  allow  the diluted  solution  to come  to room  temperature  prior  to 
administration.  
 
The solution must be discarded after 6 hours at room temperature or 96 hours under 
refrigeration.  
 
Do not freeze.  
 
P R E PA RAT  I ON 
Reconstitution  of KEYTRUDA  for Injection  (Lyophilized  Powder)  
Add 2.3 mL of Sterile  Water  for Injection,  USP by injecting  the water  along  the walls  of the 
vial and not directly  on the  lyophilized  powder (resulting  concentration  25 mg/mL).  
Slowly  swirl  the vial. Allow up to 5  minutes  for the bubbles  to clear.  Do not shake  the vial. 
 
Preparation for  Intravenous Infusion  
Visually  inspect  the solution  for particulate  matter  and discoloration  prior  to administration.  
The solution  is clear  to slightly  opalescent,  colorless  to slightly  yellow.  Discard  the vial if 
visible  particles  are observed.  
 
Dilute   KEYTRUDA   injection   (solution)   or  reconstituted   lyophilized   powder   prior   to 
intravenous  administration.  
 
Withdraw  the required  volume  from  the vial(s)  of KEYTRUDA  and transfer  into an 
intravenous  (IV) bag containing  0.9%  Sodium  Chloride  Injection,  USP or 5% Dextrose  
Injection,  USP.  Mix diluted  solution  by gentle  inversion.  The final concentration  of the 
diluted  solution  should be between  1 mg/mL  to 10  mg/mL.  
 
Discard  any unused  portion left in the  vial. 
 
DOS  I N G A N D A DMI  N IS T R ATI ON 
Dosing:  
Patients  will be treated  on a 21-day cycle  
Pembrolizumab  200mg IV Day 1 
 
Administration:  
Administer infusion  solution  intravenously  over 30 minutes  ± 10 minutes  through  an 
intravenous  line containing  a sterile,  non-pyrogenic,  low-protein  binding  0.2 micron  to 5 
micron  in-line or add-on filter.  
 
Do not co-administer  other drugs  through  the same infusion  line. 
 
PROTOCOL  # 17-0466  
PI: Christopher  H. Lieu,  MD 
Version  Date:  12.30 .2021  
 
 
 
 
 
 
    
Page 35 of 106  R O UTE  O F A D M I N I STR  AT ION  
Intravenous  administration  
 
STA  RTI N G D O SE A N D D O SE E SCA  LAT  I O N SCH  E D U LE 
Not applicable.  
 
D O SE A D J U STM  E N T S/M  O D I F ICAT  I O NS/  D E L A Y S 
See Appendix  I 
 
Any overdose  or incorrect  administration  of study  drug should be  noted  on the Study  Drug  
Administration  section  of the eCRF.  Adverse events  associated  with an overdose or 
incorrect  administration  of study  drug should be  recorded  on the Adverse Event  section of 
the eCRF.  
 
Dosing  of study  treatment beyond  RECIST  v1.1 defined  disease progression  is allowed  for 
patients  on all treatment  cohorts.  Patients  must  meet  all of the following  criteria to be  
allowed  to receive study  treatment  beyond  disease  progression:  
o Evidence  of clinical  benefit  as assessed  by the investigator  
o Absence of symptoms  and signs  indicating  unequivocal  progression  of disease.  
Patients  may continue to receive  treatment  beyond  disease  progression  in the 
absence  of clinical  signs  or symptoms  of progression  despite  a rising  CEA  level.  
o No decline in ECOG  performance  status  that can be attributed  to disease  
progression  
o Absence of tumor  progressio n at critical  anatomical  sites (e.g.,  leptomeningeal  
disease)  that cannot  be managed  by protocol allowed  medical  interventions.  
o Patients  must  provide written  consent  to acknowledge  deferring  these  treatment  
options in favor of continuing  study  treatment  at the time of RECIST  v1.1-defined  
disease  progression.  
o Approval  by the study  Medical  Monitor  
 
If the subsequent  scan continues to show  progression,  all therapy  will be discontinued and 
the patient  will be taken  off study.  
 
D URAT  I O N O F T H E RAP  Y 
Patients  in the  safety  run-in phase and in the  dose expansion phase will continue  to receive  
study  therapy  until disease progression  according  to RECIST  v1.1 (section  5.4.1),  
unacceptable  toxicity,  death, patient  or physician  decision  to withdraw,  pregnancy,  or the 
maximum  upper  limit  of pembrolizumab  therapy  (35 cycles),  whichever occurs  first. 
 
T R A CKI NG O F D O S E 
Not applicable  
 
 
 
 
A C Q U ISITIO  N + 
Pfizer  
6.1.2   BINIMETINIB  
PROTOCOL  # 17-0466  
PI: Christopher  H. Lieu,  MD 
Version  Date:  12.30 .2021  
 
 
 
 
 
 
    
Page 36 of 106   
F ORM  U L ATI ON, APP  E ARA  NCE,  P A CKA  G I NG, A ND LAB  E LIN G 
Binimetinib  drug product  is supplied  as film-coated  tablets  in a dosage  strength  of 15 mg. 
The film-coated  tablets  consist  of binimetinib,  lactose  monohydrate,  microcrystalline  
cellulose,  colloidal  silicon  dioxide,  croscarmellose  sodium,  magnesium  stearate  and a 
commercial  film coating.  The tablets  are yellow  to dark yellow  and capsule  shaped.  
 
P ROD  UCT  STO  RAG  E A N D STA B ILITY  
Binimetinib  film-coated  tablets  should not be  stored  above  25°C and should be  protected  
from  light.  Tablets  are packaged  in plastic  bottles  acceptable  for pharmaceutical  use. 
 
P R E PA RAT  I ON 
Not applicable.  
 
DOS  I N G A N D A DMI  N IS T R ATI ON 
Binimetinib  45mg  PO BID continuous  without  regard  to food,  taken  with water.  
 
R O UTE  O F A D M I N I STR  AT ION  
Oral 
 
STA  RTI N G D O SE A N D D O SE E SCA  LAT  I O N SCH  E D U LE 
Not applicable.  
 
D O SE A D J U STM  E N T S/M  O D I F ICAT  I O NS/  D E L A Y S 
See Appendix  I 
 
Dose Level  -1 = 30mg  PO BID continuous  
Dose Level  -2 = 15mg  PO BID continuous  
Dose Level -3 = 15mg PO daily  
 
Binimetinib may also be dose reduced per discretion of treating investigator.  
 
D URAT  I O N O F T H E RAP  Y 
Patients  in the  safety  run-in phase and in the  dose expansion phase will continue  to receive  
study  therapy  until disease progression  according  to RECIST  v1.1, unacceptable  toxicity,  
death,  patient  or physician  decision  to withdraw,  or pregnancy,  whichever occurs  first. 
 
T R A CKI NG O F D O S E 
Patient  will be given  a drug diary  to monitor  and record  drug compliance.  
 
 
 
 
A C Q U I S ITION 
Standard  of care medication  obtained  through  normal  commercial  acquisition  processes.  
 
6.1.3   BEVACIZUMAB  (BEVACIZUMAB -AWWB  ALSO  ALLOWED)  
PROTOCOL  # 17-0466  
PI: Christopher  H. Lieu,  MD 
Version  Date:  12.30 .2021  
 
 
 
 
 
 
    
Page 37 of 106  F ORM  U L ATI ON, APP  E ARA  NCE,  P A CKA  G I NG, A ND LAB  E LIN G 
• 100 mg  per 4 mL single -use vial 
• 400 mg  per 16 mL single -use vial 
 
P ROD  UCT  STO  RAG  E A N D STA  B I LIT Y 
Bevacizumab  vials [100 mg (NDC  50242 -060-01) and 400 mg (NDC  50242 -061-01)] are 
stable  at 2−8°C  (36−46°F).  Bevacizumab  vials  should  be protected  from  light.  Do not freeze  
or shake.  Diluted  Bevacizumab  solutions  may be stored  at 2−8°C  (36−46°F)  for up to 8 
hours.  Store  in the original  carton  until time of use. No incompatibilities  between  
Bevacizumab  and polyvinylchloride  or polyolefin  bags have been  observed.  
 
P R E PA RAT  I ON 
Use appropriate  aseptic technique.  Parenteral  drug products  should be  inspected  visually  
for particulate  matter  and discoloration  prior  to administration,  whenever  solution  and 
container permit.  
 
Withdraw necessary  amount  of Bevacizumab  and dilute  in a total volume  of 100 mL of 
0.9%  Sodium  Chloride  Injection,  USP.  Discard  any unused  portion  left in a vial, as the 
product  contains  no preservatives.  
 
DO NOT  ADMINISTER  OR MIX WITH DEXTROSE  SOLUTION.  
 
DOS  I N G A N D A DMI  N IS T R ATI ON 
Bevacizumab  7.5mg/kg  Day 1 (bevacizumab -awwb  allowed)  to be given over 30 minutes ± 10 
minutes intravenously.  
 
R O UTE  O F A D M I N I STR  AT ION  
Intravenous  infusion  
 
STA  RTI N G D O SE A N D D O SE E SCA  LAT  I O N SCH  E D U LE 
Not applicable.  
 
D O SE A D J U STM  E N T S/M  O D I F ICAT  I O NS/  D E L A Y S 
See Appendix  I 
There are no recommended  dose reductions.  
Discontinue  bevacizumab  for: 
• Gastrointestinal  perforations  (gastrointestinal  perforations,  fistula  formation  in the 
gastrointestinal  tract,  intra-abdominal  abscess),  fistula  formation  involving  an 
internal  organ  
• Wound  dehiscence  and wound  healing  complications  requiring  medical  intervention  
• Serious  hemorrhage  (i.e., requiring  medical intervention)  
• Severe  arterial  thromboembolic events  
• Life-threatening  (Grade  4) venous  thromboembolic  events,  including  pulmonary  
PROTOCOL  # 17-0466  
PI: Christopher  H. Lieu,  MD 
Version  Date:  12.30 .2021  
 
 
 
 
 
 
    
Page 38 of 106  embolism  
• Hypertensive crisis  or hypertensive  encephalopathy  
• Posterior  Reversible  Encephalopathy  Syndrome (PRES)  
• Nephrotic  syndrome  
 
Temporarily  suspend  bevacizumab  for: 
• At least 4 weeks  prior to elective  surgery  
• Severe hypertension not controlled with medical management  
• Moderate  to severe proteinuria  
• Severe  infusion  reactions  
 
D URAT  I O N O F T H E RAP  Y 
Patients  in the  safety  run-in phase and in the  dose expansion phase will continue  to 
receive  study  therapy  until disease progression  according  to RECIST  v1.1, unacceptable  
toxicity,  death,  patient  or physician  decision  to withdraw,  or pregnancy,  whichever 
occurs  first. A rising  carcinoembryonic  antigen  (CEA)  level  alone is not considered  
disease progression.  Patients  are allowed  to receive  study  treatment  beyond  disease 
progression  if certain  condition s are met. 
 
T R A CKI NG O F D O S E 
Not applicable.  
 
6.2 Study Agent Accountability Procedures  
 
The study  agent  or Investigational  Medicinal Product  (IMPs)  required  for the completion  of 
this study  will be provided  by MERCK /Pfizer  where required  by local  health  authority  
regulations.  The study  site will acknowledge  receipt  of IMPs.  Any damaged  shipments  will 
be replaced.  
 
The commercial  formulation  of bevacizumab  (Avastin) will be used as per standard  of 
care and will not be  provided  by Merck  or Pfizer . 
 
IMPs  will be disposed  at the study  site according  to the study  site’s  institutional standard  
operating  procedure.  
 
Accurate  records  of all IMPs  received  at, dispensed  from,  returned  to, and disposed  of 
by the study  site should be recorded  on the  Drug  Inventory  Log. 
 
 
 
 
7.1 Study Procedures/Evaluations  
 
Please  see Table 1 for the schedule of activities  to be performed  during  the study.  
 
7.2 Laboratory Procedures/Evaluations  
 
 
7 STUDY  PROCEDURES  AND  SCHEDULE  
PROTOCOL  # 17-0466  
PI: Christopher  H. Lieu,  MD 
Version  Date:  12.30 .2021  
 
 
 
 
 
 
    
Page 39 of 106   
Screening  
o Hematology  (CBC,  hemoglobin,  hematocrit,  WBC count  with differential  
[neutrophils,  eosinophils,  lymphocytes],  and platelet  count)  
o Serum  chemistries  (non-fasting  glucose,  BUN or urea,  creatinine,  sodium,  
potassium,  magnesium,  calcium,  phosphorus,  total bilirubin,  ALT,  AST,  ALP,  
CPK,  lipase,  amylase,  and albumin)  
o Coagulation  (INR  and aPTT)  
o Serum  pregnancy  test for women  of childbearing  potential,  including  women  who 
have  had a tubal  ligation.  
o Thyroid  function  testing  (thyroid -stimulating  hormone [TSH],  total T3, free T4) 
o HBV serology:  HBsAg,  Hepatitis  B surface antibody  (anti-HBs),  and anti-HBc 
o HBV DNA should be  obtained  prior  to enrollment  if patient  has a negative serology  
for HbsAg  and a positive serology  for anti-HBcAb.  
o HCV  serology:  HCV antibody  (anti-HCV)  
o HCV  RNA should be  obtained  prior  to enrollment  if patient  tests positive for anti- 
HCV  
o Urinalysis:  dipstick,  with 24-hour urine collection  conducted  in the  event  of 
proteinuria ≥ + 2 detected  by dipstick  test 
 
On Study Treatment  
o Hematology  (CBC,  hemoglobin,  hematocrit,  WBC count  with differential  [neutrophils,  
eosinophils,  lymphocytes],  and platelet  count)  
o Serum  chemistries  (non-fasting  glucose,  BUN or urea,  creatinine,  sodium,  potassium,  
magnesium,  calcium,  phosphorus,  total bilirubin,  ALT,  AST,  ALP,  CPK,  lipase,  
amylase,  and albumin)  
o CEA  
o Thyroid  function  testing  (TSH,  total T3, free T4)  
o Coagulation  (INR  and aPTT)  
o Urinalysis:  dipstick,  with 24-hour urine collection  conducted  in the  event  of 
proteinuria ≥ + 2 detected  by dipstick  test 
 
 
The University  of Colorado Developmental Therapeutics/Pitts  laboratory  will coordinate  the 
sample  collection  of tissue  and blood samples  for research - related  testing  at central 
laboratories.  Instruction  manuals  and supply  kits will be provided  for all central  laboratory  
assessments  including:  
• Blood samples  will be obtained  for biomarker  evaluation  (including  but 
not limited  to biomarkers  that are related  to CRC or tumor  immune  
biology)  from  all eligible  patients  in the expansion cohorts according  to 
the schedule.  Blood  sample  preparation  (to be performed  by the Pitts 
Laboratory)  is as follows:  
o Collect  whole  blood  in K2EDTA  and CPT  tubes. 
o Invert  8-10 times,  let sit at room  temperature  for 30 -60 
minutes.  
o Load  the K2EDTA specimen  tubes  in the centrifuge.  
o Centrifuge  for 10 minutes  at 4°C - 10°C at 1,600g  with brake  
7.2.1   CLINICAL  LABORATORY  EVALUATIONS  (RESEARCH  PROCEDURES)  
PROTOCOL  # 17-0466  
PI: Christopher  H. Lieu,  MD 
Version  Date:  12.30 .2021  
 
 
 
 
 
 
    
Page 40 of 106  position on.  
o Ensure the centrifuge  is balanced.  
o Spin the  specimen  tubes.  
o Remove  plasma  taking  care to not disturb  the white cellular  
interface ("buffy  coat"  layer)  
o Transfer  supernatant  to a new centrifuge  tube and store at -80 
o Spin the CPT tube at room temp at 1600g with brake off.  Remove 
plasma, taking care to not disturb the buffy coat.   
o Aspirate the plasma layer and transfer to a separate tube, label and 
store in -80 
o Aspirate  buffy  coat and transfer to an appropriately  labeled  1.5mL  
microfuge tube.  (Note,  some  contamination  of the buffy  coat by 
residual  plasma  or erythrocytes  is unavoidable  and will not 
interfere  with later steps.)  
o Wash with PBS and perform T -cell isolation  
o Perform  the above aspirations  steps  for each specimen.  
 
 
 
 
Tumor  Tissue Samples  
A University  of Colorado  Cancer  Center laboratory  (The Developmental Therapeutics/Pitts  
Laboratory  at the University  of Colorado)  will coordinate  the sample  collection  of tissue  
samples  for research  related  testing  at the University  of Colorado  or at Merck/ Pfizer . 
Instruction  manuals  and supply  kits will be provided  for all central  laboratory  assessments.  
 
 
 
Fresh  Tumor  Sample  should  be collected according to Section 4.1; Stage 2: Dose 
Expansion; Design  and collected  as follows:  
• The tumor sample   must be  obtained  once  patient  has been  enrolled  in the  study.  
• Fine-needle  aspiration,  brushing,  cell pellet  from  pleural  effusion,  and lavage  samples  
are not acceptable.  
• For core needle biopsy  specimens,  at least four cores  should be  submitted  for 
evaluation  at baseline, and at least two cores  should be  submitted  for 
evaluation on -treatment . 
 
Safely  biopsied  disease is defined  as: 
• cutaneous  lesions  (without  evidence  of active infection)  
• peripherally  accessible  lymph  nodes  (cervical,  axillary,  inguinal,  extremities)  
• liver metastases  (not immediately  adjacent  to major  vessels)  
• lung metastases  easily  accessible by percutaneous  biopsy  or endobronchial  ultrasound  
• rectal  lesions  
 
 
 
7.2.2  OTHER  ASSAYS  OR PROCEDURES  (RESEARCH)  
7.2.3   SPECIMEN  PREPARATION,  HANDLING,  AND  STORAGE  
PROTOCOL  # 17-0466  
PI: Christopher  H. Lieu,  MD 
Version  Date:  12.30 .2021  
 
 
 
 
 
 
    
Page 41 of 106   
Lesions  not allowed  for biopsy  include  brain,  mediastinum,  pelvis,  or any lesion  deemed  by 
the patient’s  primary  oncologist,  study  investigator,  or radiologist  to represent  greater  risk to 
the subject.  
 
Tumor  tissues  will be assessed  for mismatch  repair status  at baseline,  PD-L1 expression,  and 
phosphorylated  ERK  expression  in pre- and post-treatment specimens.  In addition, mRNA  
expression  of a panel  of immune markers  will also be assessed  in both pre- and post-treatment  
tissues.  
 
Tissue  acquisition:  Four  core biopsies  using  an 18-22 gauge  needle  should  yield sufficient  
material  for analysis  at baseline, and two core biopsies  should  yield sufficient  material  for 
analysis on -treatment . All of the tissue  should be  processed  as follows:  
 
Baseline  Biopsy : 
• Core biopsy  #1 and #2: immediately  placed  into a provided  specimen  cup with 
RPMI.  The container  should  immediately  be brought  over to the  lab for injection  
into mice.  This process  has been  approved  by the Institutional  Animal  Research  
Committee.  
 
• Core biopsy  #3 and #4: immediately  submerged  in 10% Neutral  Buffered  Formalin  
in a container  labeled  “#2: Formalin” and placed  into refrigerator (4°)  or stored  in 
ice. 
 
On-Treatment  Biopsy : 
• Core biopsy  #1 and #2: immediately  submerged  in 10% Neutral  Buffered  Formalin  
in a container  labeled  “#2: Formalin” and placed  into refrigerator (4°)  or stored  in 
ice. 
All samples  should be  labeled  with date,  protocol  number,  and subject identification  number.  
 
 
All samples  must  be shipped  on ice and delivered  within  24 hours  from  the time of biopsy  to: 
 
PROGRAM  FOR EXPERIMENTAL TARGETED  THERAPEUTICS LABORATORY  
 
To the address  listed in the lab manual.  
 
7.3 Study Schedule  
 
Please  see scheduling  table for  details.  
 
 
Written  informed  consent  must be  obtained  before performing  any study -related  procedures.  
Demographic  data,  medical  and CRC  history,  baseline  disease characteristics,  vital signs,  
weight,  height,  ECOG  performance status,  complete physical  examination,  list of  
7.2.4   SPECIMEN  SHIPMENT  
7.3.1   SCREENING  
PROTOCOL  # 17-0466  
PI: Christopher  H. Lieu,  MD 
Version  Date:  12.30 .2021  
 
 
 
 
 
 
    
Page 42 of 106   
medications,  ECHO  or MUGA,  12-lead ECG,  hematology,  blood chemistry,  
HIV/HBV/HCV  serologies,  coagulation  tests,  ophthalmic  exams,  urine  dipstick,  pregnancy  
test, TFTs,  and tumor baseline  assessment must be  completed  as part of the screening  
process.  
 
All screening  evaluations  must  be completed  and reviewed  to confirm that all eligibility  
criteria are  met prior to enrollment.  The investigator  will maintain  a screening  log to record  
details  of all patients  screened  irrespective  of eligibility.  
 
Demographic Data and Medical  History  
Includes  age, sex, self-reported  ethnicity,  detailed  description  of history  of cancer,  past 
medical  and surgical  history,  list of  medications  including  prescription,  OTC,  herbal,  
homeopathic,  nutritional drugs,  performance status,  social  history  including  alcohol,  tobacco  
and recreational  drug use, family  history  especially  of malignancy  and reproductive  history.  
 
History  of cancer should include stage,  date of first diagnosis,  site of primary  disease,  
previous  biopsies  particularly  date and  site of biopsy,  location  of metastases,  previous  
treatments  administered  including  all surgeries  and radiation  therapy,  previous clinical  trials  
especially  details  of any previous  use of immunotherapies,  ECOG performance status,  MSI 
status,  and mutational  testing  particularly  RAS  and BRAF.  
 
Any pre-existing  symptoms  must  be graded  and recorded  as per NCI-CTCAE  v4.03.  
 
Physical Examination  
A complete  physical  examination  should be  performed.  Any physical  exam  findings  must be  
graded  and recorded  as per NCI-CTCAE  v4.03.  
 
Investigations  
All of the above  listed  investigations  must  be completed,  reviewed  and recorded  as part of the 
screening  process.  Any pre -existing  baseline  abnormality  must  be graded  and recorded  as per 
NCI-CTCAE  v4.03.  
 
Blood/Plasma  Samples  
Site staff will collect  the blood samples  for standard  blood panels  (CBC/CMP) per  standard  of 
care.  
 
Left Ventricular  Ejection Fraction  
Must be  performed  with an echocardiogram  or MUGA  at screening.  It is strongly  encouraged  
that the same  laboratory  and operator  perform  the ECHO/MUGA  scans  for each individual  
patient.  All post - screening ECHO/MUGA scans will be in reference to a subject’s Cycle 1 Day 
1, regardless of treatment delays. Page 46 outlines specific dates for study -related ECHOs.  
 
 
 
 
 
PROTOCOL  # 17-0466  
PI: Christopher  H. Lieu,  MD 
Version  Date:  12.30 .2021  
 
 
 
 
 
 
    
Page 43 of 106  Ophthalmologic  Examination  
All patients  will require  regular  ophthalmologic  examinations  at screening  and during  study  
conduct.  Ophthalmologic  examination  must be  performed  at the time-points  listed below, 
regardless of treatment delays. All ophthalmologic exams post -screening are in reference to a 
subject’s Cycle 1 Day 1:  
o Screening  
o Cycle  2 Day 1 ± 2 week s 
o Day 1 of Cycles  5, 8, and 11 (every  three  treatment  cycles)  ± 2 weeks  
o Day 1 of Cycles  15, 19,  and 23 (every  four treatment  cycles)  ± 2 weeks  
o Day 1 of Cycles  29, 35, 41, 47, etc. (every  six treatment  cycles)  ± 2 weeks  
o End-of-study -treatment  visit  
The objective  of baseline ophthalmologic examination  is to evaluate  for evidence  of retinal  
pathology  that may be a risk factor for central  serous  retinopathy  or retinal  vein occlusion.  
 
Ophthalmologic  examination  must be  performed  by an ophthalmologist.  Risk factors  for 
retinal  vein occlusion  include uncontrolled  serum  cholesterol,  hypertriglyceridemia,  
hyperglycemia,  hypertension,  and glaucoma.  Patients  with such conditions  will be excluded  
from  the study  as detailed  in the  inclusion/exclusion  criteria.  
 
Baseline and  serial  surveillance  ophthalmologic  examination  will include visual  acuity  testing,  
intraocular  pressure  measurements  by tonometry,  slit-lamp ophthalmoscopy,  indirect  
ophthalmoscopy,  and optical  coherence  tomography  (spectral - or time-domain).  Spectral  domain  
optical  coherence  tomography,  if not available,  may be substituted  with time-domain  optical  
coherence  tomography.  
 
Tumor  and Response  Evaluations  
Baseline  tumor  assessments  should be  performed  ≤ 28 days before Cycle  1 Day 1 and 
assessed  according  to RECIST  v 1.1 (see Appendix  3) and irRC . The same  procedure  used to 
assess  disease  sites at baseline  should  be used throughout the study  (e.g.,  the same contrast  
protocol  for CT scans  or MRI  scans). To the extent  that it is feasible,  the same assessor should 
read and evaluate  the tumor  assessments  for the same patient  throughout  the study.  CT or 
MRI  scans  should include chest,  abdomen,  and pelvic  scans;  CT or MRI  scans of  the neck  
should be  included  if clinically  indicated.  At the investigator’s  discretion,  CT scans  may be 
repeated  at any time if progressive  disease is suspected.  
 
Evaluation  of tumor  response conforming  to RECIST  v1.1 must be  documented  every  9 
weeks  ± 1 week  (no matter where the patient  is in the treatment  cycle)  until documented,  
investigator−determined,  progressive disease,  loss of clinical  benefit,  withdrawal  of consent,  
death,  or study  termination  by the Sponsor -Investigator,  whichever occurs  first. Schedule  of 
tumor  assessments  are independent  of any changes to the  study  treatm ent administration  
schedule  (e.g.,  dose delay)  and may occur  mid-cycle depending  on length  of cycle.  If a tumor  
assessment  has to be  performed  early  or late, subsequent  assessments  should  be conducted  
according  to the  original  schedule  based  on the  date of first study  drug administration  (Cycle  
1, Day  1). Confirmation  of response (PR  or complete  response  [CR])  will be done  no earlier  
than 28 days from  study  entry.  In the case of SD, measurements  must  have  met the SD criteria  
at least once after study  entry  at a minimum  interval  not less than 6 weeks.  Patients  who 
discontinue study  treatment  for any reason  other than  disease progression  will continue  to 
PROTOCOL  # 17-0466  
PI: Christopher  H. Lieu,  MD 
Version  Date:  12.30 .2021  
 
 
 
 
 
 
    
Page 44 of 106  undergo  tumor response  evaluations  (approximately  every  9 weeks) until  progressive  disease.  
Rising  tumor  markers  (e.g.,  CEA) in the  absence of radiological  evidence of progression  is not  
considered  progressive  disease.  
 
Patients  who continue  to experience  clinical  benefit,  despite  evidence  of radiographic  
progression  as defined  by RECIST  v1.1, may continue  treatment  and will continue tumor  
assessments  as per the schedule listed  above.  
 
 
Any abnormality  identified  at baseline should be  recorded  on the General  Medical  History  and 
Baseline  Conditions eCRF.  
 
 
 
Medical History  
At subsequent  visits, clinically  significant  history  should be  obtained.  
 
Physical Examination  
 
At subsequent  visits (or as clinically  indicated),  limited,  symptom -directed  physical  
examinations  should be  performed.  Changes  from  baseline abnormalities  should  be recorded  
in patient  notes.  New or worsened  clinically  significant  abnormalities  should  be recorded  as 
adverse events  on the  Adverse  Event  eCRF.  Patients  will be asked  specifically  about  vision  
changes  as part of each physical  examination  in addition  to interval  medical history.  
 
Vital Signs  
Must be  collected:  
o Within 60  min prior  to infusion  
o During  infusion  if clinically  indicated  or if symptoms  occurred  in the  prior infusion.  
o Within 30  min (+/- 10 minutes)  after infusion  if clinically  indicated  or if symptoms  
occurred  in the  prior  infusion.  
o Weight  will be collected  on Day  1 of each cycle.  
 
Laboratory  Samples  
Hematology,  serum  chemistries  (non-fasting  glucose,  BUN,  creatinine,  sodium,  potassium,  
magnesium,  calcium,  phosphorous,  total bilirubin,  ALT,  AST,  ALP, CK, lipase,  amylase  and 
albumin),  CEA,  TFT,  coagulation  and urinalysis  must  be collected  at clinical  visits.  
 
Site staff will collect  blood  samples  and send to the Program  for Experimental  Targeted  
Therapeutics  Laboratory  at the University  of Colorado  when  appropriate  (please  see below).  
Instruction  manuals  and supply  kits will be provided  for all central  laboratory  testing.  Samples  
for the following  lab tests will be sent to central  laboratories  for analysis:  
 
 
 
7.3.2   ENROLLMENT/BASELINE  
7.3.3  TREATMENT  PERIOD  
PROTOCOL  # 17-0466  
PI: Christopher  H. Lieu,  MD 
Version  Date:  12.30 .2021  
 
 
 
 
 
 
    
Page 45 of 106   
1. Biomarker  assays – blood  samples  will be obtained  for biomarker  evaluation  
(including  but not limited  to biomarkers  that are related  to CRC or  tumor  immune  
biology)  from  all eligible  patients  in the expansion cohorts according  to the  schedule.  
Samples  will be processed  to obtain  plasma for  the determination  of changes  in blood 
based  biomarkers.  Proposed  biomarkers  for exploratory  research  are cytokines  and 
other  immune  regulators,  a panel  of oncogenic mutations  and overall mutation  loads  
by isolating  ctDNA from  plasma,  immune  cell infiltrates  and protein  expression  
(including  but not limited  to PD-L1 and MHC  expression),  MSI and CRC subtyping  
signatures  from  DNA and  RNA  extracted  from  tumor tissues.  
 
For sampling  procedures,  storage conditions  and shipment  instructions,  please  see the 
laboratory  manual.  
 
Any remaining  samples  post analysis  will be destroyed  unless  there is optional  patient  consent  
for banking.   
 
Tumor  Tissue Samples  
Fresh  tumor  sample:  tumor biopsy  samples  must  be obtained  for all study  patients  on expansion 
cohorts irrespective  of availability  of an archival  sample  or prior biopsy  at enrollment  and 
should be collected according to Section 4.1; Stage 2: Dose Expansion; Design . 
 
Acceptable  samples  include core needle biopsies  for deep  tumor  tissue  or tumor tissue  
resection.  At least two cores  embedded  into a  single  paraffin  block  should  be submitted  for 
evaluation.  Cytological  or fine-needle aspiration  samples  are not acceptable.  
 
Biomarker  testing  will be performed  on the fresh  tumor samples  which  will include extended  
RAS,  RAF,  MSI,  PD-LI tumor  expression,  phosphorylated  ERK expression  and mRNA  
expression  of immune  related  genes.  
 
Left Ventricular  Ejection Fraction  
Evaluation  of LVEF  by ECHO  or MUGA must  be performed  at the following  time-points:  
o Screening  
o Cycle  2 Day 1 ± 2 week s 
o Day 1 of Cycles  5, 8, and 11 (every  three  treatment  cycles)  ± 4 weeks  and then every  3 
months (± 4 weeks)  
o End-of-study -treatment  visit evaluation  of LVEF  
 
All post - screening ECHO/MUGA scans will be in reference to a subject’s Cycle 1 Day 1, 
regardless of treatment delays.  
 
Any patient who develops  clinical  signs  or symptoms  suspicious  of cardiac  failure should  
undergo  an LVEF assessment.  Evaluation  of LVEF  must be  performed  by the same  method  
(ECHO or MUGA)  for each patient.  It is strongly  encouraged  that the same  laboratory  and 
operator  perform  ECHO/MUGA  scans  for each individual  patient.  Investigators  must be  aware 
of local  institution  regulations  regarding  repeat  MUGA  scans.  The repeat  administration  of  
 
PROTOCOL  # 17-0466  
PI: Christopher  H. Lieu,  MD 
Version  Date:  12.30 .2021  
 
 
 
 
 
 
    
Page 46 of 106   
radioisotopes  is limited  in some  nuclear medicine  laboratories,  and some  patients  in this study  
could require monitoring  on four or more  occasions.  
 
Ophthalmologic  Examination  
All patients  will require  regular  ophthalmologic  examinations  at screening  and during  study  
conduct.  Ophthalmologic  examination  must be  performed  at the time-points listed below, 
regardless of treatment delays. All ophthalmologic exams post -screening are in reference to a 
subject’s Cycle 1 Day 1:  
 
Ophthalmologic  examination  must be  performed  at the following  time-points:  
• Screening  
• Cycle  2 Day 1 ± 2 week s 
• Day 1 of Cycles  5, 8, and 11 (every  three  treatment  cycles)  ± 2 weeks  
• Day 1 of Cycles  15, 19,  and 23 (every  four treatment  cycles)  ± 2 weeks  
• Day 1 of Cycles  29, 35, 41, 47, etc. (every  six treatment  cycles)  ± 2 weeks  
• End-of-study -treatment  visit ± 2 weeks  
 
The objective  of baseline ophthalmologic examination  is to evaluate  for evidence of retinal  
pathology  that may be a risk factor for central  serous  retinopathy  or retinal  vein occlusion.  
Ophthalmologic  examination  must be performed  by an ophthalmologist.  Risk factors  for retinal  
vein occlusion  include uncontrolled  serum  cholesterol,  hypertriglyceridemia,  hyperglycemia,   
hypertension,  and glaucoma.  Patients  with such conditions  will be excluded  from  the study  as 
detailed  in the  inclusion/exclusion  criteria.  
 
Baseline and  serial  surveillance  ophthalmologic  examination  will include visual  acuity  testing,  
intraocular  pressure  measurements  by tonometry,  slit-lamp ophthalmoscopy,  indirect  
ophthalmoscopy,  and optical  coherence  tomography  (spectral - or time-domain).  
Spectral  domain  optical  coherence  tomography,  if not available,  may be substituted with time- 
domain  optical  coherence  tomography.  
 
Tumor  and Response  Evaluation  
Evaluation  of tumor  response conforming  to RECIST  v1.1 must be  documented  every  9 weeks  
± 1 week  (no matter where the patient  is in the treatment  cycle)  until documented,  
investigator−determined,  progressive disease,  loss of clinical  benefit,  withdrawal  of consent,  
death,  or study  termination  by the Sponsor -Investigator,  whichever occurs  first. Schedule  of 
tumor  assessments  are independent  of any changes to the  study  treatment  administration  
schedule  (e.g.,  dose delay)  and may occur  mid-cycle depending  on length  of cycle.  If a tumor  
assessment  has to be  performed  early  or late, subsequent  assessments  should  be conducted  
according  to the  original  schedule  based  on the  date of first study  drug administration  (Cycle  1, 
Day 1). Confirmation  of response (PR  or complete  response  [CR])  will be done  no earlier  than 
28 days from  study  entry.  In the case of SD, measurements  must  have  met the SD criteria  at 
least once after study  entry  at a minimum  interval  not less than 6 weeks.  Patients  who 
discontinue study  treatment  for any reason  other than  disease progression  will continue  to 
undergo  tumor response  evaluations  (approximately  every  9 weeks) until  progressive  disease.  
Rising  tumor  markers  (e.g.,  CEA) in the  absence of radiological  evidence of progression  is not  
considered  progressive  disease.  
 
PROTOCOL  # 17-0466  
PI: Christopher  H. Lieu,  MD 
Version  Date:  12.30 .2021  
 
 
 
 
 
 
    
Page 47 of 106   
Patients  who continue  to experience  clinical  benefit,  despite  evidence  of radiographic  
progression  as defined  by RECIST  v1.1, may continue  treatment  and will continue tumor  
assessments  as per the schedule listed  above.  
 
 
A final study  visit is required  if patients  come off study  for any reason.  Patients  who 
discontinue study  drug will return  to the  clinic  for a discontinuation  visit 30  (+/- 7 days) after 
treatment  discontinuation.  
Participant s may come off study  for many  reasons  including:  
• Voluntary  withdrawal  at any time for any reason  by patient  
• Withdrawal  of patient  by investigator  due to concerns  for patient  safety  or non- 
compliance  with study  drug(s)  
• Radiological  disease progression  
• Symptomatic  deterioration  attributed  to disease  progression  as determined  by 
investigator  
• Intolerable  toxicity  related to any  study  drug 
• Any medical  condition  jeopardizing  patient  safety  if they continue  on study  drug(s)  
• Use of another non-protocol  anti-cancer  therapy  
• Pregnancy  
• Reached  maximum  recommended  upper  limit of  pembrolizumab  therapy  (35 cycles)  
 
During  a final study  visit/early  termination  visit (which can also be the end of treatment visit) , 
a medical  history along  with a physical  examination and measurement  of vital signs  must  be 
performed.  12-lead ECG,  tumor  response  evaluation,  laboratory,  biomarker,  and other  
biologic  samples,  echo/MUGA,  ophthalmological  exam, and if needed,  tumor tissue  sample  
will be assessed.   If tumor  response  evaluation,  echo/MUGA,  ophthalmological  exam  have 
been done within  3 weeks  of final study  visit/early  termination  visit then they need not be  
repeated  during  the final study  visit/early  termination  visit.  
 
 
After treatment discontinuation, s urvival follow -up information will be collected via telephone calls 
and/or clinic visits every 3 months  (+/- 2 weeks ). Follow -up information will continue until the 
participant’s death, withdrawal of co nsent , the participant is lost to follow -up, or study 
termination by the Sponsor -Investigator, whichever occurs first.  
 
 
 
Investigator  will review patient per standard  of care and  document  all pertinent information  as 
per section  7.3.3 Treatment Period.  
7.3.4   FINAL  STUDY  VISIT/EARLY  TERMINATION  VISIT  
7.3.5   SURVIVAL FOLLOW -UP 
7.3.6   UNSCHEDULED  VISIT  
PROTOCOL  # 17-0466  
PI: Christopher  H. Lieu,  MD 
Version  Date:  12.30 .2021  
 
 
 
 
 
 
    
Page 48 of 106   
 
TABLE  1. Schedule of Events  
 Screeninga Treatment  Period  q21d  cycle  
(Pembrolizumab,  Binimetinib  
and Bevacizumab)  Final Study/  
Treatment 
Discontinuation Visit b
 Survival  
Follow -Up c
 
Cycle  1 Cycle  2 Cycles  3+   
Days  (window)  -28 to -1 d1-7 1 ( 2) 1 ( 2) 1 ( 2)   
Informed  consent  d
 x       
Demographic  data x       
Medical  and CRC  
history  x       
Baseline  disease  
characteristics  x       
Vital signs  e,f
 x  x x x x  
Weight  x  x x x   
Height  x       
ECOG  performance  
status  x   x x x  
Complete  physical  
examination  x       
Limited  physical  
examination    x x x x  
ECHO  or MUGA  
scan  g
 x   x x x  
12-lead ECG  x     x  
Hematology  h
 x  x x x x  
Chemistry  i
 x  x x x x  
HIV, HBV, and HCV  
serologies j x       
Biomarker Blood Draw    x   xr  
Coagulation tests  x  x x x   
Ophthalmic exams k x   x x x  
Urine dipstickp x  x x x   
Pregnancy test l x Monthly as clinically indicated    
Thyroid function test m x  x x x   
CEA   x x x   
Binimetinib Cohort A   x  x x   
Binimetinib Cohort B & 
Run- in   x x x   
Pembrolizumab 
administration    x x x   
Bevacizumab 
administration    x x x   
Concomitant medications  x  x x x x  
Adverse events    x x x x  
Tumor biopsy - Cohort An  x x     
Tumor  biopsy - Cohort  Bo
   x x    
Tumor  assessmentsq
 x    x x  
Survival Follow -up 
Information        x 
 
 
7.3.7  SCHEDULE  OF EVENTS  
PROTOCOL  # 17-0466  
PI: Christopher  H. Lieu,  MD 
Version  Date:  12.30 .2021  
 
 
 
 
 
 
    
Page 49 of 106   
CEA =carcinoembryonic antigen;  CRC=colorectal cancer;  ECHO = echocardiogram;  ECOG  =Eastern Cooperative  Oncology  
Group;  HBV = hepatitis  B virus;  HCV = hepatitis  C virus;  MUGA  =multigated  acquisition  scan.  
a Results  of standard  of care tests  or examinations  performed  prior to obtaining  informed  consent  and within  28 days  
prior to Day 1 may be used;  such  tests  do not need  to be repeated  for screening  
b Patients  who discontinue  study  drug will return  to the clinic  for a discontinuation  visit 30 ( 7 days) after treatment  
discontinuation.  
c Required  follow -up information  will be collected  via telephone  calls and/or  clinic  visits  every  3 months  (+/- 2 weeks)  
until death,  withdrawal  of consent,  the patient  is lost to follow -up, or study  termination  by the Sponsor -Investigator,  
whichever  occurs  first. 
d Informed  consent  must  be documented  before  any study -specific  screening  procedure  is performed  and may be 
obtained  up to 28 days  before  initiation  of study  treatment.  
e Includes  heart  rate, temperature,  and systolic  and diastolic  blood  pressure  while  the patient  is in a seated  position.  
Record  abnormalities  observed  at baseline  on the General  Medical  History  and Baseline  Conditions  eCRF.  At 
subsequent  visits  record  new or worsened  clinically  significant  abnormalities  on the Adverse  Event  eCRF  
f Vital signs  at the first Pembrolizumab  infusion  will be collected  within  60 min prior to the infusion,  every  15 ( 10) min 
during  the pembrolizumab  infusion  and 30 ( 10) min after the infusion.  For subsequent  infusions,  vital signs  will be 
collected  within  60 min prior to the infusion  and should  be collected  during  the infusion  if clinically  indicated  or if 
symptoms  occurred  in the prior infusion,  and 30 ( 10) min after the infusion.  
g All patients  will undergo  evaluation  of left ventricular  dysfunction,  either  by ECHO  or MUGA,  screening.  Evaluation  of 
LVEF  by ECHO  or MUGA  must  be performed  at the following  timepoints , regardless of treatment delays (all 
ophthalmologic exams post -screening are in reference to a subject ’s Cycle 1 Day 1): : 
• Screening,  
• Cycle  2, Day 1  2 week s 
• Day 1 of Cycles  5, 8, and 11 and every  three  treatment  cycles  thereafter   4 week s 
• End-of-study -treatment  visit evaluation  of LVEF  
h Hematology  (CBC,  hemoglobin,  hematocrit,  WBC  count  with differential  [neutrophils,  eosinophils,  lymphocytes],  and 
platelet  count).  
i Serum  chemistries  (non-fasting  glucose,  BUN  or urea,  creatinine,  sodium,  potassium,  magnesium,  calcium,  
phosphorus,  total bilirubin,  ALT, AST,  ALP, CPK,  lipase,  amylase,  and albumin).  Serum  chemistry  includes  serum  
cholesterol  and triglycerides  at baseline.  
j HBV serology:  Hepatitis  B surface  antigen,  hepatitis  B surface  antibody,  and total hepatitis  B core antibody.  HBV DNA  
should  be obtained  prior to enrollment  if patient  has a negative  serology  for HbsAg  and a positive  serology  for anti-
HBcAb.  
HCV  serology:  HCV  antibody  (anti-HCV).  HCV  RNA  should  be obtained  prior to enrollment  if patient  tests positive  for 
anti-HCV.  
k All patients  will undergo  ophthalmologic  examination  (see Section  4.5.9  for exam  requirements)  at screening.  
Ophthalmologic  examination  must  be performed  at the following  timepoints , regardless of treatment delays (all 
ophthalmologic exams post -screening are in reference to a subject’s Cycle 1 Day 1) : 
• Screening  
• Cycle 2 Day 1 2 week s 
• Day 1 of Cycles 5, 8, and 11 (every three treatment cycles) 2 weeks  
• Day 1 of Cycles 15, 19, and 23 (every four treatment cycles) 2 weeks  
• On Day 1 of Cycles 29, 35, 41, 47, etc. (every six treatme nt cycles) 2 weeks  
• End-of-study -treatment  visit   
l Serum  pregnancy  test within  14 days before  Cycle  1, Day 1 and then monthly  as clinically  indicated.  
m Thyroid  function  testing  (thyroid -stimulating  hormone  [TSH],  total T3, free T4) collected  at Screening,  Cycle  1 Day 1, and 
every  cycle  thereafter.  
n Fresh  tumor  samples  should  be obtained  prior to C1D-7 (after  randomization)  and then prior to C1D1.  
o Fresh  tumor  samples  should  be obtained  pre-treatment  (after  randomization , prior to C1D1)  and on C1D21  (+/-5 day 
window) . 
p 24 hour urine  collection  conducted  in the event  of proteinuria  ≥ + 2 detected  by dipstick  test. 
q Evaluation  of tumor  response  conforming  to RECIST  v1.1 and irRC must  be documented  every  9 weeks  ± 1 week  (no 
matter  where  the patient  is in the treatment  cycle)  
r Biomarker blood draws will be taken for participants with disease progression at the Final Study Visit/End of 
Treatment. Participants with  partial response or  stable disease will have their blood drawn again at Cycle 4, Day 1. If 
blood is drawn at Cycle 4, Day 1 then blood will not drawn again at the Final Study Visit/End of Treatment.  
PROTOCOL  # 17-0466  
PI: Christopher  H. Lieu,  MD 
Version  Date:  12.30 .2021  
 
 
 
 
 
 
    
Page 50 of 106  Table 2. Schedu le of Biomarkers for Expansion Cohort  
Treatment Period  Time -point  Sample Type  
Cycle  1 Day 1 Prior  to infusion  Biomarker  
Final  Study  Visit/Treatment  
Discontinuation  Visit   BiomarkerŦ 
Ŧ Biomarker blood draws will be taken for participants with disease progression at the Final Study Visit/End 
of Treatment. Participants with partial response or stable disease will have their blood drawn again at 
Cycle 4, Day 1. If blood is drawn at Cycle 4, Day 1 then blood will not drawn again at the Final Study 
Visit/End of Treatment.  
 
 
7.4 Justification for Sensitive Procedures  
 
N/A 
 
7.5 Concomitant Medications, Treatments, and Procedures  
 
All concomitant  prescription  medications  taken  during  study  participation  will be recorded  on 
the case report  forms  (CRFs).  For this  protocol,  a prescription  medication  is defined  as a 
medication  that can be prescribed  only by a properly  authorized/licensed  clinician.  
 
Medications  reported  in the CRF  are concomitant  prescription  medications,  over-the-counter  
medications , and non-prescription  medications.  
 
7.6 Prohibited Medications, Treatments, and Procedures  
 
Any concomitant  therapy  intended  for the treatment  of cancer,  whether  health  authority  
approved  or experimental,  is prohibited  for various  time periods  prior to starting  study  
treatment,  depending  on the  anti-cancer  agent  (see Section  4.1.3),  and during  study  treatment  
until disease  progression  is documented  and patient  has discontinued  study  treatment.  This 
includes  but is not limited  to chemotherapy,  hormonal therapy,  immunotherapy,  radiotherapy,  
investigational  agents,  or herbal  therapy.  
 
The following  medications  are prohibited  while  receiving  study  treatment,  unless  otherwise  
noted:  
o Traditional herbal  medicines,  as their use may result in unanticipated  drug-drug 
interactions  that may cause  or confound  assessment  of toxicity.  
o Denosumab:  Patients  who are receiving  denosumab prior to enrollment  must  be 
willing  and eligible  to receive  a bisphosphonate instead  while  in the  study.  
o Any live, attenuated  vaccine (e.g.,  FluMist)  within  4 weeks  prior to Cycle  1 Day 1 or 
at any time during  the study  and for at least 5 months  after the last dose of 
pembrolizumab.  
PROTOCOL  # 17-0466  
PI: Christopher  H. Lieu,  MD 
Version  Date:  12.30 .2021  
 
 
 
 
 
 
    
Page 51 of 106   
For pembrolizumab:  
o Use of steroids  to premedicate  patients  for whom  CT scans  with contrast  are 
contraindicated  (i.e., patients  with contrast  allergy  or impaired  renal  clearance);  in 
such patients,  MRIs  of the chest,  abdomen,  and pelvis  with a non-contrast  CT scan of 
the anatomical  region  of interest  must be  performed.  
o Immunomodulatory  agents,  including  but not  limited  to interferons  or interleukin -2, 
during  the entire  study;  these agents  could  potentially  increase the risk for autoimmune  
conditions  when  administered  with Pembrolizumab.  
o Immunosuppressive  medications,  including  but not  limited  to cyclophosphamide,  
azathioprine,  methotrexate,  and thalidomide;  these  agents  could  potentially  alter the 
activity  and the safety  of pembrolizumab . 
o Systemic corticosteroids  and tumor  necrosis  factor -α (TNF -α) inhibitors  may attenuate  
potential  beneficial  immunologic  effects  of treatment  with pembrolizumab.  Therefore,  
in situations  where  systemic  corticosteroids  or TNF-α inhibitors  would  be routinely  
administer ed, alternatives,  including  antihistamines,  should be  considered  first by the 
treating  physician.  If the alternatives  are not feasible,  systemic corticosteroids  and 
TNF -α inhibitors  may be administered  at the discretion  of the treating  physician  (see 
Section  4.4.2) . 
o Initiation  or increased  dose of granulocyte  colony -stimulating  factors  (e.g.,  
granulocyte  colony  stimulating  factor,  granulocyte/macrophage  colony -stimulating  
factor,  and/or  pegfilgrastim)  is prohibited.  
 
For Binimetinib:  
o Concomitant  use of strong  inhibitors  or inducers  of UGT1A1,  P-gp, BCRP and 
CYP2B6  should  be used with caution.  Binimetinib  exposures  may be increased  or 
decreased  in presence  of these agents.  Patients  should  be closely  monitored for the 
occurrence of adverse  events.  
 
The above  lists of medications  are not necessarily  comprehensive.  Thus,  the investigator  
should consult  the prescribing  information  for any concomitant  medication  as well as the 
Internet  references  provided  below  when  determining  whether a certain  medication  is 
metabolized  by or strongly  inhibits or  induces  CYP.  In addition,  the investigator  should  
contact  the Medical  Monitor if questions  arise  regarding  medications  not listed  above.  
 
http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/  
Guidances/UCM292362.pdf  
 
http://medicine.iupui.edu/clinpharm/ddis/table.aspx  
 
7.7 Prophylactic Medications, Treatments, and Procedures  
 
The following  therapies  are permitted  in the study:  
o Oral contraceptives.  
o Hormone -replacement therapy.  
o Prophylactic  or therapeutic anticoagulation  therapy  (such  as low-molecular  weight  
heparin  or warfarin  at a stable dose level).  
PROTOCOL  # 17-0466  
PI: Christopher  H. Lieu,  MD 
Version  Date:  12.30 .2021  
 
 
 
 
 
 
    
Page 52 of 106   
o Palliative  radiotherapy  (e.g.,  treatment  of known  bone metastases)  provided it does not 
interfere  with assessment  of tumor  target  lesions.  
o It is not required  to withhold  any of the drugs  during  palliative  radiotherapy.  
o Inactive influenza  vaccinations  during  influenza  season  ONLY.  
o Megestrol  administered  as an appetite  stimulant.  
o Inhaled  corticosteroids  for chronic  obstructive pulmonary  disease . 
o Mineralocorticoids  (e.g.,  fludrocortisone).  
 
7.8 Rescue Medications, Treatments, and Procedures  
Anti-emetics  and anti-diarrheal medications  should  not be  administered  prophylactically  
befor e initial treatment  with study  drugs.  At the discretion  of the investigator,  prophylactic  
anti-emetic and anti-diarrheal medication(s)  may be used per standard  clinical  practice  before  
subsequent  doses  of study  drugs.  
 
Hematopoietic  growth  factors  should not be  administered  prophylactically  before  initial  
treatment  with study  drugs.  Hematopoietic  growth  factors  may be administered  according  to 
local  guidelines  if indicated  during  the course of the study.  
 
In general,  investigators  should  manage a patient’s  care with  supportive  therapies  as clinically  
indicated,  as per local  standards.  Patients  who experience  infusion -associated  symptoms  may 
be treated  symptomatically  with acetaminophen,  ibuprofen,  diphenhydramine,  and/or  
famotidine or another  H2 receptor antagonist  as per standard  practice (for sites  outside  the 
United  States,  equivalent  medications  may be substituted  per local  practice).  Serious  
infusion−associated  events  manifested  by dyspnea, hypotension,  wheezing,  bronchospasm,  
tachycardia,  reduced  oxygen  saturation,  or respiratory  distress  should be  managed  with 
supportive  therapies  as clinically  indicated  (e.g.,  supplemental oxygen  and β2-adrenergic  
agonists).  
 
Guidelines  for known  toxicities  of study  agents  are provided  in the Appendix  1. 
All medications  must be  recorded  on the  Concomitant  Medications  eCRF.  
7.9 Subject Access to Study Agent at Study Closure  
 
The manufacturer  will offer  post-trial access  to the  study  drug,  Pembrolizumab  free of charge  
to eligible  patients  in accordance with the MERCK Global  Policy  on Continued  Access  to 
Investigational  Medicinal Product,  as outlined  below.  Pfizer  will provide  binimetinib  free of 
charge to eligible  patients  in accordance with their policies.  Bevacizumab  is part of standard  
of care therapy.  A patient  will be eligible  to receive study  drugs  pembrolizumab  and 
binimetinib  after completing  the study  if all of the following  conditions  are met: 
o The patient  has a life-threatening  or severe  medical  condition  and requires  continued  
study  drug treatment  for his or  her well-being.  
o There are no appropriate  alternative  treatments  available  to the  patient.  
o The patient  and his or  her doctor  comply  with and satisfy  any legal  or regulatory  
requirements  that apply  to them.  
PROTOCOL  # 17-0466  
PI: Christopher  H. Lieu,  MD 
Version  Date:  12.30 .2021  
 
 
 
 
 
 
    
Page 53 of 106   
 
A patient  will not be  eligible to receive study  drug after completing  the study if  any of  the 
following  conditions are met: 
o The study  drug is commercially  marketed  in the  patient's  country  and is reasonably  
accessible to the patient (e.g.,  is covered  by the patient's  insurance  or wouldn't  
otherwise create  a financial  hardship  for the patient).  
o Merck/ Pfizer  has discontinued  development  of the study  drug or data suggest that the 
study  drug is not  effective  for CRC.  
o The Sponsor -Investigator  has reasonable  safety  concerns  regarding  the study  drug as 
treatment  for CRC.  
o Provision  of study  drug is not permitted  under the laws and regulations  of the patient's  
country.  
 
 
 
8.1 Specifications of Safety Parameters  
 
Safety  assessments  will consist  of monitoring  and recording  adverse  events,  including  serious  
adverse events  and adverse  events  of special  interest,  performing  protocol -specified  safety  
laboratory  assessments,  measuring  protocol -specified  vital signs,  and conducting  other  
protocol -specified  tests that are deemed  critical  to the safety  evaluation  of the study.  
 
 
Adverse event  means  any untoward  medical  occurrence associated  with the use of an 
intervention  in humans,  whether or not considered  intervention -related  (21 CFR  312.32 (a)). 
 
 
Serious  adverse  event  or serious  suspected  adverse reaction . An AE or suspected  adverse  
reaction  is considered  “serious”  if, in the  view  of either the investigator  or Merck/ Pfizer , it 
results  in any  of the following  outcomes:  death,  a life-threatening  adverse  event,  inpatient  
hospitalization  or prolongatio n of existing  hospitalization,  a persistent  or significant incapacity  
or substantial  disruption  of the ability  to conduct normal  life functions,  or a congenital  
anomaly/  birth  defect.  Important  medical  events  that may not result  in death, be  life- 
threatening,  or require  hospitalization  may be considered  serious  when,  based  upon  
appropriate  medical  judgment,  they may jeopardize  the patient  or subject  and may require  
medical  or surgical intervention  to prevent  one of the outcomes  listed  in this definition.  
Examples  of such medical  events  include  allergic bronchospasm  requiring  intensive treatment  
in an emergency  room  or at home,  blood  dyscrasias  or convulsions  that do not result  in 
inpatient  hospitalization,  or the development  of drug dependency  or drug abuse.  
8 ASSESSMENT  OF SAFETY  
8.1.1  DEFINITION  OF ADVERSE  EVENTS  (AE)  
8.1.2  DEFINITION  OF SERIOUS  ADVERSE  EVENTS  (SAE)  
PROTOCOL  # 17-0466  
PI: Christopher  H. Lieu,  MD 
Version  Date:  12.30 .2021  
 
 
 
 
 
 
    
Page 54 of 106   
 
This study  will use the COMIRB  definition of  UAP.  An unanticipated  problem  is any  event  or 
information  that was unforeseen  and indicates  that the research  procedures  caused  harm  
(including  physical,  psychological,  economic,  or social  harm)  to participants  or others  or 
indicates  that participants  or others  are at  increased  risk of harm than was previously  known  or 
recognized.  (please  see section  8.4.3)  
 
 
8.2 Classifications of an Adverse Event  
 
 
 
For AEs not included  in the protocol -defined  grading  system,  the following  guidelines  will be 
used to describe  severity.  
• Mild  – Events  require  minimal  or no treatment  and do not interfere with the 
subject’s  daily  activities.  
• Moderate – Events  result  in a low level  of inconvenience  or concern  with the 
therapeutic  measures.  Moderate events  may cause  some  interference  with 
functioning.  
• Severe  – Events  interrupt a subject’s  usual  daily  activity  and may require systemic  
drug therapy  or other treatment.  Severe events  are usually  potentially  life- 
threatening  or incapacitating.  
 
 
The clinician’s  assessment  of an AEs relationship  to study  agent  (drug,  biologic,  device)  is 
part of the documentation  process,  but it is not a factor  in determining  what  is or is not  
reported  in the study.  If there  is any doubt as to whether a clinical  observation  is an AE, the 
event  should be  reported.  All AEs must  have their relationship  to the  study  agent  assessed.  In 
a clinical  trial, the study  product  must always  be suspect.   
 
For all  collected  AEs,  the clinician  who examines  and evaluates  the subject will determine  the 
AEs causality  based on temporal  relationship  and his/her clinical judgment.  The degree of 
certainty  about  causality  will be graded  using  the categories  below.  
8.1.3   DEFINITION  OF UNANTICIPATED  PROBLEMS  (UAP)  
8.2.1    SEVERITY  OF EVENT  
8.2.2   RELATIONSHIP  TO STUDY  AGENTS  
PROTOCOL  # 17-0466  
PI: Christopher  H. Lieu,  MD 
Version  Date:  12.30 .2021  
 
 
 
 
 
 
    
Page 55 of 106   
• Definitely  Related  – There  is clear  evidence  to suggest  a causal  relationship,  and other 
possible  contributing  factors  can be ruled  out. The clinical  event,  including  an abnormal  
laboratory  test result,  occurs  in a plausible  time relationship  to drug administration  
and cannot  be explained  by concurrent  disease  or other  drugs  or chemicals.  The 
response  to withdrawal  of the drug (dechallenge)  should  be clinically  plausible.  The event  
must  be pharmacologically  or phenomenologically  definitive,  with use of a satisfactory  
rechallenge procedure if necessary.  
• Probably  Related  – There  is evidence  to suggest  a causal  relationship,  and the 
influence  of other  factors  is unlikely.  The clinical  event,  including  an abnormal  
laboratory  test result,  occurs  within  a reasonable  time after administration  of the drug,  
is unlikely to  be attributed  to concurrent  disease  or other  drugs  or chemicals,  and follows  
a clinically  reasonable  response  on withdrawal  (dechallenge).  Rechallenge  information  is 
not required  to fulfill  this definition.  
• Possibly  Related  – There  is some  evidence  to suggest a causal  relationship  (e.g.,  the event  
occurred  within  a reasonable  time after administration  of the trial medication).  However,  
other  factors  may have  contributed  to the event  (e.g.,  the subject’s  clinical  condition,  other  
concomitant  events).  Although  an AE may rate only as “possibly  related”  soon  after 
discovery,  it can be flagged  as requiring  more  information  and later be upgraded  to 
“probably  related”  or “definitely  related”,  as appropriate.  
• Unlikely  to be Related  – A clinical  event,  including  an abnormal  laboratory  test result,  
whose  temporal  relationship  to drug administration  makes  a causal  relationship  
improbable  (e.g.,  the event  did not occur  within  a reasonable  time after administration  of 
the trial medication)  and in which  other  drugs  or chemicals  or underlying  disease  
provides  plausible  explanations  (e.g.,  the subject’s  clinical  condition,  other concomitant 
treatments).  
• Not Related – The AE is completely  independent  of study  drug administration,  and/ or 
evidence exists  that the event  is definitely  related  to another etiology.  There must  be an 
alternative,  definitive etiology  documented  by the clinician.  
 
 
 
The clinician  will be responsible  for determining  whether  an SAE is expected  or unexpected.  
An SAE will be considered  unexpected  if the nature,  severity,  or frequency  of the event  is not 
consistent  with the risk information  previously  described  for the study  agent.  
 
8.3 Time Period and Frequency for Event Assessment and Follow -up 
 
The occurrence of an AE or SAE  may come to the  attention  of study  personnel  during  study  
visits and interviews  of a study  subject  presenting  for medical  care,  or upon review  by a study  
monitor.  All AEs including  local  and systemic  reactions  not meeting  the criteria  for SAEs  will 
be captured  on the  appropriate CRF.  Information  to be collected  includes  event  description,  
date of onset,  clinician’s  assessment  of severity,  relationship  to study  product (assessed  only 
by those  with the training  and authority  to make a diagnosis),  action taken with study drug, 
treatment , expectedness and date of resolution/ stabilization  of the event.  All AEs occurring   
 
8.2.3   EXPECTED  ADVERSE  EVENTS  
PROTOCOL  # 17-0466  
PI: Christopher  H. Lieu,  MD 
Version  Date:  12.30 .2021  
 
 
 
 
 
 
    
Page 56 of 106   
while  on study  must be  documented  appropriately  regardless  of relationship.  All AEs will be 
followed  to adequate  resolution.  
 
Any medical  condition  that is present  at the time that  the subject  is screened  will be 
considered  as baseline and not reported  as an AE. However,  if the study  subject’s  condition  
deteriorates  at any time during  the study,  it will be recorded  as an AE. UAPs  will be recorded  
in the  data collection  system  throughout  the study.  
 
Changes  in the  severity  of an AE will be documented  to allow an assessment  of the duration  
of the event  at each level  of severity  to be performed.  AEs characterized  as intermittent  
require  documentation  of onset  and duration  of each episode.  
 
The PI will record  all reportable  events  with start dates  occurring  any time after informed  
consent  is obtained  until 90 days after last  day of study  participation.  At each study  visit, the  
investigator  will inquire about  the occurrence of AE/SAEs  since  the last visit.  Events  will be 
followed  for outcome  information  until resolution  or stabilization.  
 
8.4 Reporting Procedures  
 
 
The investigator  is responsible for  ensuring  that all adverse events  are recorded  on the  
Adverse Event  eCRF  and reported  to Merck.  For each adverse event  recorded  on the Adverse 
Event  eCRF,  the investigator  will make an  assessment  of seriousness,  severity,  and causality.  
Investigators  will seek information  on adverse events  at each patient  contact.  All adverse 
events,  whether  reported  by the patient  or noted by study  personnel,  will be recorded  in the  
patient’s  medical  record  and on the  Adverse  Event  eCRF.  Investigators  should use  correct  
medical  terminology/concepts  when  recording  adverse events  on the Adverse Event  eCRF.  
Avoid  colloquialisms  and abbreviations.  Only  one adverse event  term should be  recorded  in 
the event  field on the  Adverse Event  eCRF.  
 
After  informed  consent  has been  obtained  but prior to initiation  of study  drug,  only serious  
adverse events  caused  by a protocol -mandated  intervention  (e.g.,  invasive procedures  such as 
biopsies,  discontinuation  of medications)  should be reported.  After  initiation  of study  drug,  all 
serious  adverse  events  will be reported  until 90 days after the last dose of study  drug.  
 
The adverse  event  severity  grading  scale for the NCI CTCAE (v4.0)  will be used for assessing  
adverse event  severity.  The following  table will be used for assessing  severity  for adverse  events  
that are not specifically  listed  in the  NCI CTCAE  (v4.0).  
 
 
 
 
 
 
 
8.4.1  ADVERSE  EVENT  REPORTING  
PROTOCOL  # 17-0466  
PI: Christopher  H. Lieu,  MD 
Version  Date:  12.30 .2021  
 
 
 
 
 
 
    
Page 57 of 106   
 
NCI CTCAE  = National  Cancer  Institute  Common  Terminology  Criteria  for Adverse  
Events.  Note:  Based  on the most  recent  version  of NCI CTCAE  (v4.0),  which  can be 
found  at:      http://ctep.cancer.gov/protocolDevelopment/electronic_applications/ctc.htm  
a Instrumental  activities  of daily living  refer to preparing  meals,  shopping  for groceries  or clothes,  
using  the telephone,  managing  money,  etc. 
b Examples  of self-care activities  of daily living  include  bathing,  dressing  and undressing,  
feeding  oneself,  using  the toilet,  and taking  medications,  as performed  by patients  who are 
not bedridden.  
c If an event  is assessed  as a "significant  medical  event,"  it must  be reported  as a serious  
adverse  event.  
d Grade  4 and 5 events  must  be reported  as serious  adverse  events.  
 
Adverse  Events  that are secondary  to other events  
In general,  adverse  events  that are secondary  to other  events  (e.g.,  cascade  events  or clinical  
sequelae)  should be  identified  by their primary  cause,  with the exception  of severe  or serious  
secondary  events.  A medically  significant  secondary  adverse event  that is separated  in time from  
the initiating  event  should be  recorded  as an independent  event  on the  Adverse Event  eCRF.   For 
example:  
o If vomiting  results  in mild dehydration  with no additional  treatment  in a healthy  adult,  
only vomiting  should be  reported  on the  eCRF.  
o If vomiting  results  in severe  dehydration,  both events  should be  reported  separately  on 
the eCRF.  
o If a severe gastrointestinal  hemorrhage  leads  to renal  failure,  both events  should  be 
reported  separately  on the  eCRF.  
o If dizziness leads  to a fall and consequent  fracture,  all three events  should be  reported  
separately  on the  eCRF.  
o If neutropenia  is accompanied  by an infection,  both events  should be  reported  
separately  on the  eCRF.  
 
All adverse  events  should  be recorded  separately  on the  Adverse Event  eCRF  if it is unclear  as to 
whether  the events  are associated.  
  
 
 
 
 
Severity  
Mild;  asymptomatic  or mild symptoms;  clinical  or diagnostic  observations  only;
or intervention  not indicated  
Moderate;  minimal,  local,  or non-invasive  intervention  indicated;  or
limiting  age-appropriate  instrumental  activities  of daily living  a 
Severe  or medically  significant,  but not immediately  life-threatening;
hospitalization  or prolongation  of hospitalization  indicated;  disabling;
or limiting  self-care activities  of daily living  b,c 
Life-threatening  consequences  or urgent  intervention  indicated  d 
Death  related  to adverse  event  d 
PROTOCOL  # 17-0466  
PI: Christopher  H. Lieu,  MD 
Version  Date:  12.30 .2021  
 
 
 
 
 
 
    
Page 58 of 106   
Persistent or Recurrent  Adverse  Events  
A persistent  adverse  event  is one  that extends  continuously,  without  resolution,  between  patient  
evaluation  time-points.  Such  events  should  only be recorded  once on the  Adverse  Event  eCRF.  
The initial  severity  (intensity  or grade) of the event  will be recorded  at the time the event  is first 
reported.  If a persistent  adverse event  becomes  more severe,  the most extreme  severity  should  
also be recorded  on the Adverse  Event  eCRF.  If the event  becomes  serious,  it should be  reported  
to the  Merck/ Pfizer  immediately  (i.e., no more  than 24 hours  after learning  that the event  became 
serious).   The Adverse  Event  eCRF  should be  updated  by changing  the event  from  "non -serious"  
to "serious,"  providing  the date that the event  became  serious,  and completing  all data fields  
related  to serious  adverse  events.  
 
A recurrent  adverse  event  is one  that resolves  between  patient  evaluation  time-points  and 
subsequently  recurs.  Each  recurrence of an adverse event  should be  recorded  as a separate  event  
on the  Adverse  Event  eCRF  
 
Abnormal  Laboratory Values  
o Not every  laboratory  abnormality  qualifies  as an adverse  event.  A laboratory  test result  
must be  reported  as an adverse event  if it meets  any of the following  criteria:  
o Is accompanied  by clinical  symptoms  
o Results  in a change  in study  treatment  (e.g.,  dosage modification,  treatment  
interruption,  or treatment  discontinuation)  
o Results  in a medical intervention  (e.g.,  potassium  supplementation  for hypokalemia)  or a 
change in concomitant  therapy  
o Is clinically  significant  in the investigator’s  judgment  
Note:  For oncology  trials, certain  abnormal  values  may not qualify  as adverse events.  
 
It is the investigator’s  responsibility  to review  all laboratory  findings.  Medical  and scientific  
judgment  should  be exercised  in deciding  whether  an isolated  laboratory  abnormality  should  be 
classified  as an adverse event.  
 
If a clinically  significant  laboratory  abnormality  is a sign of a disease or syndrome  (e.g.,  
alkaline  phosphatase and  bilirubin  5x ULN associated with cholestasis),  only the diagnosis  (i.e., 
bile duct stenosis)  should  be recorded  on the  Adverse Event  eCRF.  
 
If a clinically  significant  laboratory  abnormality  is not a sign of a disease or syndrome,  the 
abnormality  itself should  be recorded  on the  Adverse Event  eCRF,  along  with a descriptor  
indicating  whether  the test result  is above  or below the normal  range (e.g.,  "elevated  potassium,"  
as opposed  to "abnormal  potassium").   If the laboratory  abnormality  can be characterized  by a 
precise  clinical  term per standard  definitions,  the clinical term should  be recorded  as the adverse 
event.  For example,  an elevated  serum  potassium  level  of 7.0 mEq/L  should be  recorded  as 
"hyperkalemia."  
 
Observations  of the same clinically  significant  laboratory  abnormality  from  visit to visit should 
only be recorded  once on the Adverse  Event  eCRF.  
 
 
 
PROTOCOL  # 17-0466  
PI: Christopher  H. Lieu,  MD 
Version  Date:  12.30 .2021  
 
 
 
 
 
 
    
Page 59 of 106   
Abnormal  Vital  Sign  Values  
Not every  vital sign abnormality  qualifies  as an adverse event.  A vital sign result  must  be 
reported  as an adverse  event  if it meets  any of the following  criteria:  
o Is accompanied  by clinical  symptoms  
o Results  in a change  in study  treatment  (e.g.,  dosage modification,  treatment  
interruption,  or treatment  discontinuation)  
o Results  in a medical intervention  or a change in concomitant  therapy  
o Is clinically  significant  in the investigator’s  judgment  
 
It is the  investigator’s  responsibility  to review  all vital sign findings.  Medical  and scientific  
judgment  should be  exercised  in deciding  whether  an isolated  vital sign abnormality  should be  
classified  as an adverse  event.  
 
If a clinically  significant  vital sign abnormality  is a sign of a disease or syndrome (e.g.,  high 
blood pressure),  only the diagnosis  (i.e., hypertension) should be  recorded  on the Adverse  Event  
eCRF.  
 
Preexisting Medical Conditions  
A preexisting  medical  condition  should be  recorded  as an adverse  event  only if the frequency,  
severity,  or character of the condition  worsens  during  the study.  When recording  such events  on 
the Adverse Event  eCRF,  it is important to convey  the concept  that the preexisting  condition  has 
changed  by including  applicable  descriptors  (e.g.,  "more  frequent  headaches").  
 
Hospitalization or  Prolonged Hospitalization  
Any adverse event  that results  in hospitalization  (i.e., inpatient  admission  to a hospital) or 
prolonged  hospitalization  should be  documented  and reported  as a serious  adverse  event  (per the 
definition  of serious  adverse  event  in Section  5.2.2),  except  as outlined  below.  
 
The following  hospitalization  scenarios  are not considered  to be  adverse  events:  
o Hospita lization  for respite  care.  
o Planned  hospitalization  required  by the protocol  (e.g.,  for study  drug administration  or 
insertion  of access  device for  study  drug administration).  
o Hospitalization  for a preexisting  condition,  provided  that all of the following  criteria  
are met: 
▪ The hospitalization  was planned  prior  to the  study  or was scheduled  
during  the study  when  elective surgery  became necessary  because  of 
the expected  normal  progression  of the disease.  
▪ The patient  has not experienced  an adverse  event.  
▪ Hospitalization  due solely  to progression  of the underlying  cancer.  
 
The following  hospitalization  scenarios  are not considered  to be  serious  adverse  events,  but 
should be  reported  as adverse  events  instead:  
o Hospitalization  that was necessary  because of patient  requirement  for outpatient  care 
outside  of normal  outpatient  clinic  operating  hours.  
 
 
PROTOCOL  # 17-0466  
PI: Christopher  H. Lieu,  MD 
Version  Date:  12.30 .2021  
 
 
 
 
 
 
    
Page 60 of 106   
Overdose or  Error in Drug Administration  
An overdose  is the  accidental  or intentional  use of a drug in an amount  higher than  the dose 
being  studied.  An overdose or incorrect  administration  of study  treatment  is not itself an 
adverse event,  but it may result  in an adverse  event.  All adverse  events  associated  with an 
overdose  or incorrect  administration  of study  drug should be  recorded  on the Adverse Event  
eCRF.  If the associated  adverse  event  fulfills  seriousness  criteria,  the event  should be  reported  
to the  Merck/ Pfizer  immediately.  
 
Deaths  
Deaths  that occur during  the protocol - specified  adverse event  reporting  period  should be  
entered  in the Adverse Event  eCRF.  All on-study  deaths, regardless  of relationship  to study  
drug,  must be  recorded  on the  Adverse Event  eCRF  and immediately  reported  to the  
Merck/ Pfizer . 
 
Death  should  be considered  an outcome and  not a  distinct  event.  The event  or condition  that 
caused  or contributed  to the fatal  outcome  should be  recorded  as the single  medical  concept  on 
the Adverse Event  eCRF.  Generally,  only one such event  should be  reported.  The term 
"sudden  death"  should be  used only for the occurrence of an abrupt  and unexpected  death  due 
to presumed  cardiac causes  in a patient  with or without  preexisting  heart  disease,  within  1 hour  
after the onset  of acute symptoms  or, in the  case of an unwitnessed  death,  within  24 hours  after 
the patient  was last seen alive and stable.  If the cause of death  is unknown  and         cannot  be 
ascertained  at the time of reporting,  "unexplained  death"  should  be recorded  on the  Adverse 
Event  eCRF.  If the cause of death  later becomes  available (e.g.,  after autopsy),  "unexplained  
death"  should be  replaced  by the established  cause of death.  
 
During  survival  follow -up, deaths  should be  entered  in the Adverse Event  eCRF.  
 
Adverse  Events  After the Reporting Period  
After  the end of the adverse event  reporting  period, all deaths,  regardless  of cause,  should be  
reported  through  use of the Long -Term  Survival  Follow -Up eCRF.  In addition,  if the 
investigator  becomes  aware  of a serious  adverse event  that is believed  to be  related  to prior  
study  drug treatment,  the event  should be  reported  through  use of the Adverse Event  eCRF.  
 
 
The sponsor -investigator  must  notify FDA  in an IND safety  report  of potential  serious  risks as 
soon  as possible,  but in no case later than 15 calendar  days after it is determined  that the 
information  qualifies  for reporting.  (21 CFR 312.32(c)(1)) .  
 
The sponsor -investigator  must  notify  FDA  of any unexpected  fatal or life-threatening  adverse  
reactions  as soon  as possible,  but in no case later than 7 calendar  days after the sponsor - 
investigator’s  initial  receipt  of the information.  (21 CFR  312.32(c)(2)).  
 
The study  clinician  will complete  an SAE Form  within  the following  timelines:  
• All deaths  and immediately  life-threatening  events,  whether related  or unrelated,  will 
be recorded  on the  SAE Form  and submitted  to Merck/ Pfizer  within  24 hours  of site 
awareness.   
8.4.2  SERIOUS  ADVERSE  EVENT  REPORTING  
PROTOCOL  # 17-0466  
PI: Christopher  H. Lieu,  MD 
Version  Date:  12.30 .2021  
 
 
 
 
 
 
    
Page 61 of 106  • Other  SAEs,  regardless  of relationship,  will be submitted  to Merck/ Pfizer  withi n 24 
hours  of site awareness.  
 
All SAEs will be reported using the FDA 3500A Mandatory MedWatch report form. SAE form 
can be found at:  
 
http://www.fda.gov/downloads/AboutFDA/ReportsManualsForms/Forms/UCM048334.pdf  
 
After informed consent has been obtained but prior to initiation of study drug, only serious adverse 
events caused by a protocol -mandated intervention should be reported.  After initiation of study 
drug, serious adverse events and adverse events of special interest will be reported until 90 days 
after the last dose of study drug.   
 
All SA Es will also be submitted within 24 hours of knowledge of the event, regardless of the 
relationship of the event to the treatment plan regimen, to the OCRS team for determination of 
further reporting to the FDA and COMIRB in accordance with the protocol.  Please submit to 
DSMC within 5 business days. To submit an SAE, email as follows:  
 
To:    CPDM.IIT@cuanschutz.edu  
   Christopher.Lieu@cuanschutz.edu  
DSMC@cuanschutz.edu  
 
Subject:   17-0466 SAE Report Form  
 
Body of Email:  List the following information as assessed by the Investigator -  
• whether the event is expected or unexpected  
• causality of events in relation to all study medications  
• whether the SAE is related to disease progression  
• CTCAE grade   
 
FAX SAE to Merck Global Safety using the Merck cover sheet within 24 hours of knowledge 
of the event.  
   Fax #: 1 (215) 993 -1220  
 
FAX SAE to Pfizer Drug S afety Unit using the Pfizer cover sheet kit within 24 hours of 
knowledge of the event.  
   Fax #: 1 -866-997-8322  
 
All SAEs  will be followed  until satisfactory  resolution or  until the site PI deems the  event  to be  
chronic  or the adherence  to be stable.  Other  supporting  documentation  of the event  may be 
requested  by Merck/ Pfizer  and should be  provided  as soon as possible.  
 
The Sponsor -Investigator  will be responsible  for notifying  FDA  of any unexpected fatal or life- 
threatening  suspected  adverse  reaction  as soon  as possible  but in no case later than 7 calendar  
days after the sponsor -investigator’s  initial  receipt  of the information.  
 
 
 
PROTOCOL  # 17-0466  
PI: Christopher  H. Lieu,  MD 
Version  Date:  12.30 .2021  
 
 
 
 
 
 
    
Page 62 of 106   
The study  will follow  COMIRB’s  guidance  for UAP  reporting  and the DSMC’s  requirements  
as discussed  herein.  Events  that meet  the definition  of an unanticipated  problem  must  be 
reported  to the COMIRB  within  5 days of their occurrence.  
 
 
 
Adverse events of special interest (AESI) must meet the definition of an adverse event to be 
considered an AESI. Adverse events  of special  interest for Pembrolizumab  are defined  as 
Grade 2 or higher hypothyroidism,  hyperthyroidism,  pneumonitis,  infusion  reactions,  colitis,  
severe skin reactions,  adrenal  insufficiency,  myocarditis,  hepatitis,  hypophysitis,  thyroiditis,  
uveitis,  myositis,  pancreatitis,  T1DM,  nephritis,  Guillan -Barre  syndrome , myasthenic  
syndrome, encephalitis, sarcoidosis, myelitis, vasculitis, sclerosing cholangitis, fatal Stevens -
Johnson Syndrome, and Toxic Epidermal Necrosis.  
 
AESIs  for binimetinib  are defined  as Grade 2 or higher  ocular events  (retinal,  vascular  eye or 
other  events),  dermatologic  events  (rash  and other  skin events),  edema,  
myopathy/rhabdomyolysis  including  CK elevation,  cardiac events  including  LVEF  decreases,  
hypertension , GI events,  pneumonitis,  hemorrhage,  and thrombotic  and embolic  events.  
 
Events That  Occur  prior  to Study Drug  Initiation  
After  informed  consent  has been  obtained  but prior to initiation  of study  drug,  only serious  
adverse events  caused  by a protocol -mandated  intervention  should be  reported  as applicable .  
 
Events That  Occur  after  Study  Drug  Initiation  
After  initiation  of study  drug,  serious  adverse events  and adverse  events  of special  interest  will 
be reported  until 90 days after the last dose of study  drug.  Investigators  should  record  all case 
details  that can be gathered  immediately  (i.e., within  24 hours  after learning  of the event)  on 
the Serious  Adverse Event/Adverse  Event  of Special  Interest  eCRF  provided  to investigators  
and submit  to the respective drug manufacturer, Merck or Pfizer  or their designee. AESIs 
related to pembrolizumab should be sent to Merck. AESIs for binimetinib should not be sent to 
Pfizer unless the AESI meets the criteria for a serious adverse event. All Serious Adverse 
Events/Adverse Events of Special Interest should be rep orted  for each cycle (during the 
following cycle) either  by faxing  or by scanning  and emailing  the form  using  the fax number 
or email  address  provided  to investigators.  
 
 
 
Pregnancies in Female  Patients  
Female  patients  of childbearing  potential  will be instructed  to immediately  inform  the 
investigator  if they become  pregnant  during  the study  or within  180 days after the last dose of 
study  drug.  A pregnancy  report  should be  completed  and submitted  to Merck/ Pfizer  or its 
designee immediately  (i.e., no more  than 24 hours  after learning  of the pregnancy),  either by 
faxing  or by scanning and emailing  the form  using  the fax number or email  address  provided  
to investigators.  Pregnancy  should not be  recorded  on the  Adverse Event  eCRF.  The 
investigator  should  discontinue study  drug and counsel  the patient,  discussing  the risks  of the 
pregnancy  and the possible effects  on the  fetus.  Monitoring  of the patient  should  continue  
8.4.3   UNANTICIPATED  PROBLEM  REPORTING  
8.4.4  EVENTS  OF SPECIAL  INTEREST  
8.4.5   REPORTING  OF PREGNANCY  
PROTOCOL  # 17-0466  
PI: Christopher  H. Lieu,  MD 
Version  Date:  12.30 .2021  
 
 
 
 
 
 
    
Page 63 of 106  until conclusion  of the pregn ancy.  Any serious adverse  events  associated  with the pregnancy  
(e.g.,  an event  in the  fetus,  an event  in the  mother during  or after the pregnancy,  or a 
congenital  anomaly/birth  defect  in the child)  should  be reported  on the  Adverse Event  eCRF.  
In addition,  the investigator  will submit  a Clinical  Trial  Pregnancy  Reporting  Form  when  
updated  information  on the course and  outcome  of the pregnancy  becomes  available.  
 
Pregnancies in Female  Partners  of Male Patients  
Male  patients  will be instructed  through  the Informed  Consent  Form  to immediately  inform  the 
investigator  if their partner  becomes  pregnant  during  the study  or within  180 days after the last 
dose of study  drug.  A Clinical  Trial  Pregnancy  Reporting Form  should  be completed  and 
submitted  to Merck/ Pfizer  or its designee  immediately  (i.e., no more  than 24 hours  after 
learning  of the pregnancy),  either  by faxing  or by scanning  and emailing  the form  using  the fax 
number or email  address  provided  to investigators.  Attempts  should be  made  to collect  and 
report  details  of the course  and outcome  of any pregnancy  in the  partner  of a male  patient  
exposed to study  drug.  An investigator  who is contacted  by the male patient  or his pregnant  
partner may provide  information  on the  risks of the pregnancy  and the possible  effects  on the  
fetus,  to support  an informed  decision  in cooperation  with the treating  physician  and/or  
obstetrician.  
 
Abortions  
Any abortion  should be  classified  as a serious  adverse  event  (as Merck/ Pfizer  considers  
abortions  to be  medically  significant),  recorded  on the  Adverse Event  eCRF,  and reported  to 
the Merck/ Pfizer  immediately  (i.e., no more  than 24 hours  after learning  of the event).  
 
Congenital Anomalies/Birth Defects  
Any congenital  anomaly/birth  defect  in a child  born to a female patient  exposed  to study  drug 
or the female  partner of a male  patient  exposed  to study  drug should be  classified  as a serious  
adverse event,  recorded  on the  Adverse Event  eCRF,  and reported  to Merck/ Pfizer  
immediately  (i.e., no more than  24 hours  after learning  of the event).  
 
8.5 Study Halting Rules  
 
During  the safety  run-in if any of the following  situations  occur,  then further enrollment  and 
study  treatments  will be halted  immediately  until a thorough  investigation  and safety  analysis  
has been conducted.  
o If any patient  experiences  death  due to an adverse  event  that is assessed  as related  to 
study  treatment  (by investigator and/or  Merck/ Pfizer , it will lead to temporary  hold of  
study  pending  review by study  team  
o Approximately  3 or more of the 10 patients  in the safety  run-in meet  individual  
stopping  rules  defined  below.  If any of the following  situations  of potentially  
overlapping  toxicities  occur and are assessed  as related  to study  treatment  by the 
investigator,  the study  treatment will be halted  immediately  for the individual  patient,  
and a thorough  investigation  and safety  analysis  will be conducted:  
- Grade 3 hypertension  for > 14 days.  
- Grade 3 hemorrhage (symptoms and transfusion  of packed  RBCs  indicated)  
- Grade 3 pneumonitis  (symptomatic,  interfering  with activities  of daily  living;  
PROTOCOL  # 17-0466  
PI: Christopher  H. Lieu,  MD 
Version  Date:  12.30 .2021  
 
 
 
 
 
 
    
Page 64 of 106  oxygen  indicated)  
- Recurrent  Grade 2 pneumonitis  
- Grade 3 left ventricular  dysfunction  (symptomatic  congestive heart  failure  
responsive  to intervention)  
 
- Grade 3 colitis  or diarrhea  not responsive  to anti-diarrheal  agents  (greater  than 7 
stools per day over baseline; incontinence;  IV fluids  for 24 hours;  hospitalization)  
- ALT or AST greater  than 5 xULN  in combination  with total bilirubin  greater  than 
2 xULN.  
 
 
 
 
Study  Oversight  
The sponsor investigator will be responsible for monitoring the trial per the trial monitoring 
plan, in addition to overseeing the safety and efficacy of the trial including any specimens 
collected, executing the data and safety monitoring (DSM) plan, and complying with all 
reporting requirements to local and federal authorities. This oversight will be accomplished 
through additional oversight from the Data and Safety Monitoring Committee (DSMC) at the 
University of Colorado Cancer Center (CU Cancer Center) . The DSMC is responsible for 
ensuring data quality and study participant safety for all clinical studies at the CU Cancer 
Center, which is the coordinating institution of this trial. A summary of the DSMC’s activities 
is as follows:  
 
•  Conduct of intern al audits  
• Ongoing review of all unanticipated adverse device effects, serious adverse events 
(SAEs), and unanticipated problems (UAPs)  
•  May submit recommendations for corrective actions to the CU Cancer Center’s 
Executive Committee  
 
Per the CU Cance r Center Institutional DSM Plan, SAEs and UAPs are reported to the 
DSMC, IRB and the sponsor investigator per protocol. All SAEs and UAPs including 
unanticipated adverse device effects are to be reported to the DSMC within 7 (for fatal or life -
threatening events) or 15 (non -life-threatening events) calendar days of the sponsor 
investigator receiving notification of the occurrence.  
 
Each subject’s treatment outcomes will be discussed by the site PI and appropriate staff at 
regularly scheduled meetings. Data regarding number of subjects, adverse device effects, 
treatment modifications and treatment responses will be discussed and documented in the 
meeting’s minutes.  
 
The sponsor investigator will provide a DSM progress report to the CU Cancer Center DSMC 
on a recurring basis (either every six or twelve months based on DSMC vote). The DSM 
report will include a protocol summary, current enrollment numbers, summary of toxicity data 
to include , SAEs, UAPs and AEs, any dose modifications, all protocol deviations, a nd 
protocol amendments. The DSM progress report submitted to the DSMC will also include, if 
applicable, the results of any efficacy data analysis conducted. Results and recommendations 
from the review of this progress report by the DSMC will then be provid ed to the sponsor 
9 STUDY  OVERSIGHT  AND  CLINICAL  MONITORING  
PROTOCOL  # 17-0466  
PI: Christopher  H. Lieu,  MD 
Version  Date:  12.30 .2021  
 
 
 
 
 
 
    
Page 65 of 106  investigator in a DSMC review letter. The sponsor investigator is then responsible for 
ensuring this letter is submitted to the site’s IRB of record at the time of IRB continuing 
review.  
 
Quality Control and Quality  Assurance  
 
1. Clinical  site monitoring  will be conducted  to ensure  that the rights  and well-being  of 
human  subjects  are protected,  that the reported  trial data are accurate,  complete,  and 
verifiable,  and that the conduct  of the trial is in compliance  with the currently  
approved  protocol/  amendment(s),  with GCP,  and with applicable  regulatory  
requirement(s).  
 
Monitoring  for this study  will be performed  by CU Cancer  Center  Clinical  Monitor  in 
accordance  with the clinical  monitoring  plan (CMP),  incorporated  herein  by reference.  
The CMP  describes  in detail  who will conduct  the monitoring,  at what  frequency  
monitoring  will be done,  at what  level  of detail  monitoring  will be performed,  and the 
distribution  of the monitoring  reports.  
 
2. Independent  audits  will be conducted  by the CU Cancer  Center  DSMC  to ensure  
monitoring  practices  are performed  consistently  across  all participating  sites,  if 
applicable,  and that monitors  are following  the CMP.  In addition,  audits  may be 
conducted  at any time by appropriate regulatory  authorities  and/or  the IRB. 
 
 
 
 
10.1 Statistical and Analytical Plans  
 
The primary  analysis  will be based  on patient  data collected  through  study  discontinuation  or 
at the end of study.  All analyses  will be conducted  using  the safety -evaluable  population,  
defined  as all patients  who receive any amount  of study  drug.  
 
No formal  hypothesis  testing  is planned.  The safety,  tolerability,  and clinical  activity  of 
binimetinib  with pembrolizumab  and bevacizumab  will be described  and summarized.  
 
Data will be described  and summarized  as warranted  by sample  size. That is, listings  may be 
used in lieu of tables  in the event  of small sample  size. 
 
Descriptive  statistics  will be used to summarize  the safety  and clinical  activity  of treatment  
regimens.  Continuous  variables  will be summarized  using  mean,  standard  deviation,  median,  
and range;  categorical  variables  will be summarized  using  count  and percentage.  
 
10.2 Statistical Hypotheses  
 
• Primary  Endpoint(s):  
Response  rate based  on CT imaging,  defined  as complete or partial  response according  
to RECIST  v1.1.  
 
10 STATISTICAL  CONSIDERATIONS  
PROTOCOL  # 17-0466  
PI: Christopher  H. Lieu,  MD 
Version  Date:  12.30 .2021  
 
 
 
 
 
 
    
Page 66 of 106  • Secondary  Endpoint(s):  
1. Progression  free survival,  defined  as the time from  enrollment  to the  first 
observation  of progressive disease  or death  from  any cause.  
2. Overall  survival,  defined  as the time from  enrollment  to death  from  any cause.  
3. Grade 1, 2, 3, 4 toxicities  associated with pembrolizumab,  bevacizumab,  and 
binimetinib  as defined  by CTCAE  v4. 
 
10.3 Analysis Datasets  
 
Not applicable.  
 
10.4 Description of Statistical Methods  
 
 
 
This study  will include up to 7 5 participants ( to reach a total of 50 evaluable participants), 
who have advanced or metastatic  colorectal  adenocarcinoma  refractory  to standard  
therapy.  The first  10 patients  will be included  in the safety  lead-in. 
 
The expected  ORR  for colorectal  adenocarcinoma in the  third line setting  is less than 5%. We 
will thus use  the null hypothesis  that the ORR  is 5%. The combination  of pembrolizumab,  
trametinib,  and bevacizumab  will be considered  worthy  of further  study  if the observed  ORR  
is promising  (ie significantly  greater than  5%).  
 
The sample  size was  calculated  based  on using  an upper  1-sided  exact  binomial test, 
controlling  the type 1 error rate at 0.025 and using  a null proportion  of 0.05.  Using  38 
subjects  would  provide exactly  80.0%  power  to detect  an alternative  value of 0.20.  A sample  
size of 40 subjects  was decided  upon in order to have slightly  better  power (83.9%).  With 40 
subjects,  an upper  one-sided  exact  binomial  test will have at least 80% power to detect  true 
ORR  values  of at least 0.20,  when  the null ORR  is 0.05 and the type 1 error  rate is controlled  
at 0.025.  The table  below displays  the power available  to detect  a range of ORRs.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The primary  efficacy  endpoint of  objective  response rate (ORR)  will be tested  statistically  
using  an upper 1 -sided  exact  binomial  test. The null ORR  will be set to 0.05 and the type 1 
error rate  will be controlled  at 0.025.  The upper critical  value  is 6 (i.e. if 6 or more  of the 40 
subjects  respond,  the null hypothesis,  H0: p = 0.05, will be rejected).  
10.4.1  General Approach  
10.4.2  Analysis of the Primary Efficacy Endpoint(s)  Alternative  
ORR  Power  
0.20 0.839  
0.25 0.957  
0.30 0.991  
0.35 0.999  
0.40 > 0.999  
 
PROTOCOL  # 17-0466  
PI: Christopher  H. Lieu,  MD 
Version  Date:  12.30 .2021  
 
 
 
 
 
 
    
Page 67 of 106   
Besides  the results  from the formal  statistical  test, the primary  efficacy  ORR  endpoint  will be 
summarized  using  the proportion  and 95% exact  binomial  confidence  interval.   Individual  
subject -level  results  will also be reported  using  a listing.  
  
 
 
 
The secondary  endpoints  of progression -free survival  (PFS)  and overall  survival  (OS)  will be 
measured  from  the start of protocol  therapy  until the  first evidence of any disease  progression  
or death,  respectively.  The Kaplan -Meier  product -limit  method  will be used to summarize  the 
time-to-event  results.  Point  estimates  (e.g. the median  time-to-event  and proportion  at 6 
months)  and 95% confidence  intervals  will be calculated.   Results  will additionally  be 
displayed  in figures  using  Kaplan -Meier  survival  curves.  
 
 
 
 
Safety  will be assessed  through  summaries  of adverse events.   Adverse  events  will include  
exposure  to the  study  treatment,  changes  in vital signs,  and changes  in laboratory  values.  
Additionally,  separate  summaries  will be created  which  will include  only serious adverse  
events  (SAEs).  When subjects  experience multiple events  of varying  severity,  the highest  
grade will be used in the  subject -level summaries.  
 
Toxicity  will be summarized  and tabulated  based  on organ  and severity.  
 
 
 
 
Subject  retention  and compliance  with the protocol  will be reported  using:  
1) A CONSORT  diagram illustrating  the subject  flow through  the trial 
2) Tables  summarizing  retention  and compliance  
3) Listings  showing  retention  and compliance  results  at the individual  subject  level  
 
 
 
 
Subject  characteristics  at baseline will be summarized  using  descriptive statistics.  Continuous  
variables  will be summarized  by reporting  the mean,  standard  deviation  and quartiles  
(minimum,  Q1, median,  Q3, and maximum).  Categorical  variables  will be summarized  using  
counts  and percentages.  
 
 
 
Due to the  small  sample  size, no planned  interim analysis  will be performed  
 
 
 
10.4.3  Analyses of the Secondary Endpoints(s)  
10.4.4  Safety Analyses  
10.4.5  Adherence and Retention Analyses  
10.4.6  Baseline Descriptive Statistics  
10.4.7  Planned Interim Analyses  
PROTOCOL  # 17-0466  
PI: Christopher  H. Lieu,  MD 
Version  Date:  12.30 .2021  
 
 
 
 
 
 
    
Page 68 of 106   
No additional  sub-group  analyses  are planned.  
 
 
 
There  will be no adjustments  for multiple testing.  
 
 
 
 
Tabulation  data sets will be created  which  provide a tabular listing  of subject  data for all 
domains  (e.g. demographics,  outcomes,  adverse  events,  etc). 
 
 
 
Potential biomarkers  include  PD-L1 levels,  phophoryalted  ERK expression,  mismatch  repair  
status,  among  others.  Exploratory  analyses  will be performed  in an effort  to investigate  if 
there  is an association  between  these  potential  biomarkers  and 1) response  to treatment  and 2) 
adverse events.  
 
10.5 Sample Size  
 
This study  will include up to 7 5 participants ( to reach a total of 50 evaluable participants)  
with advanced  or metastatic  colorectal  adenocarcinoma  refractory  to at least two lines  of 
prior  standard  therapy.  The first  10 participant s will be included  in the  safety  lead-in. 
 
10.6 Measures to Minimize Bias  
 
Subjects  will be randomized  to the  2 Cohorts  (Cohort  A vs Cohort  B) using  a blocked  
randomization.  The randomization  list will be generated  by the study  biostatistician  and 
provided  only to the  study  personnel  who will be responsible for assigning  the each subject  to 
a cohort  of the study.  
 
 
 
Quality  Control  (QC)  procedures  will be implemented  beginning  with the data entry  system  and 
data QC checks  that will be run on the database  will be generated.  Any missing  data or data 
anomalies  will be communicated  to the site(s)  for clarification/  resolution.  
 
Following  written  SOPs,  the study  monitor  will verify  that the clinical  trial is conducted  and 
data are generated,  documented  (recorded),  and reported  in compliance  with the protocol,  GCP,  
and the applicable  regulatory  requirements  [e.g., Good  Laboratory  Practices  (GLP),  Good  
Manufacturing  Practices  (GMP) ]. 
 
 
10.4.8  Additional Sub -Group Analyses  
10.4.9  Multiple Comparison/Multiplicity  
10.4.10  Tabulation of Individual Response Data  
10.4.11  Exploratory Analyses  
11 QUALITY  ASSURANCE  AND  QUALITY  CONTROL  
PROTOCOL  # 17-0466  
PI: Christopher  H. Lieu,  MD 
Version  Date:  12.30 .2021  
 
 
 
 
 
 
    
Page 69 of 106   
The investigational  site will provide  direct  access  to all trial-related  sites,  source  data/ 
documents,  and reports  for the purpose  of monitoring  and auditing  by the DSMC  audit  team,  
and inspection  by local  and regulatory  authorities.  
 
 
 
12.1 Ethical Standard  
 
The PI will ensure  that this study  is conducted  in full conformity  with regulations  for the 
Protection  of Human  Subjects  of Research  codified  in 45 CFR  Part 46, 21 CFR Part 50, 21 CFR 
Part 56. ICH E6 may also be followed  to the extent  it has been  adopted  by and is in accordance  
with FDA  regulations.  
 
12.2 Institutional Review Board  
 
The protocol,  informed  consent  form(s),  recruitment  materials,  and all participant  (subject)  
materials  will be submitted  to the Colorado  Multiple Institutional  Review  Board  (COMIRB)  for 
review  and approval.  Approval  of both the protocol  and the consent  form  must  be obtained  
before  any subject  is enrolled.  Any amendment  to the protocol  will require  review  and approval  
by COMIRB  before the changes  are implemented  to the study.  All changes  to the consent  form  
will COMIRB approved;  a determination  will be made regarding  whether previously  consented  
subjects  need  to be  re-consented.  
 
12.3 Informed Consent Process  
 
The Consent  Forms  must  be signed  and dated  by the patient  or the patient’s  legally  authorized  
representative  before his or  her participation  in the study.  The case history  or clinical  records  
for each patient shall  document  the informed  consent  process  and that written  informed  
consent  was obtained  prior to participation  in the  study.  
 
The Consent  Forms  should  be revised  whenever there are changes  to study  procedures  or 
when  new information  becomes  available  that may affect  the willingness  of the patient  to 
participate.  The final  revised  IRB/EC -approved  Consent  Forms  must be  provided  to 
Merck/ Pfizer  for review.  
 
 
Patients  must be  re-consented  to the  most current  version  of the Consent  Forms  (or to a 
significant  new information/findings  addendum  in accordance with applicable  laws and 
IRB/EC  policy)  during  their participation  in the study.   For any updated or  revised  Consent  
Forms,  the case history  or clinical  records  for each patient  shall document  the informed  
consent  process  and that written  informed  consent  was obtained  using  the updated/revised  
Consent  Forms  for continued  participation  in the  study.  
 
A copy  of each signed  Consent  Form  must be  provided  to the  patient  or the patient’s  legally  
authorized  representative.  All signed  and dated  Consent  Forms  must remain  in each patient’s  
study  file or in the  site file and  must be  available  for verification  by study  monitors  at any 
time.  
 
12 ETHICS/PROTECTION  OF HUMAN  SUBJECTS  
PROTOCOL  # 17-0466  
PI: Christopher  H. Lieu,  MD 
Version  Date:  12.30 .2021  
 
 
 
 
 
 
    
Page 70 of 106  Consent  Form  may also include patient  authorization  to allow  use and disclosure of personal  
health  information  in compliance  with the U.S. Health  Insurance  Portability  and 
Accountability  Act (HIPAA)  of 1996.  If the site utilizes a  separate Authorization  Form  for 
patient  authorization  for use and disclosure  of personal  health  information  under  the HIPAA  
regulations,  the review,  approval,  and other  processes  outlined  above  apply  except  that IRB 
review  and approval  may not be  required  per study  site policies.  
 
 
 
Consent  forms  describing  in detail  the study  agent,  study  procedures,  and risks are given  to the 
subject and  written  documentation  of informed  consent  is required  prior  to starting  intervention/  
administering  study  product.  
 
 
 
Informed  consent  process  will be initiated  prior  to the individual’s  agreeing  to participate  in the  
study  and continues  throughout  the individual’s  study  participation.  Extensive  discussion  of 
risks  and possible benefits  of participation  will be provided  to the  subjects  and their families.  
 
Consent  forms  will be IRB-approved  and the subject  will be asked  to read and review  the 
document.  The investigator  will explain  the research  study  to the subject  and answer  any 
questions  that may arise.  All subjects  will receive  a verbal  explanation  in terms  suited  to their 
comprehension  of the purposes,  procedures,  and potential  risks of the study  and of their rights  
as research  subjects.  Subjects  will have  the opportunity  to carefully review  the written  consent  
form  and ask questions  prior  to signing.  The subjects  will have  the opportunity  to discuss  the 
study  with their surrogates  or think  about  it prior  to agreeing  to participate.  The subject  will sign 
the informed  consent  document  prior to any  procedures  being  done  specifically  for the study.  
 
The subjects  may withdraw  consent  at any time throughout  the course  of the trial. A copy  of the 
informed  consent  document  will be given  to the subjects  for their records.  The rights  and welfare  
of the subjects  will be protected  by emphasizing  to them  that the quality of their medical  care 
will not be  adversely  affected  if they decline to participate  in this  study.  
 
The study  allows  the inclusion  of non-English  speaking  and non-reading  subjects.  Witnesses  
to these  consent  processes  will be individuals  not associated  with the trial and will not have a 
conflict  of interest.  
 
12.4 Participant and Data Confidentiality  
 
Participant  confidentiality  is strictly  held in trust by the participating  PI, their staff,  and 
Merck/ Pfizer  and their agents. This confidentiality  is extended  to cover  testing  of biological  
samples  and genetic  tests in addition  to the  clinical information  relating  to subjects.  Therefore,  
the study  protocol,  documentation,  data,  and all other information  generated  will be held in 
strict  confidence.  No information  concerning  the study  or the data will be released  to any  
unauthorized  third  party  without  prior  written  approval  of the sponsor -investigator.  
 
The study  monitor,  other authorized  representatives  of the sponsor -investigator,  
representatives  of the IRB or pharmaceutical  company  supplying  study  product may  inspect  
12.3.1  Consent/Assent and Other Informational Documents Provided to Subjects  
12.3.2  Consent Procedures and Documentation  
PROTOCOL  # 17-0466  
PI: Christopher  H. Lieu,  MD 
Version  Date:  12.30 .2021  
 
 
 
 
 
 
    
Page 71 of 106  all documents  and records  required  to be  maintained  by the investigator,  including  but not  
limited  to, medical  records  (office,  clinic,  or hospital) and  pharmacy  records for the subjects  in 
this study.  The clinical  study  site will permit  access  to such records.  
 
The study  subject’s  contact  information  will be securely  stored for internal  use during  the 
study.  At the end  of the study,  all records  will continue  to be  kept in a secure  location  for as 
long a period  as dictated  by local  IRB and Institutional  regulations.  
 
Study  subject research  data,  which  is for purposes  of statistical  analysis  and scientific  
reporting,  will be transmitted  to and stored  at the University  of Colorado  Cancer Center.  This 
will not include the subject’s  contact  or identifying  information.  Rather,  individual  subjects  
and their research  data will  be identified  by a unique  study  identification  number.  The study  
data entry  and study  management  systems  used by the clinical  site and by the University  of 
Colorado  Cancer  Center research  staff will  be secured  and password  protected.  At the end of 
the study,  all study  databases  will be de-identified  and archived  at the University  of Colorado  
Cancer  Center  
 
 
 
• Intended  Use:  Samples  and data collected  under this protocol  may be used to assess  
Tumor Infiltrating  Lymphocytes  (TILs)  to study  patterns  of resistance  to 
immunotherapy.  No genetic testing  will be performed.  
• Storage:  Access  to stored  samples  will be limited  to research  personnel  only.  Samples  
and data will be stored  using  codes  assigned  by the investigators.  Data will be kept in 
password -protected  computers.  Only  investigators  will have access  to the  samples  and 
data. 
• Disposition  at completion  of the study : Consent  will be obtained  from  all patients  for 
tumor  tissue  banking.  Patients  can withdraw consent  for tumor banking  at any time.  
All stored  samples  will be sent to the  University  of Colorado  Biorepository.  Study  
subjects  who request destruction  of samples  will be notified  of compliance  with such  
• request  and all supporting  details  will be maintained  for tracking.  
 
12.5 Future use of Stored Specimens  
 
Specimens collected during the study will not be banked nor used for future research.  
 
 
 
13.1 Data Collection and Management Responsibilities  
 
Data  collection  is the responsibility  of the clinical  trial staff at the site under  the supervision  of 
the PI. The PI is responsible  for ensuring  the accuracy,  completeness,  legibility,  and 
timeliness  of the data reported.  
 
 
 
12.4.1  Research Use of Stored Human Samples, Specimen, and Data  
13 DATA  HANDLING  AND  RECORD  KEEPING  
PROTOCOL  # 17-0466  
PI: Christopher  H. Lieu,  MD 
Version  Date:  12.30 .2021  
 
 
 
 
 
 
    
Page 72 of 106  Source  Documentation  
 
All source  documents  should  be completed  in a neat,  legible  manner to ensure accurate  
interpretation  of data.  When  making  changes  or corrections,  cross  out the  original  entry  with a  
 
single  line, and initial  and date the change.  DO NOT ERASE,  OVERWRITE,  OR USE  
CORRECTION  FLUID  OR TAPE  ON THE  ORIGINAL.  
 
Source  documents  (paper  or electronic) are those  in which  patient  data are recorded  and 
documented  for the first time.  They  include,  but are  not limited  to, hospital  records,  clinical  
and office  charts,  laboratory  notes,  memoranda,  patient -reported  outcomes,  evaluation  
checklists,  pharmacy  dispensing  records,  recorded  data from  automated  instruments,  copies  of 
transcriptions  that are certified  after verification  as being  accurate and complete,  microfiche,  
photographic  negatives,  microfilm  or magnetic media,  X-rays, patient  files,  and records  kept 
at pharmacies,  laboratories,  and medico -technical departments  involved  in a clinical  trial. 
 
Before study  initiation,  the types  of source documents that are to be  generated  will be clearl y 
defined  in the  Trial  Monitoring  Plan.  This includes  any protocol data to be  entered  directly  
into the  eCRFs  (i.e., no prior written  or electronic  record  of the data) and  considered  source  
data. 
 
Source  documents  that are required  to verify  the validity  and completeness  of data entered  
into the  eCRFs  must not  be obliterated  or destroyed  and must be  retained  per 
the policy  for retention  of records  described  in Section  7.5. 
 
To facilitate  source data  verification,  the investigators  and institutions  must  provide  
Merck/ Pfizer  direct  access  to applicable  source documents  and reports  for trial-related  
monitoring,  Sponsor -Investigator  audits,  and IRB/EC  review.  The study  site must also allow  
inspection  by applicable health  authorities.  
 
When clinical  observations  are entered  directly  into a  study  site’s  computerized  medical  
record  system  (i.e., in lieu of original  hardcopy  records),  the electronic  record  can serve as  the 
source  document  if the system  has been  validated  in accordance with  health  authority  
requirements  pertaining  to computerized  systems  used in clinical  research.  
 
An acceptable  computerized  data collection  system  allows  preservation  of the original  
entry  of data.  If original  data are modified,  the system  should maintain  a viewable  audit  
trail that shows  the original  data as well as the reason  for the change,  name of the person  
making  the change,  and date of the change.  
 
Electronic  Case Report  Forms  (eCRF)  
 
Clinical  data (including  AEs,  concomitant  medications,  and expected  adverse  reactions  data)  and 
clinical  laboratory  data will be entered  into a electronic  data capture  system  provided  by the 
University  of Colorado.  
 
eCRFs  are to be  completed  through  use of a Sponsor -Investigator  designated  EDC  system.  Sites  
will receive  training  and have access  to a manual  for appropriate  eCRF  completion.  The data 
system includes  password  protection  and internal  quality  checks,  such as automatic  range  
PROTOCOL  # 17-0466  
PI: Christopher  H. Lieu,  MD 
Version  Date:  12.30 .2021  
 
 
 
 
 
 
    
Page 73 of 106  checks,  to identify  data that appear  inconsistent,  incomplete,  or inaccurate.  Clinical  data will be 
entered  directly  from  the source documents.  All eCRFs  should be  completed  by designated,  
trained  site staff.  eCRFs  should  be reviewed  and electronically  signed  and dated  by the 
investigator  or a designee.  
 
At the end of the study,  any hard copy  of patient  data received  by the investigator for  his or  
her site must be  stored  safely  with the study  records. Acknowledgement  of receipt  of the 
compact  disc is required.  
 
Copies  of the electronic  CRF  (eCRF)  will be provided  for use as source documents  and 
maintained  for recording  data for each  subject  enrolled  in the  study.  Data reported  in the  
eCRF  derived  from  source documents  should be  consistent  with the source  documents  or the 
discrepancies  should be  explained  and captured  in a progress  note and maintained  in the  
subject’s  official  electronic  study  record.  
  
Data  Quality Assurance  
 
The Sponsor -Investigator  will be responsible  for data management  of this study,  including  
quality  checking  of the data.  Data entered  manually  will be collected  via EDC  through  use of 
eCRFs.  Site will be responsible for  data entry  into the EDC  system.  
 
The Sponsor -Investigator  will produce  an EDC  Study  Specification  document  that describes  
the quality  checking  to be performed on the  data.  
 
eCRFs  and correction  documentation  will be maintained  in the EDC  system’s  audit  trail. 
System  backups  for data stored  by the Sponsor -Investigator  and records  retention  for the study  
data will be consistent  with the Sponsor -Investigator’s  standard  procedures.  
 
13.2 Study Records Retention  
Study  documents  should  be retained  for a minimum  of 2 years  after the last approval  of an 
investigational  marketing  application  and until there are no pending  or contemplated  marketing  
applications  or until at least 2 years  have  elapsed  since  the formal  discontinuation  of clinical  
development  of the investigational  product.  These  documents  should  be retained  for a longer  
period,  however,  if required  by local  regulations,  or institution  policies.  No records  will be 
destroyed  without  the written  consent  of Merck/ Pfizer , if applicable.  It is the responsibility  of 
the Merck/ Pfizer to inform the  PI when  these documents  no longer  need  to be retained.  
 
13.3 Protocol Deviations  
 
A protocol  deviation  is any noncompliance  with the clinical  trial protocol,  GCP,  or SOP 
requirements.  The noncompliance  may be either  on the part of the subject,  the investigator,  or 
the study site  staff.  As a result  of deviations,  corrective  actions  are to be developed  by the site 
and implemented  promptly.  These practices  are consistent  with ICH E6, sections:  
• 4.5 Compliance  with Protocol,  sections  4.5.1, 4.5.2,  and 4.5.3.  
• 5.1 Quality  Assurance and Quality  Control,  section  5.1.1.  
• 5.20 Noncompliance,  sections  5.20.1 and 5.20.2.  
 
 
PROTOCOL  # 17-0466  
PI: Christopher  H. Lieu,  MD 
Version  Date:  12.30 .2021  
 
 
 
 
 
 
    
Page 74 of 106  It is the  responsibility  of the study  team  to use  continuous vigilance  to identify  and report  
deviations.  Deviations  will be reported  to the  DMSC  and IRB according  to UCCC  DSM  plan 
and institutional policy.  
 
13.4 Publication and Data Sharing Policy  
 
This study  will comply  with the NIH Public  Access  Policy,  which  ensures  that the public  has 
access  to the published  results  of NIH-funded  research.  It requires  scientists  to submit  final 
peer-reviewed  journal  manuscripts  that arise  from  NIH funds  to the digital  archive  PubMed  
Central  upon acceptance  for publication.  
 
The International  Committee  of Medical  Journal  Editors  (ICMJE)  member  journals  have 
adopted  a clinical  trials  registration  policy  as a condition  for publication.  The ICMJE  defines  a 
clinical  trial as any research  project  that prospectively  assigns  human  subjects  to intervention  
or concurrent  comparison  or control  groups  to study  the cause -and-effect  relationship  between  
a medical  intervention  and a health  outcome.  Medical  interventions  include  drugs,  surgical  
procedures,  devices,  behavioral  treatments,  process -of-care changes,  and the like. Health  
outcomes  include  any biomedical  or health -related  measures  obtained  in patients  or subjects,  
including  pharmacokinetic  measures  and adverse  events.  The ICMJE  policy,  and the Section  
801 of the Food  and Drug  Administration  Amendments  Act (FDAAA)  of 2007  requires  that 
all clinical  trials  be registered  in a public  trials  registry  such as ClinicalTrials.gov,  which  is 
sponsored  by the National  Library  of Medicine.  Other  biomedical  journals  are considering  
adopting  similar  policies.  For interventional  clinical  trials  performed  under  NIH IC grants  
and cooperative  agreements,  it is the  grantee’s  responsibility  to register the trial in an acceptable 
registry,  so the research  results  may be considered  for publication  in ICMJE  member  journals.  
The ICMJE  does not review  specific  studies  to determine  whether  registration  is necessary;  
instead,  the committee  recommends  that researchers  who have  questions  about  the need to 
register  err on the side of registration  or consult  the editorial  office  of the journal  in which  they 
wish  to publish.  
 
FDAAA mandates  that a “responsible party”  (i.e., the sponsor -investigator)  register  and report  
results  of certain  “applicable  clinical  trials”.  
• Trials  of Drugs  and Biologics: Controlled,  clinical investigations,  other  than Phase  
I investigations,  of a product  subject  to FDA regulation;  
• Trials  of Devices: Controlled  trials  with health  outcomes  of a product  subject  to 
FDA regulation  (other  than small  feasibility  studies) and pediatric  postmarket  
surveillance  studies.  
 
 
 
Not applicable.  
 
 
 
Independence  of this study  from  any actual  or perceived  influence,  such as by the 
pharmaceutical  industry,  is critical.  Any actual  conflict  of interest  of persons  who have  a role 
14 STUDY  ADMINISTRATION  
15 CONFLICT  OF INTEREST  POLICY  
PROTOCOL  # 17-0466  
PI: Christopher  H. Lieu,  MD 
Version  Date:  12.30 .2021  
 
 
 
 
 
 
    
Page 75 of 106  in the design,  conduct,  analysis,  publication,  or any aspect  of this trial will be disclosed  and 
managed.by  the University  of Colorado  Denver’s  (UCD)  Office  of Regulatory  Compliance   
 
Conflict  of Interest  and Commitment  Management  (COIC)  program.  Persons  with a perceived  
conflict  of interest  will have  such conflicts  managed  in a way that is appropriate  to their 
participation  in the trial. Conflict  of Interest  management  plans  are project -specific  and are 
reviewed  at least annually.  UCD has integrated  the institutional  conflict  of interest management  
program  with its existing  program.  
 
 
 
 
1. National  Cancer  Institute  - Surveillance,  E., and End Results  Program,  Cancer  Stat Facts:  Colon  and 
Rectum  Cancer.  
2. Martinelli,  E., et al., Cancer  resistance  to therapies  against  the EGFR -RAS-RAF pathway:  The role of 
MEK.  Cancer  Treat  Rev,  2017.  53: p. 61-69. 
3. Andreyev,  H.J., et al., Kirsten  ras mutations  in patients  with  colorectal  cancer:  the 'RASCAL  II' study.  Br J 
Cancer,  2001.  85(5): p. 692-6. 
4. Phipps,  A.I., et al., KRAS -mutation  status  in relation  to colorectal  cancer  survival:  the joint  impact  of 
correlated  tumour  markers.  Br J Cancer,  2013.  108(8): p. 1757 -64. 
5. Hanahan,  D. and R.A. Weinberg,  Hallmarks  of cancer:  the next  generation.  Cell, 2011.  144(5): p. 646- 
74. 
6. Kakavand,  H., et al., PD-L1 Expression  and Tumor -Infiltrating  Lymphocytes  Define  Different  Subsets  of 
MAPK  Inhibitor -Treated  Melanoma  Patients.  Clin Cancer  Res, 2015.  21(14):  p. 3140 -8. 
7. Loi, S., et al., RAS/MAPK  Activation  Is Associated  with  Reduced  Tumor -Infiltrating  Lymphocytes  in 
Triple -Negative  Breast  Cancer:  Therapeutic  Cooperation  Between  MEK  and PD-1/PD -L1 Immune  
Checkpoint  Inhibitors.  Clin Cancer  Res, 2016.  22(6): p. 1499 -509.  
8. Liu, L., et al., The BRAF  and MEK  Inhibitors  Dabrafenib  and Trametinib:  Effects  on Immune  Function  and 
in Combination  with  Immunomodulatory  Antibodies  Targeting  PD-1, PD-L1, and CTLA -4. Clin Cancer   
Res, 2015.  21(7): p. 1639 -51. 
9. Blank,  C., et al., Blockade  of PD-L1 (B7-H1) augments  human  tumor -specific  T cell responses  in vitro.  Int 
J Cancer,  2006.  119(2): p. 317-27. 
10. Iwai,  Y., et al., Involvement  of PD-L1 on tumor  cells  in the escape  from  host  immune  system  and tumor  
immunotherapy  by PD-L1 blockade.  Proc  Natl  Acad  Sci U S A, 2002.  99(19):  p. 12293 -7. 
11. McDermott,  D.F. and M.B.  Atkins,  PD-1 as a potential  target  in cancer  therapy.  Cancer  Med,  2013.  2(5): 
p. 662-73. 
12. Nishimura,  H., et al., Development  of lupus -like autoimmune  diseases  by disruption  of the PD-1 gene  
encoding  an ITIM  motif -carrying  immunoreceptor.  Immunity,  1999.  11(2): p. 141-51. 
13. Nomi,  T., et al., Clinical  significance  and therapeutic  potential  of the programmed  death -1 
ligand/programmed  death -1 pathway  in human  pancreatic  cancer.  Clin Cancer  Res, 2007.  13(7): p. 
2151 -7. 
14. Okudaira,  K., et al., Blockade  of B7-H1 or B7-DC induces  an anti-tumor  effect  in a mouse  pancreatic  
cancer  model.  Int J Oncol,  2009.  35(4): p. 741-9. 
15. Merck  Sharp  & Dohme,  C., Pembrolizumab  - Investigator's  Brochure.  2021. 
16. Gabrilovich,  D.I., et al., Production  of vascular  endothelial  growth  factor  by human  tumors  inhibits  the 
functional  maturation  of dendritic  cells.  Nat Med,  1996.  2(10):  p. 1096 -103.  
17. Manzoni,  M., et al., Immunological  effects  of bevacizumab -based  treatment  in metastatic  colorectal  
cancer.  Oncology,  2010.  79(3-4): p. 187-96. 
18. Ohm,  J.E. and D.P. Carbone,  VEGF  as a mediator  of tumor -associated  immunodeficiency.  Immunol  Res, 
2001.  23(2-3): p. 263-72. 
19. Ebert,  P.J., et al., MAP  Kinase  Inhibition  Promotes  T Cell and Anti-tumor  Activity  in Combination  with  
PD-L1 Checkpoint  Blockade.  Immunity,  2016.  44(3): p. 609-21. 
16 LITERATURE  REFERENCES  
PROTOCOL  # 17-0466  
PI: Christopher  H. Lieu,  MD 
Version  Date:  12.30 .2021  
 
 
 
 
 
 
    
Page 76 of 106  20. Ribas,  A., et al., Pembrolizumab  in combination  with  dabrafenib  and trametinib  for BRAF -mutant  
advanced  melanoma:  Phase  1 KEYNOTE -022 study.  J Clin Oncol,  2016.  34(suppl;  abstr  3014).  
21. Elamin,  Y.Y., et al., Immune  effects  of bevacizumab:  killing  two birds  with  one stone.  Cancer  
Microenviron,  2015.  8(1): p. 15-21. 
22. Osada,  T., et al., The effect  of anti-VEGF  therapy  on immature  myeloid  cell and dendritic  cells in cancer  
patients.  Cancer  Immunol  Immunother,  2008.  57(8): p. 1115 -24. 
23. Terme,  M., E. Tartour,  and J. Taieb,  VEGFA/VEGFR2 -targeted  therapies  prevent  the VEGFA -induced  
proliferation  of regulatory  T cells  in cancer.  Oncoimmunology,  2013.  2(8): p. e25156.  
PROTOCOL  # 17-0466  
PI: Christopher  H. Lieu,  MD 
Version  Date:  12.30 .2021  
 
 
 
 
 
 
    
Page 77 of 106   
 
 
Appendix 1  
GUIDELINES  FOR  TOXICITY MANAGEMENT  
 
Binimetinib may continue at the discretion of the investigator per medical judgment if subjects are 
receiving benefit . Written communication or documentation should be present denoting that all 
research personnel are aware of the decision.  
 
Table  3. Guidelines  for the Management  of Pembrolizumab - and Binimetinib -Associated  
Hepatotoxicity  
 
LFT Abnormalities  Management  
AST/ALT  ULN to  3  ULN 
with total bilirubin   2 ULN  
(Grade 1) • Continue pembrolizumab, binimetinib, and bevacizumab.  
• Continue with the standard monitoring plan (i.e., 
LFTs q4w before dosing).  
AST/ALT   3  baseline  
values  to  5  ULN  with 
total bilirubin   2  ULN  
(Grade 2) • Hold  binimetinib  until  LFT abnormalities  decrease  to 
grade  1. 
• Monitor  LFTs  at least  weekly.  
• Consider  referral  to a hepatologist  and liver  biopsy.  
• For suspected  immune  related  events  of > 5 days  
duration  
- Consider  withholding pembrolizumab  c 
- Consider  administering  0.5-1 mg/kg/day  oral 
prednisone  or equivalent  followed  by ≥ 1-month  taper  
- Restart  pembrolizumab  if event  resolves to Grade  1 
or better  within  12 weeks  a,   b 
- Permanently  discontinue  pembrolizumab  and 
binimetinib  if event  does not resolve  to Grade  1 or better  
within  12 weeks  a, b,  c 
AST/ALT   5  baseline  
values  to  10  ULN  with 
total bilirubin   2  ULN  
(Grade 3) • Hold  binimetinib  until  LFT abnormalities  decrease  to 
grade 1.  
• Monitor  LFTs  at least  weekly.  
• Consider  referral  to a hepatologist  and liver  biopsy.  
• For suspected immune -related  events:  
- Withhold pembrolizumab  
- Consider  administering  1-2 mg/kg/day   oral 
prednisone  or equivalent  followed  by ≥ 1 month  taper  
- If event  does not improve  within  48 hours  after  
initiating  corticosteroids, consider  adding  an 
immunosuppressive  agent.  If event  resolves  to 
- Grade  1 or better,  taper  corticosteroids  over  1 
- month.  
- Permanently  discontinue  pembrolizumab  and 
binimetinib  if event  does not resolve  to Grade  1 or better  
within  12 weeks  a, b,  c 
17 APPENDICES  
PROTOCOL  # 17-0466  
PI: Christopher  H. Lieu,  MD 
Version  Date:  12.30 .2021  
 
 
 
 
 
 
    
Page 78 of 106  Table  4. Guidelines  for the Management  of Pembrolizumab - and Binimetinib -
Associated  Hepatotoxicity  (cont.)  
 
AST/ALT   3 ULN with 
bilirubin   2 ULN • Bevacizumab  may continue  at the discretion  of the 
investigator  per medical judgment . 
• Withhold  pembrolizumab  and binimetinib.  
• Consult  hepatologist  and consider  liver  biopsy.  
• Consider  administering  1-2 mg/kg/day  oral prednisone  
or equivalent  followed  by ≥ 1 month  taper  (for possible  
autoimmune  hepatitis).  
• If LFTs  do not decrease  within  48 hr after  
initiation  of systemic  steroids,  consider  adding  an 
immunosuppressive  agent  (e.g.,  mycophenolate  or 
TNF -antagonist).  
• Monitor  LFTs  every  48-72 hours  until  decreasing  and 
then follow  weekly.  
• Restart  pembrolizumab  at fixed  dose and binimetinib  at 1 
dose reduction  after  discussion  with  medical  monitor  if 
AST/ALT  > 3 x ULN  with  bilirubin  > 2 x ULN  and 
steroid  dose < 10 mg oral prednisone  equivalent  per day.a,b,c 
 
• Permanently  discontinue  pembrolizumab  and binimetinib  
for life-threatening  hepatic  events,  and contact  the 
Medical  Monitor.  
AST/ALT   10  ULN  • Bevacizumab  may continue  at the discretion  of the  
investigator  per medical judgment . 
• Permanently  discontinue  pembrolizumab  
and binimetinib.  c 
• Consult  hepatologist  and consider  liver  biopsy.  
• Consider  administering 1−2 mg/kg/day oral prednisone  
or equivalent  (for possible  autoimmune hepatitis).  If 
event  resolves  to Grade  1 or better,  taper  corticosteroids  over  
1 month.  
• If LFTs  do not  decrease  within  48 hours  after  initiation  
of systemic  steroids,  addition  of an alternative  
immunosuppressive  agent  (e.g.,  mycophenolate  or TNF - 
antagonist)  or dose escalation  of corticosteroids  may be 
considered.  
• Monitor LFTs  every  48−72 hours  until  decreasing  and 
then follow  weekly.  
IV = intravenous;  LFT = liver function  test; q4w = every  4 weeks;  TNF = tumor  necrosis  factor;  ULN = 
upper  limit of normal.  
a If corticosteroids  have been initiated, they must  be tapered  over  1 month  to  10 mg/day  oral prednisone  
or equivalent  before  pembrolizumab  can be resumed.  
b Pembrolizumab  may be withheld  for a period  of time beyond  12 weeks  to allow  for corticosteroids to be reduced  to  10 
mg/day  oral prednisone  or equivalent.  The investigator  and the Medical  Monitor  must  agree  upon  the acceptable  length  of 
the extended  period  of time.  
c Resumption  of pembrolizumab  may be considered  in patients  who are deriving  benefit  and have fully recovered  from  the 
immune -related event.  Patients  can be rechallenged  with pembrolizumab  only after approval  has been documented  by 
both the investigator  (or an appropriate  delegate)  and the Medical  Monitor.  
 
  
PROTOCOL  # 17-0466  
PI: Christopher  H. Lieu,  MD 
Version  Date:  12.30 .2021  
 
 
 
 
 
 
    
Page 79 of 106  Pulmonary  Events  
Mild -to-moderate  events  of pneumonitis  have been reported  with pembrolizumab  and 
binimetinib.  All pulmonary  events  should  be thoroughly  evaluated  for other  commonly  
reported  etiologies  such as pneumonia/infection,  lymphangitic  carcinomatosis,  pulmonary  
embolism,  heart  failure,  chronic  obstructive  pulmonary  disease,  or pulmonary  hypertension.  
Patients  who experience  pulmonary  events  should  be managed  per the guidelines  provided  
in Table  5. 
 
For events  concerning  for pneumonitis,  consider  comprehensive  infectious  evaluation  
including  viral etiologies . 
 
Table  5. Guidelines  for the Management  of Pembrolizumab - and Binimetinib -
Associated  Pulmonary  Events  
 
Pulmonary  Events  Guidance  
General  Guidance  • Mild -to-moderate  events of pneumonitis  have been reported  with 
pembrolizumab  and binimetinib.  All pulmonary  events  should  be thoroughly  
evaluated  for other  commonly  reported  etiologies  such as 
pneumonia/infection,  lymphangitic  carcinomatosis,  pulmonary  
embolism,  heart  failure,  chronic  obstructive  pulmonary  disease,  or 
pulmonary  hypertension.  
• For events concerning for pneumonitis, consider comprehensive 
infectious evaluation including viral etiologies.  
Pneumonitis,  Grade  1 
(asymptomatic)  • Continue  pembrolizumab,  bevacizumab,  and binimetinib.  
• Re-evaluate  on serial  imaging.  
• Consider  patient  referral to pulmonary  specialist.  
• For recurrent  pneumonitis,  treat  as Grade  3 or 4   event.  
Pneumonitis,  Grade  2 • Bevacizumab  may continue at the discretion  of the investigator  
per medical  judgment.  
• Withhold  pembrolizumab  and binimetinib.  
• Refer  patient  to pulmonary  and infectious  disease  specialists  
and consider bronchoscopy  or BAL.  
• Add prophylactic antibiotics for opportunistic infections  
• If bronchoscopy  is consistent  with  immune -related  etiology,  
initiate  treatment  with  1−2 mg/kg/day  oral prednisone  or 
equivalent.  
• Resume pembrolizumab  and binimetinib  if event  resolves  to 
Grade  1 or better  within  12 weeks.  a,    b 
• Permanently  discontinue  pembrolizumab  and binimetinib  and 
contact  Medical  Monitor  if event  does not resolve  to Grade  1 
or better  within  12 weeks.  a, b,   c 
• For recurrent  events,  treat  as a Grade  3 or 4 event.  
PROTOCOL  # 17-0466  
PI: Christopher  H. Lieu,  MD 
Version  Date:  12.30 .2021  
 
 
 
 
 
 
    
Page 80 of 106   
 
IV = intravenous;  BAL  = bronchoscopic  alveolar  lavage.  
a If corticosteroids  have been initiated  (initial dose of 1 to 2 mg/kg) , they must  be tapered over  1 month to  10 mg/day  
oral prednisone  or equivalent  before  pembrolizumab  can be resumed.  
b Pembrolizumab  may be withheld  for a period  of time beyond  12 weeks  to allow  for corticosteroids  to be 
reduced  to  10 mg/day  oral prednisone  or equivalent.   The acceptable  length  of the extended  period  of 
time must  be agreed  upon  by the investigator  and the Medical  Monitor.  
c Resumption  of pembrolizumab  may be considered  in patients  who are deriving  benefit  and have fully recovered  from  
the immune -related event.  Patients  can be rechallenged  with pembrolizumab  only after approval  has been documented  
by both the investigator  (or an appropriate  delegate)  and the Medical  Monitor.  
 
  
Pneumonitis,  Grade  3/4 
 Bevacizumab  may continue  at the discretion  of the investigator  
per medical  judgment.  
Permanently  discontinue  pembrolizumab  and  binimetinib.c 
Refer  patient  to pulmonary  and infectious  disease  specialists
and consider bronchoscopy  or BAL.  
Add prophylactic antibiotics for opportunistic 
infections  
If bronchoscopy  is consistent  with  immune -related  etiology,
initiate  treatment  with  1−2 mg/kg/day  oral prednisone  or
equivalent.  
If pulmonary  event  does not improve  within  48 hr or worsens,
consider  adding  an immunosuppressive  agent (e.g.,  infliximab,
cyclophosphamide,  IV Ig, or mycophenolate  mofetil ). 
If event  resolves  to Grade  1 or better,  taper  corticosteroids
over ≥ 1 month.  
PROTOCOL  # 17-0466  
PI: Christopher  H. Lieu,  MD 
Version  Date:  12.30 .2021  
 
 
 
 
 
 
    
Page 81 of 106   
Dermatologic  Toxicity  
Treatment -emergent  rash has been associated  with pembrolizumab  and binimetinib.  The 
majority  of the cases  of rash were mild in severity  and self-limited,  with or without  
pruritus.  
 
A dermatologist  should  evaluate  persistent  and/or  severe  rash or pruritus.  A biopsy  should  
be considered  unless  contraindicated.  
 
Dermatologic  toxicity  and rash should  be managed  according  to the guidelines  in 
Table  6. 
 
Table  6. Guidelines  for the Management  of Pembrolizumab - and Binimetinib  -
Associated  Rash  
 
Dermatologic  Toxicity  Management  
General  guidance  • A dermatologist  should  evaluate persistent  and/or  severe  
rash or pruritus.  A biopsy  should  be considered  unless  
contraindicated.  
Dermatologic  event,  Grade  
1-2 • Continue  pembrolizumab,  bevacizumab  and binimetinib.  
• Initiate  supportive  care (e.g.,  antihistamines,  topical  
corticosteroids).  If event  does not improve  consider  
treatment  with higher -potency  topical  corticosteroids.  
• For Grade  2 rash,  consider  referral  to dermatologist.  
Acneiform  rash:  
• Consider  topical  corticosteroids  (e.g.,  hydrocortisone  2.5%,  
alclometasone) and oral antibiotics  (minocycline,  doxycycline,  or 
antibiotics  covering  skin flora)  as clinically  indicated.  
PROTOCOL  # 17-0466  
PI: Christopher  H. Lieu,  MD 
Version  Date:  12.30 .2021  
 
 
 
 
 
 
    
Page 82 of 106  Dermatologic  event,  Grade  3 • Bevacizumab  may continue  at the discretion  of the 
investigator  per medical  judgment.  
• Withhold  pembrolizumab  and binimetinib.  
• Refer  patient  to dermatologist.  A biopsy  should  be 
performed  if appropriate.  
• Consider  initiating  treatment  with  10 mg/day  
oral prednisone  or equivalent,  increasing  dose to 
1-2 mg/kg/day  if event  does not improve  within  48-72 
hours.  
• If event  resolves  to Grade  2 or better  within  12 weeks,  
resume  pembrolizumab  at fixed  dose.  If not, permanently  
discontinue  pembrolizumab  and binimetinib.  a,b 
• Permanently  discontinue  pembrolizumab  and binimetinib  
and contact  Medical  Monitor  if event  does not resolve  to 
Grade  1 or better  within  12 weeks.a, b,     c 
• If event  resolves  to Grade  2 or better  within  28 days,  
resume  binimetinib  with  dose reduced  by one level.  If 
not, permanently  discontinue  binimetinib.  
Acneiform  rash:  
• Consider  continuation  of topical  corticosteroids  
(e.g.,  2.5%  alclometasone)  and oral antibiotics  
(e.g.,  minocycline,  doxycycline  or antibiotics  
covering  skin flora)  when  restarting  binimetinib.  
Dermatologic  event,  Grade  4 
 • Permanently  discontinue  pembrolizumab  and binimetinib,  
and contact  Medical  Monitor.   c 
 
 
BID = twice  daily;  BSA = body  surface  area;  PRN  = as needed.  
a If corticosteroids  have  been initiated,  they must  be tapered  over  1 month  to  10 mg/day  
oral prednisone  or equivalent  before  pembrolizumab  can be   resumed.  
b Pembrolizumab  may be withheld  for a period  of time beyond  12 weeks  to allow  for 
corticosteroids  to be reduced  to  10 mg/day  oral prednisone  or equivalent.  The acceptable  length  
of the extended  period  of time must  be agreed  upon  by the investigator  and the 
Medical  Monitor.  
c Resumption  of pembrolizumab  may be considered  in patients  who are deriving  
benefit  and have  fully  recovered  from  the immune -related  event.   Patients  can be 
rechallenged  with  pembrolizumab  only after approval  has been documented  by both the 
investigator  (or an appropriate  delegate)  and the Medical  Monitor.  
 
  
PROTOCOL  # 17-0466  
PI: Christopher  H. Lieu,  MD 
Version  Date:  12.30 .2021  
 
 
 
 
 
 
    
Page 83 of 106  Rhabdomyolysis  and CPK  Elevations  
Rhabdomyolysis  and CPK  elevation  have been seen with binimetinib  (see 
binimetinib  Investigator’s  Brochure).  Permanent  discontinuation  of binimetinib  
treatment  
should  be considered  if rhabdomyolysis  or symptomatic  CPK  elevations  are 
attributed  to binimetinib  and do not improve  after temporary  interruption.  Guidelines  
for the management  of CPK  elevations  and rhabdomyolysis  are provided  in Table  7. 
 
In case of CPK  elevation  or rhabdomyolysis  treatment  with bevacizumab  may 
continue  at the discretion  of the investigator  per medical  judgment.  
 
Table  7. Guidelines  for the Management  of Grade  3 or Higher  Elevations  in CPK  and 
Rhabdomyolysis  
 
Rhabdomyolysis  or CPK  elevation  Management  
General  guidance  • Rule  out cardiac  cause  (check  ECG,  serum  cardiac  
troponin,  and CPK -isoforms  M and B fraction)  and 
rule out rhabdomyolysis  (clinical  examination;  serum  
creatinine,  potassium,  calcium,  phosphorus,  uric acid,  
and albumin;  and urine  myoglobin).  
• Assess  patient  for any history  of strenuous  physical  
activity,  blunt  trauma,  or recent  IM injections.  
Grade   3 CPK elevations  that 
are asymptomatic  and deemed  not 
clinically  significant  • Bevacizumab  may continue  at the discretion  of the 
investigator  per medical  judgment.  
• Binimetinib  and pembrolizumab  dosing  does not 
need  to be modified  or interrupted  to manage  
asymptomatic  Grade   3 CPK  elevations.  
• Recheck  CPK  at least  once a week.  
For Grade  4 CPK elevations  that 
are asymptomatic  and deemed  
not clinically  significant  • Bevacizumab  may continue  at the discretion  of the 
investigator  per medical  judgment.  
• Interrupt  binimetinib  and pembrolizumab  treatment.  
• If improved  to Grade  ≤ 3 within  4 weeks,  restart  
binimetinib  at a dose  reduced  by 30 mg, if clinically  
indicated.  
• If CPK  elevations  do not improve  to Grade  ≤3 within  
4 weeks  following  dose interruption,  permanently  
discontinue  binimetinib  treatment.  
• Resumption of pembrolizumab  may be considered  in 
patients  who are deriving  benefit.  
IM = intramuscular.  
 
 
 
PROTOCOL  # 17-0466  
PI: Christopher  H. Lieu,  MD 
Version  Date:  12.30 .2021  
 
 
 
 
 
 
    
Page 84 of 106  Potential  Eye Toxicity  
An ophthalmologist  should  evaluate  visual  complaints.  
 
Uveitis  or episcleritis  and other  immune -mediated  ocular  disease  may be associated  with 
pembrolizumab  and may be treated  with topical  corticosteroid  eye drops.  
Pembrolizumab  should  be permanently  discontinued  for immune -mediated  ocular  disease  
that is unresponsive  to local immunosuppressive  therapy.  
Pembrolizumab  and/or  binimetinib  -associated  ocular  toxicity  should  be managed  
according  to the guidelines  in Table  8. 
 
Serous  retinopathy  events  have been associated  with binimetinib  with most  events  in 
clinical  trials  resolved  or improved  to asymptomatic  grade  1 following  dose 
interruption  or reduction.  If serous  retinopathy  is diagnosed,  treatment  should  be 
withheld  until  visual  symptoms  improve  to Grade  ≤1. Serous  retinopathy  can be 
managed  with treatment  interruption,  dose reduction  or with treatment  discontinuation.  
 
Retinal  vein occlusion  (RVO)  has been reported  in patients  treated  with MEK  
inhibitors  other  than binimetinib.  
PROTOCOL  # 17-0466  
PI: Christopher  H. Lieu,  MD 
Version  Date:  12.30 .2021  
 
 
 
 
 
 
    
Page 85 of 106  Table  8. Guidelines  for the Management  of Pembrolizumab - and Binimetinib -
Associated  Ocular  Toxicity  
 
Ocular  Toxicity  Management  
General  guidance  • An ophthalmologist  should  evaluate  visual  complaints.  
• Uveitis  or episcleritis  and other  immune −mediated  ocular  disease  
may be associated  with pembrolizumab  and may be treated  with 
topical  corticosteroid  eye drops.  Pembrolizumab  should  be 
permanently  discontinued  for immune -related  ocular  event  that is 
unresponsive  to local immunosuppressive  therapy.  
• Serous  retinopathy  is associated  with binimetinib.  In clinical  trials,  
most  events  were  Grade  1 (asymptomatic)  or 2 (symptomatic).  
Most  events  in clinical  trials  resolved  or improved  to asymptomatic  
grade  1 following  dose interruption  or reduction.  If serous  
retinopathy  is diagnosed,  binimetinib  should  be withheld  until  
visual  symptoms  improve  to Grade   1. Serous  retinopathy  can be 
managed  with treatment  interruption,  dose reduction  or with 
treatment  discontinuation.  
• RVO  has been reported  in patients  treated  with MEK  inhibitors  
other  than binimetinib. 
Serous  retinopathy  
 
Severity  grade  
assessment  based  on NCI 
CTCAE  v4 “Eye  
Disorders  – Other”  scale 
a-d Serous  retinopathy,  Grade  1 a or 2  b (tolerable):  
• Continue  binimetinib,  bevacizumab,  and pembrolizumab  without  
dose change.  
• Continue  ophthalmology follow -up as clinically indicated.  
Serous  retinopathy,  Grade  2 b (intolerable)  or 3/4  c/d: 
• Interrupt  binimetinib  until  Grade   1. 
• Continue  pembrolizumab  and bevacizumab  as clinically  indicated.  
• Consult  ophthalmology  and undergo  complete  ophthalmologic  
examination,  which  includes  visual  acuity  testing,  intra -ocular  
pressure  measurements,  slit lamp  ophthalmoscopy,  indirect  
ophthalmoscopy,  visual  field,  and OCT.  Consider  a fluorescein  
angiogram  and/or  indocyanine  green  angiogram,  if clinically  
indicated.  
• Binimetinib  should  be dose reduced  by 1 dose level when  
restarting.  
• Consider  permanent  discontinuation  of binimetinib  if serous  
retinopathy  recurs  despite  2 dose level reductions  
Potential  
immune -related  ocular  
toxicity  (e.g.,  uveitis,  
iritis,  episcleritis,  or 
retinitis)  • Follow guidelines  provided  in the pembrolizumab  Investigator's  
Brochure.  
• Continue  binimetinib  and bevacizumab  as clinically  indicated.  
PROTOCOL  # 17-0466  
PI: Christopher  H. Lieu,  MD 
Version  Date:  12.30 .2021  
 
 
 
 
 
 
    
Page 86 of 106   
 
 
 
ADL  = activities  of daily  living;  NCI CTCAE  = National  Cancer  Institute  Common  
Terminology  Criteria  for Adverse  Events;  RVO  = retinal  vein occlusion;  OCT  
= optical  coherence  tomography.  
a Grade  1: Asymptomatic  or mild symptoms;  clinical  or diagnostic  observations  only;  
intervention  not indicated . 
b Grade  2: Moderate;  minimal,  local or noninvasive  intervention  indicated;  limiting  age appropriate  
instrumental  ADL . 
c  Grade  3: Severe  or medically  significant  but not immediately  sight  threatening;  
hospitalization  or prolongation  of existing  hospitalization  indicated;  disabling;  limiting  self- care ADL . 
d Grade 4: Sight -threatening  consequences;  urgent  intervention  indicated;  blindness (20/200    or 
worse)  in the affected  eye . 
 
  
 
Retinal  vein occlusion
(any grade)  
If RVO  (any grade)  is diagnosed,  binimetinib  dosing  should  be
permanently  discontinued  and RVO  treated  per institutional
guidelines.  
Continue  pembrolizumab.  
Bevacizumab  may  continue  at the discretion  of the
investigator  per medical  judgment . 
PROTOCOL  # 17-0466  
PI: Christopher  H. Lieu,  MD 
Version  Date:  12.30 .2021  
 
 
 
 
 
 
    
Page 87 of 106   
 
Gastrointestinal  Events:  Diarrhea  
Diarrhea  can frequently  be managed  with anti-diarrheal  agents  but can also progress  to 
clinically  significant  dehydration  and/or  electrolyte  imbalances  with effects  on other  organs,  
possibly  resulting  in renal,  hepatic,  and/or  cardiac  failure.  Patients  should  be instructed  to 
promptly  contact  the investigators  if they develop diarrhea.  Investigators  should  treat 
diarrhea  and intervene  promptly  for patients  who appear to be at increased  risk of 
developing  significant  dehydration,  electrolyte  imbalances,  and/or  multi -organ  failure.  
Patients  should  receive  maximum  supportive  care per institutional  guidelines.  
 
In case of diarrhea,  treatment  with bevacizumab  may continue  at the discretion  of the 
investigator  per medical  judgment.
 
Colitis  
Immune -related  colitis  has been associated  with the administration  of pembrolizumab.  
For events  of significant  duration  or severity  or associated  with signs  of systemic  
inflammation  or acute  phase  reactants,  check  for immune -related  colitis  . 
In case of colitis,  treatment  with bevacizumab  may continue  at the discretion  of the 
investigator  per medical  judgment.  
 
Refer  to Table  9 for guidelines  for the management  of colitis.  
 
Gastrointestinal  Obstruction  
Guidelines  for the management  of gastrointestinal  perforation  and bowel  obstruction  are 
provided  in Table  9. 
 
  
PROTOCOL  # 17-0466  
PI: Christopher  H. Lieu,  MD 
Version  Date:  12.30 .2021  
 
 
 
 
 
 
    
Page 88 of 106  Table  9. Guidelines  for the Management  of Gastrointestinal  Toxicity   
PROTOCOL  # 17-0466  
PI: Christopher  H. Lieu,  MD 
Version  Date:  12.30 .2021  
 
 
 
 
 
 
    
Page 89 of 106  Gastrointestinal  
Toxicity  Guidance  
Gastrointestinal  events:  
general  guidance  • All events  of diarrhea  or colitis  should  be thoroughly  evaluated  for 
more  common  etiologies  other  than drug -induced effects.  
• For events  of significant  duration  or severity  or associated  with 
signs  of systemic  inflammation  or acute  phase  reactants,  check  for 
immune -related colitis.  
• Administer  anti-diarrheal  agents  and other  maximal  supportive  
care per institutional  guidelines  such as: at the first report  of 
watery  diarrhea  or loose  stool,  initiate  maximal  anti-diarrheal  
supportive  care (Lomotil  and loperamide).  
• Suggested  regimen:  
o Loperamide:  Initiate  dose with 4 mg, then 4 mg every  6 hours  
around  the clock,  alternating  with Lomotil.  
o Lomotil  (diphenoxylate  and atropine):  2 tablets  (diphenoxylate  
5 mg, atropine  0.05 mg) every  6 hours  around  the clock  
o Continue  Lomotil  and loperamide  until  no loose  stools  for 
24 hours.  
o If Grade   2 diarrhea  persists  after 48 hours  total treatment  with 
Lomotil  and loperamide,  consider  second -line agents  
(e.g.,  octreotide,  budesonide,  tincture  of opium).  
• Oral supplementation:  
o Initiate  oral supplementation  of potassium  and/or  magnesium  if 
serum  levels  are <LLN.  
o Consider  oral rehydration  therapy  (e.g.,  Pedialyte→) for 
Grade  1 diarrhea  or vomiting.  
• Dietary  modifications:  
o Stop all lactose -containing  products  and eat small  meals.  
o The BRAT  (banana,  rice, apples,  toast)  diet, without  fiber (other  
vegetables  and fruits),  may be helpful. 
• Encourage  adequate  hydration  with salt-containing liquids,  
such as broth  or Gatorade.  
Diarrhea,  Grade  1 or Grade  2 
(tolerable)  • Continue  pembrolizumab,  bevacizumab,  and binimetinib.  
• Initiate  supportive  care and monitor  patient  closely.  
• Investigate  etiology,  referring  patient  to GI specialist  for 
evaluation  of possible  colitis  if appropriate.  
PROTOCOL  # 17-0466  
PI: Christopher  H. Lieu,  MD 
Version  Date:  12.30 .2021  
 
 
 
 
 
 
    
Page 90 of 106  Diarrhea,  Grade  2 
(intolerable)  or Grade  3 • Bevacizumab  may continue  at the discretion  of the 
investigator  per medical  judgment.  
• Withhold  pembrolizumab  and binimetinib.  
• Initiate  supportive  care and monitor  patient  closely.  
• Discontinue  medications  that may exacerbate  colitis  
(e.g.,  NSAIDS)  while  investigating  etiology.  
• Investigate  etiology,  referring  patient  to GI specialist  for 
evaluation  of possible  colitis,  including  biopsy  if appropriate.  
• If event resolves  to Grade  1 or better  within 12 weeks,  resume  
pembrolizumab  at fixed  dose. If  not, permanently  discontinue  
pembrolizumab  and binimetinib.  a- c 
• If event  resolves  to Grade  1 or better  within  28 days,  resume  
binimetinib  with dose reduced  by one level.  If not, permanently  
discontinue  binimetinib.  
Diarrhea,  Grade  4 • Bevacizumab  may continue  at the discretion  of the 
investigator  per medical  judgment.  
• Permanently  discontinue  pembrolizumab  and binimetinib,  
and contact  Medical  Monitor.  c 
• Participants with diarrhea/colitis should be advised to drink liberal 
quantities of clear fluids. If sufficient oral fluid intake is not feasible, 
fluid and electrolytes should be substituted via IV infusion  
• Initiate  supportive  care and monitor  patient  closely.  
• Discontinue  medications  that may exacerbate  colitis  
(e.g.,  NSAIDS)  while  investigating  etiology.  
• Rule  out bowel  perforation.  
• Investigate  etiology,  referring  patient  to GI specialist  for evaluation  
of possible  colitis,  including  biopsy  if appropriate.  
Colitis,  Grade  1 • Continue  pembrolizumab,  bevacizumab  and binimetinib.  
• Initiate  supportive  care and monitor  patient  closely.  
• Discontinue  medications  that may exacerbate  colitis  
(e.g.,  NSAIDS).  
• Refer  patient  to gastrointestinal  specialist  for evaluation  and 
confirmatory  biopsy  if symptoms  persist  for > 7 days.  
PROTOCOL  # 17-0466  
PI: Christopher  H. Lieu,  MD 
Version  Date:  12.30 .2021  
 
 
 
 
 
 
    
Page 91 of 106  Colitis,  Grade  2 • Bevacizumab  may continue  at the discretion  of the 
investigator  per medical  judgment.  
• Withhold  pembrolizumab  and binimetinib.  
• Initiate  supportive  care and monitor  patient  closely.  
• Discontinue  medications  that may exacerbate  colitis  
(e.g.,  NSAIDS).  
• Refer  patient  to gastrointestinal  specialist  for evaluation  and 
confirmatory biopsy. 
• For recurrent  events  or events  that persist   5 days,  initiate  
treatment  with 1−2 mg/kg/day  oral prednisone  or equivalent.  
• If event resolves  to Grade  1 or better  within 12 weeks,  resume  
pembrolizumab  at fixed  dose. If  not, permanently  discontinue  
pembrolizumab  and binimetinib.  a-c 
• If event  resolves  to Grade  1 or better  within  28 days,  resume  
binimetinib  with dose reduced  by one level.  If not, permanently  
discontinue  binimetinib.  
Colitis,  Grade  3 • Bevacizumab  may continue  at the discretion  of the 
investigator  per medical  judgment.  
• Withhold  pembrolizumab  and binimetinib.  
• Initiate  supportive  care and monitor  patient  closely.  
• Discontinue  medications  that may exacerbate  colitis  
(e.g.,  NSAIDS).  
• Refer  patient  to gastrointestinal  specialist  for evaluation  and 
confirmatory biopsy. 
• Initiate  treatment  with 1−2 mg/kg/day  IV methylprednisolone  or 
equivalent  and convert  to 1−2 mg/kg/day  oral prednisone  or 
equivalent  upon improvement. 
• If event resolves  to Grade  1 or better  within 12 weeks,  resume  
pembrolizumab  at fixed  dose. If  not, permanently  discontinue  
pembrolizumab  and binimetinib.  a-c 
• If event  resolves  to Grade  1 or better  within  28 days,  resume  
binimetinib  with dose reduced  by one level.  If not, permanently  
discontinue  binimetinib.  
PROTOCOL  # 17-0466  
PI: Christopher  H. Lieu,  MD 
Version  Date:  12.30 .2021  
 
 
 
 
 
 
    
Page 92 of 106  Colitis,  Grade  4 • Bevacizumab  may continue  at the discretion  of the 
investigator  per medical  judgment.  
• Permanently  discontinue  pembrolizumab  and binimetinib,  
and contact  Medical  Monitor.  c 
• Participants with diarrhea/colitis should be advised to drink liberal 
quantities of clear fluids. If sufficient oral fluid intake is not feasible, 
fluid and electrolytes should be substituted via IV infusion  
• Initiate  supportive  care and monitor  patient  closely.  
• Discontinue  medications  that may exacerbate  colitis  
(e.g.,  NSAIDS).  
• Refer  patient  to GI specialist  for evaluation  and confirmatory  
biopsy.  
• Initiate  treatment  with 1−2 mg/kg/day  IV methylprednisolone  or 
equivalent  and convert  to 1−2 mg/kg/day  oral prednisone  or 
equivalent  upon improvement. 
• If event  does not improve  within  48 hours  after initiating  
corticosteroids,  consider  adding  an immunosuppressive  agent.  
• If event  resolves  to Grade  1 or better,  taper  corticosteroids over  
 1 month.  
Gastrointestinal   perforation,  
any grade  • Discontinue  bevacizumab.  
• Binimetinib  may continue  without  interruption  and/or  dose 
reduction  at the discretion  of the investigator  per medical  
judgment.  
• Pembrolizumab  may continue  without  interruption  at the discretion  
of the investigator  per medical  judgment.  
Bowel  obstruction,  Grade  2 • Hold  binimetinib  and bevacizumab  for partial  obstruction  
requiring  medical  intervention.  Patient  may restart  upon  
complete  resolution.  
• Pembrolizumab  may continue  without  interruption  at the discretion  
of the investigator  per medical  judgment.  
Bowel  obstruction,  Grade  
3−4 • Hold  binimetinib  and bevacizumab  for complete  obstruction.  If 
surgery  is necessary,  patient  may restart  binimetinib  and 
bevacizumab  after full recovery  from surgery  and at 
investigator’s discretion.  
• Pembrolizumab  may continue  without  interruption  at the discretion  
of the investigator  per medical  judgment.  
 
GI =gastrointestinal;  IV=intravenous;  LLN  =lower  limit  of normal;  NSAID =non-steroidal  anti-inflammatory  drug.  
a If corticosteroids  have been initiated  (initial dose of 1 to 2 mg/kg) , they must  be tapered over  1 month to  10 mg/day  oral 
prednisone  or equivalent  before  pembrolizumab  can be resumed.  
b Pembrolizumab  may be withheld  for a period  of time beyond  12 weeks  to allow  for corticosteroids  to be reduced  to  10 
mg/day  oral prednisone  or equivalent.  The acceptable  length of  the extended  period of time must  be agreed  upon  by the 
investigator  and the Medical  Monitor.  
C Resumption of pembrolizumab may be considered in patients who are deriving benefit and have fully recovered from 
the immune -related event. Patients can be rechallenged with pembrolizumab only after approval has been documented 
by both the investigator (or an appropriate delegate) and the Medical Monitor.  
PROTOCOL  # 17-0466  
PI: Christopher  H. Lieu,  MD 
Version  Date:  12.30 .2021  
 
 
 
 
 
 
    
Page 93 of 106  Guidelines  for the management  of reduction  in left ventricular  ejection  fraction  are provided  
in Table  10. 
 
In case of cardiac  adverse  events  treatment  with pembrolizumab  may continue  without  
interruption  at the discretion  of the investigator  per medical  judgment.  
 
Table  10. Guidelines  for the Management  of Reduction  in Left  Ventricular  Ejection  
Fraction  
 
Left Ventricular  Ejection  Fraction  (LVEF)  Decrease  From  Baseline  
Patient  LVEF  value  Recommended  action  
with binimetinib,  
bevacizumab  and 
pembrolizumab  LVEF  value  
following  
treatment  break  Recommended  
binimetinib  daily  
dose 
Asymptomatic   50%  
(or 40%−49%  
and  10%  absolute  
decrease  from BL) Continue  
pembrolizumab,  
bevacizumab  and 
binimetinib  at current  
dose N/A N/A 
 40%  (or 
40%−49% 
and  10%  absolute  
decrease  from BL) Interrupt  binimetinib  
treatment  for 2 wk 
 
 
Continue   pembrolizumab  
as clinically  indicated  
 
Hold  bevacizumab  
and strong  
consideration  should  
be given  to 
permanently  
discontinuing  
bevacizumab  if 
deemed  causally  
related.   10%  absolute  
decrease  from BL First  occurrence:  
40 mg 
Second  occurrence:  
20 mg 
Third  occurrence:  
permanent  
discontinuation  
 40%  
(or  10%  
absolute  
decrease  from 
BL) Permanent  
discontinuation  
PROTOCOL  # 17-0466  
PI: Christopher  H. Lieu,  MD 
Version  Date:  12.30 .2021  
 
 
 
 
 
 
    
Page 94 of 106  Table  10. Guidelines  for the Management  of Reduction  in Left  Ventricular  Ejection  
Fraction  (cont.)  
 
Symptomatic  N/A Interrupt  binimetinib  
treatment  for 4 wk. 
 
Hold  bevacizumab  
and strong  
consideration  should  
be given  to 
permanently  
discontinuing  
bevacizumab  if 
deemed  causally  
related.  
 
Consider  withholding  
pembrolizumab  
Discuss  with Medical  
Monitor  regarding  
resumption  of 
pembrolizumab.  
 
Cardiology  
consultation  is 
strongly  
recommended.  Asymptomatic  
and  10%  
absolute  
decrease  from 
BL First  occurrence:  
40 mg 
Second  occurrence:  
20 mg 
Third  occurrence:  
Permanent  
discontinuation  
Asymptomatic  
and  40%  
(or  10%  
absolute  
decrease  from 
BL) Permanent  
discontinuation  
Symptomatic  
regardless  of 
LVEF  Permanent  
discontinuation  
BL = baseline;  LVEF  = left ventricular  ejection  fraction;  N/A = not applicable.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
PROTOCOL  # 17-0466  
PI: Christopher  H. Lieu,  MD 
Version  Date:  12.30 .2021  
 
 
 
 
 
 
    
Page 95 of 106  Hypertension  
For hypertension  Grade  2 or above,  start  antihypertensive  therapy.  
 
Guidelines  for the management  of Grade  2 or higher  hypertension  are provided  in 
Table  11. 
 
Table  11. Guidelines  for the Management  of Hypertension  
 
Event  Guidance  
Hypertension  
Grade  2 • Hold  bevacizumab.  
• Once  blood  pressure   140/90  mmHg,  patient  may continue bevacizumab  
therapy.  
• Binimetinib  may continue  without  interruption  and/or  dose  reduction  at the 
discretion  of the investigator  per medical  judgment.  a 
• Pembrolizumab  may continue  without  interruption  at the discretion  of 
the investigator  per medical  judgment.  b 
Hypertension  
Grade  3 • If blood  pressure  is not controlled  to 140/90  mmHg  with  medication,  
discontinue  bevacizumab  
• If bevacizumab  is discontinued,  binimetinib  should  be held at the same  
time that  bevacizumab  is discontinued.  When  the event  resolves  to Grade  
 3, binimetinib  may be re-initiated  without  dose reduction  at  the discretion  
of the investigator  per medical  judgment.  a 
• If bevacizumab  is not discontinued,  binimetinib  may continue  without  
interruption  and/or  dose  reduction  at the discretion  of the investigator  per 
medical  judgment.  a 
• Pembrolizumab  may continue  without  interruption  at the discretion  of 
the investigator  per medical  judgment.  b 
Hypertension  
Grade  4 • Discontinue  bevacizumab.  
• Binimetinib  should  be held at the same  time that bevacizumab  is 
permanently  discontinued.  When  the event  resolves  to Grade   3, 
binimetinib  may be re-initiated  without  dose  reduction  at the discretion  of 
the investigator  per medical  judgment.  a 
• Pembrolizumab  may continue  without  interruption  at the discretion  of 
the investigator  per medical  judgment.  b 
a Events  of hypertension  have  been  reported  in binimetinib  clinical  studies.  Although  primarily  
reported  as non-serious  and low grade  events,  or reported  as occurring  in patients  with important  
confounding  risk factors,  in the pivotal  study  reported  events  were  more  frequent  in the active  
binimetinib  arm than the control  arm. [Reference:  Binimetinib  IB] 
b Vascular  disorders  (including  hypertension  and hypotension)  are possible  adverse  events  of 
pembrolizumab,  considering  the mechanism  of action . 
 
 
 
 
 
 
PROTOCOL  # 17-0466  
PI: Christopher  H. Lieu,  MD 
Version  Date:  12.30 .2021  
 
 
 
 
 
 
    
Page 96 of 106  Hemorrhage  
Guidelines  for the management  of hemorrhage  are provided  in Table  12. 
 
 
Table  12. Guidelines  for the Management  of Hemorrhage  
 
Hemorrhage         Action  to be Taken  
Grade  3 hemorrhage  • Patients  who are also receiving  full-dose anticoagulation  will be 
discontinued  from  receiving  bevacizumab.  All other  patients  
will 
• have  bevacizumab  held until  all of the following  criteria  are met:  
• The bleeding  has resolved  and hemoglobin  is stable.  
• No bleeding  diathesis  would  increase  the risk of therapy.  
• No anatomic  or pathologic  condition  significantly  increases  the risk 
of hemorrhage  recurrence  
• After  administration  of bevacizumab  is restarted,  if the 
patient  experiences  another  Grade 3 hemorrhagic  event,  
bevacizumab  should  be discontinued.  
• Interrupt  binimetinib  treatment.  There  are no data on the effectiveness  
of binimetinib  dose modification  for hemorrhage  events.  Clinical  judgment  
should  be applied  when  considering  restarting  binimetinib  treatment.  
• Continue  pembrolizumab  treatment.  
Grade  4 hemorrhage,  •  Discontinue  bevacizumab.a 
or any  grade  pulmonary      •  Interrupt  binimetinib  treatment.  Permanently    discontinue  
hemorrhage,  or  binimetinib  for hemorrhage  events  attributed  to binimetinib.  
any grade  cerebral  •  Continue  pembrolizumab  treatment.  
Hemorrhage  
 
 
a Note  for Grade  1 events:  Patients  who are also receiving  full-dose anticoagulation  will be 
discontinued  from  receiving  bevacizumab.  All other  patients  will have  bevacizumab  held until  all of 
the following  criteria  are met: the bleeding  has resolved  and hemoglobin  is stable;  no bleeding    
diathesis  would  increase  the risk of therapy;  and no anatomic  or pathologic  condition  significantly  increases  
the risk of hemorrhage  recurrence.   After  administration  of bevacizumab  is restarted,  if the patient  
experiences  another  Grade  1 pulmonary  or CNS  (intracranial)  hemorrhagic  event,  bevacizumab  should  be 
discontinued.  
 
  
PROTOCOL  # 17-0466  
PI: Christopher  H. Lieu,  MD 
Version  Date:  12.30 .2021  
 
 
 
 
 
 
    
Page 97 of 106   
Thromboembolic  Events  
Guidelines  for the management  of venous  thromboembolism  and arterial  
thromboembolic  events  are provided  in Table  13 and Table  14, 
respectively.  
 
Table  13. Guidelines  for Management  of Venous  Thromboembolic  Events  
 
Event  Guidance  
Venous 
thromboembolic 
event  Grade   3 • For Grade  3 thromboembolic  events,  hold bevacizumab  for  3 weeks.  
Bevacizumab  treatment  may be resumed  during  the period  of 
therapeutic -dose  event  Grade   3 anticoagulant  therapy  once  the 
level of anticoagulation  therapy  is stabilized:  
- Patients  receiving  heparin  treatment  should  have  an a PTT 
1.5−2.5  ULN.  
- Patients  receiving  full-dose  LMWH  should  receive  the dose  
appropriate  for the patient’s  weight  according  to the 
Package  Insert.  
-     Patients receiving coumarin derivatives should have an INR 
between 2.0 and  3.0 assessed in 2 consecutive measurements 
1
4 days  apart.  
-    After administration  of bevacizumab  is restarted,  if the                   
patient  experiences another Grade 3 venous 
thromboembolic  event, bevacizumab should be 
discontinued.  
• For Grade  4 thromboembolic  events,  discontinue  bevacizumab.   
             Binimetinib  may continue  without  interruption  and/or  dose 
reduction  at the discretion  of the investigator  per medical  
judgment.  
Pembrolizumab may continue without interruption at the discretion 
of the investigator per  medical judgment.  
 
LMWH  = low-weight  molecular  heparin.  
 
 
 
 
 
 
 
 
 
 
 
 
PROTOCOL  # 17-0466  
PI: Christopher  H. Lieu,  MD 
Version  Date:  12.30 .2021  
 
 
 
 
 
 
    
Page 98 of 106  Table  14. Guidelines  for the Management  of Arterial  Thromboembolic  Events  
 
Event  Guidance  
Arterial  
thromboembolic  
event,  any 
Grade  Discontinue   bevacizumab.  
Binimetinib  may continue  without  interruption  and/or  dose  reduction  at the 
discretion  of the investigator  per medical  judgment.  
Pembrolizumab  may continue  without  interruption  at the discretion  of 
the investigator  per medical  judgment . 
 
 
 
 
 
 
 
 
  
PROTOCOL  # 17-0466  
PI: Christopher  H. Lieu,  MD 
Version  Date:  12.30 .2021  
 
 
 
 
 
 
    
Page 99 of 106  Proteinuria  
Guidelines  for the management  of proteinuria  are provided  in Table  15. 
 
Table  15. Guidelines  for the Management  of Proteinuria  
 
Event  Guidance  
Proteinuria  No bevacizumab  dose interruptions  for proteinuria  2 + by dipstick.  
first For proteinuria   2 + or 3 + by dipstick,  administer  bevacizumab  as  planned  and 
occurrence,  no collect  24-hour  urine  for determination  of total  protein  within  3 days  before  diagnosis  of
 next scheduled  bevacizumab  administration.  
nephrotic  If 24-hour  proteinuria   2 g, the next bevacizumab  dose can be administered  as syndrome
 scheduled.  
If 24-hour  proteinuria   2 g, hold bevacizumab  treatment.  Continue  to do 24-hour  urine  collections  
for determination  of total protein  within  3 days of each scheduled  bevacizumab  dose and continue  
to hold scheduled  bevacizumab  until  proteinuria  has decreased  to  2 g/24 hours.  
When  proteinuria  has decreased  to  2 g/24 hours,  scheduled  bevacizumab  may be administered  as 
planned.  However,  continue  to do 24-hour  urine  collections  for determination  of total  protein  
within  3 days  of each scheduled  bevacizumab  dose until  proteinuria  has improved  to  1 
g/24   hours.  
Binimetinib  may continue  without  interruption  and/or  dose reduction  at the 
discretion  of the investigator  per medical  judgment.  
Pembrolizumab may continue  without  interruption  at the discretion  of the investigator  
per medical  judgment . 
Proteinuria  No bevacizumab  dose interruptions  for proteinuria   3 + by dipstick. second  and
 For proteinuria  3 + by dipstick,  administer  bevacizumab  as planned    and 
subsequent   collect  24-hour  urine  for determination  of total  protein  within  3 days  before  
occurrences,  no next scheduled bevacizumab  administration.  
diagnosis  of If 24-hour  proteinuria   2 g, the next bevacizumab  dose can be administered  as nephrotic 
syndrome  scheduled. 
If 24-hour  proteinuria   2 g, hold bevacizumab  treatment.  Continue  to do 
24-hour  urine  collections  for determination  of total protein  within  3 days of each scheduled  
bevacizumab  dose,  and continue  to hold scheduled  
bevacizumab  until  proteinuria  has decreased  to  2 g/24 hours.  
If urine protein continues to be  2 grams  by dipstick, recommend checking 24 -hour urine protein 
every 3 months to ensure that proteinuria is < 2 grams per day  
When  proteinuria  has decreased  to  2 g/24 hours,  scheduled  bevacizumab  may be administered  as 
planned.  
However,  continue  to do 24-hour urine  collections  for determination  of total protein  within  3 days of 
each scheduled  bevacizumab  dose until  proteinuria  has improved  to  1 g/24 hr. 
Binimetinib  may continue  without  interruption  and/or  dose reduction  at the 
discretion  of the investigator  per medical  judgment.  
Pembrolizumab may continue  without  interruption  at the discretion  of the investigator  per 
medical  judgment . 
 
. 
PROTOCOL  # 17-0466  
PI: Christopher  H. Lieu,  MD 
Version  Date:  12.30 .2021  
 
 
 
 
 
 
    
Page 100 of 106  Proteinuria  Discontinue  bevacizumab.  
with  diagnosis  Binimetinib  may continue  without  interruption  and/or  dose reduction  at the of 
nephrotic  discretion  of the investigator  per medical  judgment.  
syndrome  Pembrolizumab may continue  without  interruption  at the discretion  of the 
                             investigator  per medical  judgment  
 
 
Fistula  
Guidelines  for the management  of proteinuria  are provided  in Table  16. 
 
Table  16. Guidelines  for the Management  of Fistula  
 
Event  Guidance  
Tracheoesophagael 
fistula, any grade  • Discontinue  bevacizumab.  
• Binimetinib  may  continue  without  interruption  and/or  dose  
reduction  at the discretion  of the investigator  per medical  judgment.  
• Pembrolizumab  may  continue  without  interruption  at the discretion  of 
the investigator  per medical   judgment.  
Fistula (non -
tracheoesophageal), 
Grade 4  • Discontinue  bevacizumab.  
• Binimetinib  may  continue  without  interruption  and/or  dose  reduction  
at the discretion  of the investigator  per medical  judgment  
• Pembrolizumab  may  continue  without  interruption  at the discretion  of 
the investigator  per medical judgment . 
 
 
Wound  Dehiscence  
Guidelines  for the management  of wound  are provided  in Table  17. 
 
Table  17. Guidelines  for the Management  of Wound  Dehiscence  
 
Event  Guidance  
Wound dehiscence, 
any grade  • Discontinue  bevacizumab.  
• Binimetinib  may  continue  without  interruption  and/or  dose  
reduction  at the discretion  of the investigator  per medical  judgment.  
• Pembrolizumab  may  continue  without  interruption  at the discretion  of 
the investigator  per medical   judgment or the surgical therapy.  
 
 
 
 
 
 
 
 
 
 
PROTOCOL  # 17-0466  
PI: Christopher  H. Lieu,  MD 
Version  Date:  12.30 .2021  
 
 
 
 
 
 
    
Page 101 of 106  Posterior  Reversible  Encephalopathy  Syndrome/Reversible  Posterior  
Leukoencephalopathy  Syndrome  
Guidelines  for the management  of posterior  reversible  encephalopathy/reverse  posterior  
leukoencephalopathy  are provided  in Table  18. 
 
Table  18. Guidelines  for the Management  of Posterior  Reversible  Encephalopathy  
Syndrome/Reversible  Posterior  Leukoencephalopathy  Syndrome  
 
Event  Guidance  
PRES/RPLS, any 
grade confirmed by 
MRI  • Discontinue  bevacizumab.  
• Binimetinib  may  continue  without  interruption  and/or  dose  
reduction  at the discretion  of the investigator  per medical  judgment.  
• Pembrolizumab  may  continue  without  interruption  at the discretion  of 
the investigator  per medical   judgment.  
MRI =magnetic  resonance  imaging;  PRES  = posterior  reversible  encephalopathy  syndrome;  
RPLS = reversible  posterior  leukoencephalopathy  syndrome.  
 
Pancreatitis  
In case of pancreatitis,  treatment  with bevacizumab  and binimetinib  may continue  
without  interruption  (and  in the case of binimetinib  without  dose reduction)  at 
the discretion  of the investigator  per medical  judgment.  For pembrolizumab  
treatment  modification,  refer to the Pembrolizumab  Investigator’s  Brochure.  
 
Neurologic  Disorders  
In case of autoimmune  neuropathy,  treatment  with  bevacizumab  and binimetinib  may 
continue  without  interruption  (and  in the case of binimetinib  without  dose reduction)  
at the discretion  of the investigator  per medical  judgment.  For pembrolizumab  
treatment  modification,  refer  to the Pembrolizumab  Investigator’s  Brochure.  
 
Guidelines  for the management  Guillain -Barre  are provided  in Table  19 . 
 
Table  19. Management  Guidelines  for Guillain -Barre  
 
Event  Guidance  
Grade 1 -4 • For pembrolizumab information, see Investigator’s Brochure.  
• Hold bevacizumab for myasthenia gravis or Guillain -Barre. 
Patient may restart upon complete resolution.  
• Binimetinib  may  continue  without  interruption  and/or  dose  
reduction  at the discretion  of the investigator  per medical  
judgment.  
 
 
 
 
 
PROTOCOL  # 17-0466  
PI: Christopher  H. Lieu,  MD 
Version  Date:  12.30 .2021  
 
 
 
 
 
 
    
Page 102 of 106  Infusion -Related   Reactions  
Patient  may development  infusion -related  reactions  during  the administration  of 
bevacizumab  and/or  pembrolizumab.  
 
Close  observation  of the patient  during  and following  the administration  of bevacizumab  is 
recommended  as expected  for any infusion  of a therapeutic  humanized  monoclonal  
antibody.  If a reaction  occurs,  the infusion  should  be discontinued  and appropriate  
medical  therapies  should  be administered.  Medical  therapies  are at discretion  of the 
investigator  per medical  judgment  and may include  antihistamines,  antipyretics,  
glucocorticoids,  epinephrine,  bronchodilators,  and oxygen.  A systemic  premedication  is not 
warranted.  
 
Premedication  is allowed  for administration  of Cycle  1 of pembrolizumab.  Patients  
who are not premedicated  and who experience  an infusion -related  reaction  with  
Cycle  1 of pembrolizumab  may receive  premedication  with antihistamines  or 
antipyretics/analgesics  (e.g.,  acetaminophen)  for subsequent  infusions.  
 
Guidelines  for the management  of infusion -related  reactions  are provided  in Table  20. For 
severe  hypersensitivity  reactions,  permanently  discontinue  all study  treatment.  For 
anaphylaxis  precautions,  refer  to Appendix  4. 
PROTOCOL  # 17-0466  
PI: Christopher  H. Lieu,  MD 
Version  Date:  12.30 .2021  
 
 
 
 
 
 
    
Page 103 of 106  Table  20. Management  Guidelines  for infusion -related  reactions  
 
 
Event  Binimetinib  Bevacizumab  Pembrolizumab  
Infusion - 
related  
reactions  
Grade  1 Binimetinib  may Reduce  infusion  rate to 
continue  without  < 50% or interrupt  
interruption  at the infusion  at the 
discretion  of the discretion  of the 
investigator  per medical  investigator  per medical  
judgment.  judgment.  
 
If the infusion  is 
interrupted,  it may be 
resumed  at < 50% of the 
rate prior to the reaction  
after the patient’s  
symptoms  have  
adequately  resolved  and 
increased  in 50% 
increments  up to the full 
rate if well tolerated.  
Infusions  may be 
restarted  at 
the full rate during  the 
next cycle.  For pembrolizumab  
information,  see the 
Investigator’s  
Brochure.  
Infusion - 
related  
reactions  
Grade  2 Binimetinib  may Reduce  infusion  rate to 
continue  without  < 50% or interrupt  
interruption  and/or  dose  infusion  at the 
reduction  at the discretion  of the 
discretion  of the investigator  per medical  
investigator  per medical  judgment.  
judgment.  
If the infusion  is 
interrupted,  it may be 
resumed  at < 50% of the 
rate prior to the reaction  
after the patient’s  
symptoms  have  
adequately  resolved  and 
increased  in 50% 
increments  up to the full 
rate if well tolerated.  
Infusions  may be 
restarted  at 
the full rate during  the 
next cycle.  For pembrolizumab  
information,  see the 
Investigator’s  
Brochure.  
PROTOCOL  # 17-0466  
PI: Christopher  H. Lieu,  MD 
Version  Date:  12.30 .2021  
 
 
 
 
 
 
    
Page 104 of 106   
Event  Binimetinib  Bevacizumab  Pembrolizumab  
Infusion - 
related  
reactions  
Grade  3-4 Binimetinib  may continue  
without  interruption  and/or  
dose  reduction  at the 
discretion  of the 
investigator  per medical  
judgment.  Stop infusion  
Discontinue  
bevacizumab  For pembrolizumab  
information,  see the 
Investigator’s  
Brochure.  
IRR=  infusion -related  reactions  
 
 
Endocrine  Events  
Thyroid  disorders  or adrenal  insufficiency  has been associated  with the administration  of 
pembrolizumab.  
 
Patients  with unexplained  symptoms  such as fatigue,  myalgias,  impotence,  mental  status  
changes,  or constipation  should  be investigated  for the presence  of thyroid,  pituitary,  or 
adrenal  endocrinopathies,  as well as for hyponatremia  or hyperkalemia.  An endocrinologist  
should  be consulted  if an endocrinopathy  is suspected.  
 
Thyroid -stimulating  hormone  and free thyroxine  (T4) levels  should  be obtained  to 
determine  whether  thyroid  abnormalities  are present.  Thyroid -stimulating  hormone,  
prolactin,  and a morning  cortisol  level will help to differentiate  primary  adrenal  
insufficiency  from primary  pituitary  insufficiency.  
 
For pembrolizumab  information,  see the Investigator’s  Brochure.  Binimetinib  and 
bevacizumab  may continue  without  interruption  and/or  dose reduction  at 
the discretion  of the investigator  per medical  judgment.  
 
Immune  Related  Adverse  Events  
Down -modulating  PD-L1/PD -1 signaling  may permit  the emergence  of auto-reactive  T 
cells and clinical  autoimmunity.  Adverse  events  associated  with drug  exposure  and 
consistent  with an autoimmune  etiology  are termed  immune  related  adverse  events.  
 
Patients  should  be informed  of and carefully  monitored  for evidence  of 
clinically  significant  systemic  immune  related  adverse  event  (e.g.,  systemic  
lupus  erythematosus -like diseases)  or organ -specific  immune  related  adverse  
event  (e.g.,  rash,  colitis,  uveitis,  hepatitis,  thyroid  disease).  Efforts  should  be 
made  to rule out neoplastic,  infectious,  metabolic,  toxin,  or other  etiologic  
causes  prior  to labeling  an adverse  event  an immune  related  adverse  events.  
Serological,  immunological,  and histological  (biopsy)  data should  be used to 
PROTOCOL  # 17-0466  
PI: Christopher  H. Lieu,  MD 
Version  Date:  12.30 .2021  
 
 
 
 
 
 
    
Page 105 of 106  support  the diagnosis  of an immune -mediated  toxicity.  
Although many low-grade immu ne-related adverse events respond well to symp tomatic 
therapy, high-grade immune-related adverse events require corticosteroid therapy and, in 
rare corticosteroid -refractory  cases,  the use of other  immune -suppressive therapies,  such as 
infliximab  or mycophenolate  mofetil . 
 
Other  Unspecified  Adverse  Events  
Guidelines  for the management  of non-laboratory  related  adverse  events  are provided  in Table  
21, and guidelines  for the management  of unspecified  Grade  3 and higher  laboratory  related  
adverse  events  are provided  in Table  22. 
 
Table  21. Guidelines  for the Management  of Unspecified  Related  Adverse  Events  Grade  3 
or Higher  Other  than  Laboratory  Abnormalities  
 
Event  Modification(s)  
Other  
unspecified  
related  events  
(other  than 
laboratory  
abnormalities),  
Grade  3 Interrupt  dosing  of attributable  study  drug at the discretion  of the investigator.  
During  this time,  treatment  may continue  with non-attributable  study  drugs.  
If attributable  study  drug has been  held and the event  resolves  to Grade   1 
within  28 days,  then restart  dosing  of attributable  study  drug).  
If attributable  has been  held and the event  does  not resolve  to Grade   1 
within  28 days,  then discontinue  attributable  study  drug.  If attributable  study  
drug is discontinued,  treatment  may continue  with other  study  drugs  at the 
discretion  of the investigator.  
Other  If the Grade  4 event  is attributed  to bevacizumab:  
unspecified  
related  events  
(other  than 
laboratory  
abnormalities),  
Grade  4 first 
occurrence  Discontinue  bevacizumab.  During  this time,  treatment  may continue  with 
non-attributable  study  drugs.  
If the Grade  4 event  is attributed  to binimetinib  or pembrolizumab:  
Interrupt  dosing  of the attributable  study  drug at the discretion  of the 
investigator.  During  this time,  treatment  may continue  with non-attributable  
study  drugs.  
If the attributable  study  drug has been  held and the event  resolves  to 
Grade   1 within  28 days,  then restart  dosing  of the attributable  study  drug.  
If the attributable  study  drug has been  held and the event  does  not resolve  to 
Grade   1 within  28 days,  then discontinue  the attributable  study  drug.  If the 
attributable  study  drug is discontinued,  treatment  may continue  with other  
study  drugs  at the discretion  of the investigator.  
Other  If the Grade  4 event  is attributed  to binimetinib  or pembrolizumab:  
unspecified  
related  events  
(other  than 
laboratory  
abnormalities),  
Grade  4 second  
occurence  If the Grade  4 event  recurs  despite  reduction  of the attributable  study  drug by 
1 dose  level,  discontinue  the attributable  study  drug at the discretion  of the 
investigator.  During  this time,  treatment  may continue  with non-attributable  
study  drugs.  
[Not applicable  to bevacizumab,  which  would  be discontinued  after the first 
Grade  4 occurrence  attributed  to bevacizumab.]  
 
PROTOCOL  # 17-0466  
PI: Christopher  H. Lieu,  MD 
Version  Date:  12.30 .2021  
 
 
 
 
 
 
    
Page 106 of 106  Table  22. Guidelines  for Grade  3 and Higher  Unspecified  Laboratory  Abnormality  Adverse  
Events  
 
 
Note:  Not every  laboratory  abnormality  qualifies  as an adverse  event.  Refer  to Section  5.3.5.5  for 
more  information.  
 
 
  
Modification(s)  
For Grade   3 toxicities  associated  primarily  with laboratory  abnormalities  only
and for which  guidance  has not already  been  specified  elsewhere  in this 
events  that protocol  (e.g.,  elevation  of lipase  or amylase,  or decreases  in phosphorus are
without  clinical  or other  evidence  of pancreatitis  or other  hepatic  dysfunction),
all study  drugs  may continue  without  interruption  and/or  dose  reduction  
Grade   3 (binimetinib  or pembrolizumab)  or as scheduled  (bevacizumab)  at the
discretion  of the investigator  per medical judgment.  
Page 1 of 23CONSENT AND AUTHORIZATION FORM
Principal Investigator:
Christopher Lieu, MD
COMIRB No: 17-0466
Version Date: April 15, 2021
Study Title: Phase II study of  pembrolizumab in combination with 
binimetinib and bevacizumab in patients with refractory 
colorectal cancer
You are being asked to participate in a research study. A member of the research team 
will explain what is involved in this study
 and how it will affect you. This consent form 
describes the study procedures, the risks and benefits of participation, as well as how 
your confidentiality will be maintained. Please take your time to ask questions and feel 
comfortable making a decision whether to participate or not. This process is called 
informed consent.  If you decide to participate in this study, you will be asked to sign this 
form.  
Why is this study being done?
The purpose of this study is to see how  well the combination of three drugs, 
pembrolizumab, binimetinib, and bevacizumab works in people with refractory colorectal 
cancer. 
You are being asked to be in this research study because you have colorectal cancer 
that has not 
responded to standard treatment for this disease. 
Binimetinib is an experimental drug, which means that it is not approved by the U.S. 
FDA. Pembrolizumab and bevacizumab are approved by the FDA for the treatment of 
certain cancers but not specifically for refractory colorectal cancer. Therefore, the use of 
pembrolizumab and bevacizumab in this study is also considered experimental. 
Throughout the rest of this form, when these  drugs are referenced by themselves they 
will be called pembrolizumab, binimetinib, and bevacizumab, but when referenced 
together or in combination they will be called the “study drug combination.”
Other people in this study
Up to 70 people from your area will participate in the study. 
What happens if I join this study?
If you join the study, you will be asked to sign this consent form. You will be given a 
copy to keep and the original form will be kept at 
the clinic. You can withdraw from the 
study at any time and without giving a reason. This will not affect the standard medical 
care you receive. 
COMIRB
APPROVED
For Use
16-Jun-2021
16-Feb-2022
COMIRB #17-0466
PI:  Christopher H. Lieu, MD
Version Date:  04/15/2021
Page 2 of 23There are two parts to this study. In Stage 1, subjects will be enrolled to see if 
pembrolizumab, binimetinib, and bevacizumab can be given safely in combination 
without serious or severe side effects. 
If the study drug combination is safe and tolerable, subjects will be enrolled into Stage 2 
of the
 study to see if the study drug combination is effective for your disease. Whether 
you participate in Stage 1 or Stage 2 of the study will depend on when you are enrolled. 
Pembrolizumab (200mg) will be given on Day 1 of each 21-day cycle intravenously (IV). 
Binimetinib (45 mg) is taken by mouth (orally) twice daily during each cycle. 
Bevacizumab (7.5mg/kg) will be given on Day 1 of each 21-day cycle intravenously (IV). 
In Stage 2, subjects will be assigned to one of two groups to receive the study drug 
combination. If you are enrolled into Stage
 2 of the study, Group A will receive 
binimetinib alone for 7 days prior to Cycle 1 then go on to receive pembrolizumab and 
bevacizumab on Day 1 of Cycle 1. The study drug combination will be given starting 
Day 1 of each subsequent cycle. Group B will receive the study drug combination 
starting on Day 1 of Cycle 1 and each cycle thereafter. 
This next section is an overview of what will be expected of you, and what you can 
expect if you take part in this study. 
Study Procedures:
The time points when these study procedures will  take place are specified in the Study 
Procedures Table.
Below are the study procedures and schedule of events (when each procedure will take 
place) for
 this study.  Some procedures you receive while taking part in this study are 
“standard of care procedures” for treatment of your disease. If you have had some of 
these procedures recently, they may not need to be repeated. Some procedures are 
required only for this research study and will be called “research” procedures. 
Informed Consent  
This informed consent form will be discussed with you and you will be given a 
copy of this document. If you join the study, you will be asked to sign this consent 
form before you receive any study related tests or procedures.
Medical and Cancer History 
Before you start the study, we will record your date of birth, race, ethnicity, and 
complete medical history. This medical history will look at the background and 
history of your cancer and any treatments you have received for your disease. 
COMIRB #17-0466
PI:  Christopher H. Lieu, MD
Version Date:  04/15/2021
Page 3 of 23Physical Examination
A physical examination will be
 completed as part of your standard of care at 
screening and throughout the duration
 of the study. After you join the study, we 
will assess if the study drugs are affecting your body functions including lungs, 
heart, abdomen, extremities, skin, head (eyes, ears, nose, hair, etc.) and your 
neurological function. 
Vital Signs 
We will take your blood pressure, heart rate, respiratory rate, body temperature 
and weight.  Height will be measured only during screening.
Performance Status  
We will assess how well you are performing your daily  activities.
Current Medications
Your study doctor will let you know which drugs you can and cannot take while 
taking part in this study.  You will need to check with the study doctor before 
taking any new medications, including over the counter drugs and herbal 
supplements. From the time you first receive the study drugs through 30 days 
after the last dose, we will record medications you may be taking. 
Review of Side Effects (AEs)—Research 
Some risks have been identified because of the disease process  or through use 
of the study drugs. These are commonly called side effects and will be followed 
very closely by your doctor and the study staff. More information about these will 
be provided in the Risk section of this consent form. 
Echocardiogram (ECHO) or Multigated Acquisition (MUGA) Scan—
Research
This is 
a noninvasive scan of the heart using sound waves.  This test will be used 
to see how 
well your heart pumps blood.  
Electrocardiogram (ECG) —Research 
This is 
a noninvasive procedure that records the electrical activity of the heart. 
Electrodes  are placed  on the skin of the chest  and connected  in a specific  order 
to a machine.  Output  usually  appears  on a long scroll  of paper  that displays  a 
printed  graph.  This will check the electrical activity of  your heart.
Blood and Urine Samples—Standard of Care
These tests are sometimes called safety labs so the study doctor can be sure it is 
safe for you to take part in this study and to be given the study drugs.  
oPregnancy test:  Women who are able to become pregnant will be given 
either a urine or 
a blood pregnancy test.  A positive pregnancy test prior to 
being given the study drugs will exclude you from starting or continuing to 
take part in the study. 
COMIRB #17-0466
PI:  Christopher H. Lieu, MD
Version Date:  04/15/2021
Page 4 of 23oComplete blood count (CBC)
oComprehensive metabolic panel (CMP)
oBlood clotting tests (PT/INR, and PTT)
oThyroid function tests (TSH) 
oTesting for HIV (human immunodeficiency virus), HBV (hepatitis B virus), 
and HCV (hepatitis C virus)  
Blood Samples—Research 
These tests are being done specifically
 because you are participating in this  
study. 
oBiomarker blood testing:  These tests will look at how and if your cancer is 
responding to the treatment.
oCarcinoembryonic Antigen (CEA) test:  This test will look at  how and if your 
cancer is responding to the treatment.
Your doctor may order additional blood tests  that he/she feels are needed to plan 
treatment, dose modification, or further evaluations.
Eye Exam—Research
An ophthalmologist will examine your eyes  to check for signs of damage to the 
retina that may be caused by the study drug combination. 
Imaging (CT or MRI) —Standard of Care 
These tests will be performed to check
 the status of your disease. 
oCT: A computed tomography scan uses x-rays to make detailed pictures 
of parts of the body and the structures inside the body.
oMRI:  Magnetic resonance imaging  is a test that uses a magnetic field and 
pulses of radio wave energy to make pictures of organs and structures 
inside the body.
Tumor Tissue Samples—Research 
oArchived Tissue:   If you had surgery for your cancer in the past, you must 
agree to allow us
 to contact the institution where you had your surgery and 
ask them to send us a portion of your tumor tissue that they have stored 
so we may use it for this research.  
Survival Follow-up Information
oFollow-up information will be collected by  telephone calls or clinic visits 
every 3 months. 
COMIRB #17-0466
PI:  Christopher H. Lieu, MD
Version Date:  04/15/2021
Page 5 of 23Table 1. Study Procedures
Treatment Period (21-day cycle) 
(Pembrolizumab, Binimetinib and Bevacizumab)Final Study/ 
Treatment 
Discontinuation 
VisitSurvival 
Follow-UpScreening
Cycle 1 Cycle 2 Cycles 3+
Days (window) -28 to -1 Day -7 Day 1 
( 2)Day 1 ( 2) Day 1 ( 2) 30 days after 
treatment (  7)Every 3 months
( 2 weeks)
Informed consent x
Demographic data; medical & 
CRC History; baseline 
characteristics x
Complete physical 
examinationx
Vital signs x x x x x
Weight x x x x
Height x
ECOG performance status x x x x
Concomitant medications x x x x
ECHO or MUGA
scan x x x x
12-lead ECG x x
Hematology & Chemistry x x x x x
HIV, HBV, and HCV
testing x
Imaging (CT or MRI) x x x
COMIRB #17-0466
PI:  Christopher H. Lieu, MD
Version Date:  04/15/2021
Page 6 of 23Screening Treatment Period (21-day cycle) 
(Pembrolizumab, Binimetinib and Bevacizumab)Final Study/ 
Treatment 
Discontinuation 
VisitSurvival 
Follow-Up
Cycle 1 Cycle 2 Cycles 3+
Days (window) -28 to -1 Day -7 Day 1 
( 2)Day 1 ( 2) Day 1 ( 2) 30 days after 
treatment (  7)Every 3 months
( 2 weeks)
Coagulation tests x x x x
Ophthalmic exams x x x x
Urine collection x x x x
Pregnancy test x Monthly as clinically indicated
Thyroid function test x x x x
Limited physical 
examinationx x x x
CEA test x x x
Binimetinib Group A x x x
Binimetinib Group B & Run-
inx x x
Pembrolizumab 
administration x x x
Bevacizumab administration x x x
Biomarker blood draw x x x x
Adverse events x x x x
Tumor biopsy-Arm A x x
Tumor biopsy-Arm B x x
Survival Follow-up Information x
COMIRB #17-0466
PI:  Christopher H. Lieu, MD
Version Date:  04/15/2021
Page 7 of 23How long will I be in the study?
Y
our study participation is expected to last at least 1 year. The amount of time you 
participate in this study will depend on how your disease responds and how you tolerate 
the treatment. You will continue in the study until there is evidence that your disease has 
relapsed, your side effects are too severe, you request to stop participation, the study 
doctor feels that you will not benefit from further dosing, you do not follow the study 
instructions, or (for women) you become pregnant.
Reasonably Foreseeable Side Effects and Risks of the Study 
As with any study drug, side effects may  occur when taking this study drug. While taking 
part in this study, and being treated with the study drugs, you will be watched carefully 
for any side effects. Some side effects may go away after you stop taking the study 
drug. Some side effects can be long lasting and may never go away or may even lead 
to death.
You should talk to your study doctor  about any side effects or discomfort you may have. 
The study doctor may give you some medicine that will help with some side effects. The 
study doctor may also interrupt or discontinue the study drug.
You will be notified by your study doctor of any new side effects seen in other patients 
that occur during the time you are on
 the study. This may affect you wanting to continue 
in this research study.
Risks of Binimetinib
Binimetinib is an investigational drug and not all of the side effects are known. Serious 
side effects, including death, are possible. The long-term effects of binimetinib are also 
unknown.
Side effects in cancer patients treated with binimetinib may include those described 
below.
VERY COMMON SIDE EFFECTS (more than 20 out of 100 people):
Alteration of the light sensing part  of the back of the eye that may affect your 
vision*
Feeling weak, tired, or lacking in energy
Rash, acne or skin irritation including redness, raised bumps, dryness or 
itching
Swelling due to fluid retention or a worsening of pre-existing fluid retention in 
specific areas of the body. This can occur throughout your body or in specific 
areas such as your abdomen or arms, legs, hands, feet or face.  
COMMON SIDE EFFECTS (more than 10 but less  than 20 out of 100 people:
Muscle spasms, muscle pain or inflammation
COMIRB #17-0466
PI:  Christopher H. Lieu, MD
Version Date:  04/15/2021
Page 8 of 23UNCOMMON SIDE EFFECTS (1 person up to 10 out of 100 people):
Alteration in how things taste or loss  of the ability of taste
Blockage or tear  in stomach or intestine (especially if you have had cancer or 
surgery in this area of your body) that can cause pain, bloating, constipation, 
and vomiting
Bleeding events involving the  nose or stomach 
Blood clots in veins in the legs, in veins of the eyes or in arteries of the lungs 
Changes in heart rhythm
Decrease in the heart’s ability to  pump blood (decreased ejection fraction or 
left ventricular dysfunction)*
Diarrhea
Dizziness
Fever
High blood pressure
Increase in lab test  results that check how well the liver is working
Increase in a lab test result called creatinine phosphokinase (an enzyme 
found in the blood that may indicate muscle inflammation or damage)
Infection of the skin or beneath the skin
Muscle 
weakness including weakness of the neck muscles resulting in 
difficulty holding the head
 up
Nausea
Reduction in red blood cells
Skin cracking
Stomach pain
Vomiting
*Additional information about eye
 disorders and  decreased ejection fraction side effects:
Eye disorders:  Binimetinib has caused mild to moderate visual changes in some 
subjects. These changes include swelling and/or inflammation in and around the eyes 
and changes in the retina. While this type of visual impairment may resolve, there is a 
risk that the visual changes may continue. Blurred vision and, in some cases, loss of 
vision may be observed with binimetinib. There is the possibility that these changes 
could affect the activities of your daily life (i.e. driving a car or operating machinery). 
Participants with a history of or current retina blood vessel abnormalities will not be able 
to participate in this study. It is important to tell your doctor about any pre-existing eye 
problems you have and visual changes that occur while taking the study drug as your 
doctor may decide to change or stop your treatment with the study drug.
Decreased ejection fraction:  A decrease in ejection fraction has been reported in studies 
with binimetinib. This means that the heart’s ability to pump blood throughout the body 
is decreased. This side effect has also been seen with other similar drugs. Your cardiac 
function will be evaluated before and during the study. Participants with severe and 
recent cardiac abnormalities or events should not receive binimetinib.
COMIRB #17-0466
PI:  Christopher H. Lieu, MD
Version Date:  04/15/2021
Page 9 of 23Rare but important serious side effects seen in subjects receiving binimetinib (less than 
1 person out of 100 people):
One participant experienced acute liver failure (the liver rapidly lost its ability to 
function normally) leading to death
. Due to this event and the observed increase in 
the value of liver enzymes, your liver function will be evaluated frequently.
Hypertensive crisis was described in  a single agent study with binimetinib. Increase 
of blood pressure may be a potential risk when receiving binimetinib. Subjects at risk 
for high blood pressure will be monitored closely. If necessary these subjects will 
receive specific treatment for hypertension.
Cases of serious adverse events of inflammation of the lung tissue (pneumonitis) 
have been reported in 
clinical studies of binimetinib. Difficulty breathing, often 
accompanied by a cough and fever, is the most common symptom of pneumonitis. 
Please inform your doctor should you experience any of the symptoms described 
above. 
A severe skin reaction including serious illness with blistering of the skin, mouth, 
eyes and genitals has been reported in a
 patient who received binimetinib in 
combination with another experimental drug (BYL719). It is possible that one of 
these drugs may have caused this reaction. Please contact your physician 
immediately in case of such symptoms.
A small number of patients and subjects in clinical trials developed hives and/or 
swelling in the throat, 
also known as angioedema, which can be a sign of an allergic 
reaction.  Your doctor should be notified immediately if you experience tightness in 
your throat which may be associated with difficulty breathing.
Severe muscle damage with breakdown of muscle tissue (rhabdomyolysis) which 
may result in organ damage such
 as kidney failure.  
Risks of Pembrolizumab
Pembrolizumab, which is approved in the USA and some other countries, is available by 
prescription to treat several different cancers, but may not be approved to treat your 
type of cancer. 
Pembrolizumab works by helping your immune system to fight  your cancer.
However, pembrolizumab can also cause your immune system to attack normal 
organs and tissues in your body and can affect the way they work, which can result in 
side effects that may become serious or life-threatening , and in some cases, may 
lead to death, and/or may occur after you stop taking pembrolizumab. These side 
effects can affect more than one of your normal organs and tissues at the same time.
COMIRB #17-0466
PI:  Christopher H. Lieu, MD
Version Date:  04/15/2021
Page 10 of 23VERY COMMON, SOME MAY BE SERIOUS (i.e. causing hospitalization, life-
threatening
 or where noted, may cause death) – occurring in more than 20 people out 
of 100 people:
Itching of the skin
Loose or watery stools
Cough
COMMON, SOME MAY BE SERIOUS (i.e. causing hospitalization, life-threatening, 
or where noted, may cause death) occurring in at least 5 but less than 20 people out 
of 100 people:
Joint pain
Rash
Fever
Back pain
Pain in your belly
Loss of skin
 color
Not enough
 thyroid hormone, so you may feel tired, gain weight, feel 
cold, 
or have infrequent or hard stools (hypothyroidism)
Low levels of salt in the blood that may cause you to feel tired,  feel confused, 
have a headache, have muscle cramps, and/or
 feel sick to your stomach 
(hyponatremia)
UNCOMMON, SOME MAY BE SERIOUS - i.e. causing hospitalization, life-
threatening
, or where noted, may cause death)– occurring in at least 1 to less than 5 
people out of 100 people:
Inflammation of the lungs so you may feel  short of breath and cough. 
Rarely this might lead to death. (pneumonitis)
Too much thyroid hormone, so you may feel anxious, feel angry, have 
trouble sleeping, feel 
weak, tremble, sweat, feel tired, have loose and watery 
stools (hyperthyroidism)
Infusion reaction, where you may feel dizzy or faint, feel flushed, get a rash, 
have a fever, feel short of breath, experience a 
decrease in your blood 
pressure at the time of receiving your infusion (IV) or just after, or have pain 
at the site of infusion
Inflammation of the bowels/gut that can cause severe stomach pain with 
loose or watery stools, or stools that are black, tarry, sticky or stools with 
blood or  mucus (colitis)
A condition called Stevens Johnson Syndrome (SJS) or Toxic Epidermal 
Necrosis (TEN). This condition
 involves inflammation of the skin so you may 
have peeling of the skin, itchiness, and/or skin redness. The skin 
inflammation (i.e., peeling, itching and redness) could also be widespread 
throughout your body. More severe skin reactions may involve the inside of 
your mouth, the surface of your eye and genital areas, and/or may cause the 
COMIRB #17-0466
PI:  Christopher H. Lieu, MD
Version Date:  04/15/2021
Page 11 of 23top layer of your skin to peel from all over your body, which can cause 
severe infection. These severe conditions can rarely lead 
to death.
RARE, SOME MAY BE SERIOUS (i.e. causing hospitalization, life-threatening , or 
where noted, may cause death) – in less than 1 out of 100 people:
Inflammation of the nerves (Guillain-Barré syndrome) that may cause
o Pain
o Weakness
o Tingling in the hands and feet, and may spread to the legs, arms 
and upper body leading to severe muscle weakness and possible 
temporary paralysis
Inflammation of the muscles (myositis), so you may feel  weak or have pain 
in the muscles
Inflammation of the pancreas (pancreatitis), a gland in your abdomen that  
controls sugar levels so you may
o Have severe upper belly pain that may move to the  back
o Feel sick to your stomach
o Have vomiting that gets worse when you  eat
Inflammation of the eye (uveitis) that may cause
o Eye redness
o Blurred vision
o Sensitivity to light
o Eye pain
o Floaters
o Headaches
   Inflammation of the liver (hepatitis) that may make you have
oUpset stomach and vomiting
oFeel like not eating
oFeel tired
oMild fever
oPain in the right side of your belly
oYellow eyes and  skin
oDark urine
 Inflammation of the pituitary gland (hypophysitis), a gland in the  head, which may 
cause you 
to have
oUpset stomach or headaches
oChanges in behavior
oDouble
 vision
oFew to no menstrual cycles
oWeakness
oVomiting and dizziness
oFainting
COMIRB #17-0466
PI:  Christopher H. Lieu, MD
Version Date:  04/15/2021
Page 12 of 23Adrenal glands (adrenal insufficiency), glands on top of the kidneys, that may 
not produce enough  hormone which could
 cause
oTiredness
oWeight loss
oMuscle weakness
oFeeling faint
oJoint, muscle, and belly aches
oNausea
oVomiting
oLoose or watery stools
oFever
oSalt craving
oDarkening of the skin like a suntan
Type 1 Diabetes,  a condition that can cause too much sugar in the blood, 
which may make
 you
o Feel thirstier than usual
o Frequently urinate
o Lose weight 
o Need regular insulin shots
Inflammation of the kidney (nephritis) where you may 
o Pass less  urine
o Have cloudy or bloody urine
o Have swelling
o Have low back pain
Inflammation of the middle layer of your heart  (myocarditis) that may cause 
your heart to have
 difficulty pumping blood throughout your body, which can 
cause
o Chest pain
o Shortness of breath
o Swelling of the legs
o Fast or irregular heartbeat (that may cause dizziness or fainting)
o Death
Inflammation of the thyroid gland (thyroiditis), an organ that  makes and 
stores thyroid hormones. This condition may lead to change in your
o Heart rate
o Blood pressure
o Body temperature 
o Metabolism (the rate at which food is converted into energy)
A condition that may make you feel weak and tired and may cause 
drooping of the
 eyelids, blurred or double vision, difficulty swallowing, 
slurred speech, weakness in your arms and legs, or difficulty breathing 
(myasthenic syndrome/myasthenia gravis including exacerbation)
The formation of small clusters of immune cells (called granulomas) in 
parts of your body such 
as your lymph nodes, eyes, skin, or lungs 
(sarcoidosis)
COMIRB #17-0466
PI:  Christopher H. Lieu, MD
Version Date:  04/15/2021
Page 13 of 23Inflammation of the brain (encephalitis) with confusion and fever, which may 
include:
oDisorientation
oMemory problems
oSeizures (fits)
oChanges in personality and behavior
oDifficulty speaking
oWeakness or loss of movement in some parts of your body
oLoss of consciousness
Inflammation of the spinal cord (myelitis), which may cause
oPain
oNumbness
oTingling or weakness in the arms or legs
oBladder or bowel problems including needing to urinate frequently
oUrinary incontinence
oDifficulty urinating
oConstipation
Inflammation of the blood vessels (vasculitis)
Additionally, since pembrolizumab was approved in September 2014, the following side 
effects have been reported by people receiving pembrolizumab. These side effects 
were voluntarily reported from a group of people of unknown size. It is not possible to 
estimate the frequency of this side effect:
Inflammation of the joints which may  include joint pain, stiffness and/or
Swelling (arthritis).
Severe responses of the immune system that cause the body to attack its 
own blood cells, spleen, liver, lymph nodes, skin 
and brain. This may include 
fever, rash, inflammation of the liver, yellowing of the skin, an enlarged liver 
and spleen, low blood counts, and enlarged lymph nodes. The nervous 
system may also be affected and cause confusion, seizures, and even coma 
(hemophagocytic lymphohistiocytosis).
Changes in eyesight, eye pain, whitish  patches on the skin and hearing loss 
(Vogt-Koyanagi-Harrada syndrome).
Inflammation and scarring of the bile ducts (tubes that carry digestive fluid 
that is made in the liver). This can cause symptoms similar to those seen with 
inflammation of the liver (hepatitis) such as pain in right side of your bellow, 
yellow eyes and skin, feeling tired, and itching (sclerosing cholangitis).
If you have had an allogeneic stem cell transplant (a procedure in which a person 
receives blood-forming stem cells from a donor), you may experience graft versus 
host disease (GvHD), which may include diarrhea, skin rashes, and liver damage, 
after receiving pembrolizumab. Sometimes this condition can lead to death.
COMIRB #17-0466
PI:  Christopher H. Lieu, MD
Version Date:  04/15/2021
Page 14 of 23Risks of Bevacizumab
COMMON SIDE EFFECT (In 100 people receiving bevacizumab, 
more than 20 and up to 100 may have): 
High blood pressure which may cause headache or blurred vision 
OCCASIONAL SIDE EFFECTS (In 100 people receiving bevacizumab, 
from 4 to 20 may have): 
Anemia, which may require blood transfusion 
Low white cell count that may increase the risk of infection 
Infection, including collection of pus  in the belly or rectum 
Abnormal heartbeat which may cause palpitations or fainting  
Pain in the belly, rectum, chest, joints, muscles, or tumor 
Low appetite, constipation, diarrhea, heartburn, nausea, vomiting, or 
dehydration 
Internal bleeding which may cause black tarry stool, blood in vomit, coughing 
up of blood, or blood in
 urine 
Bleeding from other sites, including the vagina or nose 
Blockage of internal organs, which may cause vomiting or inability to pass 
stool 
Sores in mouth 
Allergic reaction during or after infusion of bevacizumab, which may cause 
fever, chills, rash, itching, hives, low blood pressure,
 wheezing, shortness of 
breath, swelling of the face or throat 
Delay in healing of wounds or spontaneous opening of wounds 
Weight loss, tiredness, or dizziness 
Damage to the jawbone, which may cause loss of teeth 
Headache 
Numbness, tingling, or pain in the fingers  or toes 
Hoarseness, stuffy nose, or cough 
Blood clot
 in limbs or lungs, which may cause swelling, pain, or shortness of 
breath 
Leakage of protein in the urine, which can  rarely lead to damage to the kidney
RARE AND SERIOUS SIDE EFFECTS (In 100 people receiving  bevacizumab, 3 or 
fewer may have): 
Clots in the arteries, causing stroke (which may cause paralysis or weakness) 
or heart
 attack (which may cause chest pain or shortness of breath). This risk 
is significantly increased in patients who are elderly or with history of diabetes 
COMIRB #17-0466
PI:  Christopher H. Lieu, MD
Version Date:  04/15/2021
Page 15 of 23Heart failure which may cause shortness of breath, swelling of ankles, or 
tiredness 
Bowel perforation (a tear in the bowel) that can cause pain or bleeding and 
require surgery to
 repair 
A tear or hole (fistula) in internal organs such as the nose, throat, lungs, 
esophagus, rectum,
 or vagina. These conditions may cause serious infections 
or bleeding and require surgery to repair 
Flesh-eating bacteria syndrome, an infection in the deep layers of skin 
Bleeding in the tumor, brain, belly, or lungs,  which may cause confusion, 
blood in stool or coughing up blood 
Brain damage, which may cause headache, seizure, blindness (also known 
as Reversible Posterior 
Leukoencephalopathy Syndrome) 
Kidney damage which may require dialysis 
Additional Notes on Possible Side Effects for Bevacizumab: 
Risk in pre-menopausal women: more likely to develop menopause when 
taking bevacizumab.
Risks Associated with Study Procedures  
Risks of Having an IV Inserted in Your  Vein
In this study we will insert a needle, connected to a plastic tube, into a vein in 
your arm. We will use the 
tube to take blood samples and to give you the study 
drugs and fluids. You will feel some pain when we first insert the tube into your 
vein. You may have some redness, swelling, or bruising where the tube goes 
under your skin. In some cases, this type of tube can cause an infection where it 
goes under the skin. In rare cases, it can cause a blood clot in the vein. You will 
have this tube inserted for about 24 hours.
Risks of Having Blood Taken
In this study, depending on the study visit, we will need to get about 4-10 
tablespoons of blood from you
 at each study visit. We will get blood by putting a 
needle into one of your veins and letting the blood flow into a vacuum tube.  You 
may feel some pain when the needle goes into your vein.  A day or two later, you 
may have a small bruise where the needle went under the skin. There is also a 
small risk of infection or rarely, fainting. 
COMIRB #17-0466
PI:  Christopher H. Lieu, MD
Version Date:  04/15/2021
Page 16 of 23Risks of Biopsy
In this study, if you agree to participate, we will take 2 biopsies from you. There 
are some risks to taking a biopsy. There
 is a small chance that you could get an 
infection where the needle goes in. You may also experience redness, swelling, 
minor bleeding or bruising at the site where the cut was made or the needle 
inserted. You may experience mild to moderate pain at the site of the needle 
puncture. There is also a small chance that you could have an allergic reaction to 
the numbing medicine. After your skin heals up, you may have a small scar 
where we take the samples. If an X-ray is used to help place the needle, you will 
be exposed to additional radiation. The amount of radiation you receive during 
each biopsy procedure is approximately equal to the radiation you would receive 
in about 4 years in your normal environment.
Risks of having an EKG
An electrocardiogram (EKG) is a  test that records the electrical activity of the 
heart.  Skin irritation is rare but could occur during an EKG from the electrodes or 
gel that is used.
Risks of Magnetic Resonance Imaging (MRI)
In this study we may take an MRI of your chest, abdomen, and pelvis, The MRI 
machine uses powerful
 magnetic waves to take pictures inside the body. The 
waves themselves are not harmful, but they can cause metal to heat up and 
electronics to stop working.
You should NOT have an MRI if you have metal or electronic devices inside 
your body. Heart pacemakers and insulin pumps are examples 
of electronic 
devices.
The MRI machine is a small round tube. It might make you uncomfortable if you 
do not like tight spaces.
The most common side effect of having  an MRI is flashing lights in the eyes. This 
is caused by the magnetic waves and is not harmful. Some people also 
experience warmth and reddening of the skin. This usually goes away after a few 
minutes.
Risks of Computed Tomography (CT) Scans
As part of this study we may perform a CT scan of your chest, abdomen, and 
pelvis (CAP). 
CT is a way of taking detailed pictures inside your body by using X-
rays, which is a type of radiation.
You get some radiation from your environment. You get radiation from bricks and 
concrete, from some foods, and from radon gas, which 
is an invisible gas that 
seeps out of the ground. The amount of radiation that this CT scan will deliver to 
COMIRB #17-0466
PI:  Christopher H. Lieu, MD
Version Date:  04/15/2021
Page 17 of 23your body (give you) is about the same as you would get from living in your 
environment for 5 years.
This is an estimate. The amount
 of radiation you get could be higher or lower, 
depending on the machine, the power setting,
 and your body weight. Exposure to 
radiation at high levels increases a risk of developing cancer. There is no 
evidence of such risks for diagnostic procedures. 
The risk of this procedure is not equal for everyone.  The risk is much higher for 
unborn babies if the mother has this procedure.  The risk is also much higher for 
young children and teenagers.  The risk is much lower for people over the age of 
30. 
Risks associated with HIV and/or Hepatitis B & C testing
If you test positive for HIV (Human Immunodeficiency Virus) and/or Hepatitis in 
this study,  we must report your name to the Colorado Department of Public 
Health and Environment.  Finding out that
 you have HIV or Hepatitis may make it 
hard for you to get insurance.
 
Other Risks
Loss of Confidentiality
There is a risk that people outside of the research team will see your research 
information.  We will do all that we can to protect your information, but it cannot 
be guaranteed.
Reproductive Risks 
The use of the study drugs in pregnant females and nursing mothers has not 
been studied. 
The effects of the study drugs on human eggs and sperm has not 
been studied. The risks to a human fetus are unknown. However, based on the 
way the drugs work, it cannot be ruled out that there is potential for the study 
drugs to cause birth defects in humans. If the study drugs are taken during 
pregnancy, they may cause birth defects or death to an unborn baby. Females 
must not become pregnant while taking the study drugs.
If you are a woman that can get pregnant you must agree to remain abstinent 
(refrain from heterosexual
 intercourse) or agree to use highly effective 
contraception for the duration of the study and for 6 months after your last dose 
of the study drugs. 
If you are a man you must agree to remain abstinent (refrain from heterosexual 
intercourse) or agree to use a condom with
 your female partner for the duration 
of the study and for 6 months after your last dose of the study drugs. Men must 
also refrain from donating sperm during this same period. 
COMIRB #17-0466
PI:  Christopher H. Lieu, MD
Version Date:  04/15/2021
Page 18 of 23Your physician will discuss your contraception method to ensure that it is 
appropriate for your participation in this study. 
There may be other risks that  could arise which are not reasonably foreseeable. 
If new information becomes available which could influence your willingness to 
continue, this new information will be discussed with you. 
What are the possible benefits of the study?
If you agree to take part in this study,  there may or may not be direct medical benefit to 
you. Also, there could be risks to being in this study. These risks are described in the 
“Reasonably Foreseeable Side Effects and Risks of the Study” section. We hope the 
information learned from this study will benefit other individuals with colorectal cancer in 
the future. 
Are there alternative treatments? 
There may be other ways of treating your colorectal cancer.  These other ways include:
Receiving an approved drug or approved drug combination  for your disease
Participation in another clinical trial for your  disease
Comfort Care, also referred to as palliative  care, where treatment is directed at 
your symptoms and not your disease
You can also choose to receive no treatment 
Third-line standard of care treatment options do  exist for the treatment of refractory 
colorectal cancer.  Research studies show that these options may increase your overall 
life expectancy and these options should be discussed with your treating physician. 
You should talk to your doctor about your  choices.  Make sure you understand all of 
your choices before you decide to take part in this study.  You may leave this study and 
still have these other choices available to you. 
Who is paying for this study? 
Merck & Co, Inc. is providing a grant of funding support for this study. Merck 
manufactures one of the study drugs, Pembrolizumab,
 and will provide this drug for the 
study. The funding for this study will also pay for any tests or procedures that are 
related to the research study. 
Pfizer, Inc. manufactures one of the  study drugs, binimetinib, and will provide this drug 
for the study. 
This research is being conducted by Dr. Christopher Lieu. 
COMIRB #17-0466
PI:  Christopher H. Lieu, MD
Version Date:  04/15/2021
Page 19 of 23Will I be paid for being in the study?  
You will not
 be paid to be in the study. 
Will I have to
 pay for anything?
The drug Bevacizumab is considered standard treatment for your type of cancer. This 
drug will be obtained through your insurance, and you will be responsible for any 
applicable copays required by your insurance policy. 
There are some medical procedures that you would get for your condition whether you 
were in this study or not, such as blood draws and tumor imaging. These are 
considered standard of care. You and/or your health insurance may be billed for the 
costs of medical care during this study, if these expenses are related to standard of care 
procedures. If you have health insurance, the cost of these services will be billed to your 
insurance company. If your insurance does not cover these costs, or you do not have 
insurance, these costs will be your responsibility. 
Ask your study doctor to discuss the costs that will or  will not be covered by this 
research study. This discussion should include the costs of treating possible side effect. 
Otherwise, you might have unexpected expenses from being in this study.
Is my participation voluntary?
Taking part in this study is voluntary.  You  have the right to choose not to take part in 
this study.  If you choose to take part, you have the right to stop at any time.  If you 
refuse or decide to withdraw later, you will not lose any benefits or rights to which you 
are entitled. 
If you leave this study,  you will still receive your normal medical care.  The only medical 
care that you will lose is the medical care you are getting as part of this study.  You 
might be able to get that same kind of medical care outside of the study.  Ask your study 
doctor. 
COMIRB #17-0466
PI:  Christopher H. Lieu, MD
Version Date:  04/15/2021
Page 20 of 23Can I be removed from this study? 
The study doctor may decide  to stop your participation without your permission if the 
study doctor thinks that being in the study may cause you harm, or for any other reason. 
Also, the funder of the study may stop the study at any time. 
What happens if I am injured or hurt during the  study? 
If you have an injury while you are in this study, you should call Dr. Lieu immediately. 
His phone number is 303-724-6390. 
We will arrange to get you medical care if you have an injury that is caused by this 
research.  However, you or your insurance company will have to pay for that care. 
Who do I call if I have questions?
The researcher carrying out  this study is Dr. Christopher Lieu. You may ask any 
questions you have now. If you have questions, concerns, or complaints later, you may 
call Dr. Lieu at 303-724-6390. You will be given a copy of this form to keep.  
You may have questions about your rights as someone in this study. You can call Dr. 
Lieu with questions.  You can also call the 
responsible Institutional Review Board 
(COMIRB).  You can call them at 303-724-1055. 
A description of this  clinical trial will be available on http://www.Clinical Trials.gov, as 
required by U.S. Law. This Web site will not include information that can identify you. At 
most, the Web site will include a summary of the results. You can search this Web site 
at any time.
Who will see my research information?
The 
University of Colorado Denver (UCD) and its affiliated hospital(s)  have rules to 
protect information about you.  Federal and state laws including the Health Insurance 
Portability and Accountability Act (HIPAA) also protect your privacy.   This part of the 
consent form tells you what information about you may be collected in this study and 
who might see or use it.  
The institutions involved in this study include:
University of  Colorado Denver
University of  Colorado Hospital
COMIRB #17-0466
PI:  Christopher H. Lieu, MD
Version Date:  04/15/2021
Page 21 of 23We cannot do this study without your permission to see, use and give out your 
information.  You do not have to give us this permission.  If you do not, then you may 
not join this study.  
We will see, use and disclose your information only as described in this form and in our 
Notice of 
Privacy Practices; however, people outside the UCD and its affiliate hospitals 
may not be covered by this obligation.
We will do everything we can to maintain the confidentiality of your personal information 
but confidentiality cannot be
 guaranteed. 
The use and disclosure of your information has no time limit.  You can cancel your 
permission to 
use and disclose your information at any time by writing to the study’s 
Principal Investigator (PI), at the name and address listed below.  If you do cancel your 
permission to use and disclose your information, your part in this study will end and no 
further information about you will be collected.  Your cancellation would not affect 
information already collected in this study.  
Dr. Christopher Lieu, MD
University of Colorado
 Denver
Anschutz Medical Campus
8117 HSC
12801 East 17th Avenue
Aurora, CO 80045
Both the research records
 that identify you  and the consent form signed by you may be 
looked at by others who have a legal right to see that information, such as:.  
Federal offices such as the Food and Drug Administration (FDA) and the Office 
of Human Research 
Protections (OHRP) that protect research subjects like you.
People at the Colorado Multiple Institutional Review Board (COMIRB)
The study doctor and the rest of the study team.
Merck & Co., who is the company funding this research study and providing 
Pembrolizumab.
Pfizer, a company providing binimetinib.
Officials at  the institution where  the research is conducted and officials who are 
in charge of making sure that we follow all of the rules for research.
We might talk about this research  study at meetings.  We might also print the results of 
this research study in relevant journals.  But we will always keep the names of the 
research subjects, like you, private. 
COMIRB #17-0466
PI:  Christopher H. Lieu, MD
Version Date:  04/15/2021
Page 22 of 23You have the right to request access to your personal health information from the 
Investigator. 
Information about
 you that will be seen, collected, used and disclosed in this 
study:
Name and Demographic Information (age, sex, ethnicity, address, phone 
number, etc.)
Portions of your previous and  current Medical Records that are relevant to this 
study, including but not limited to Diagnosis(es), History and Physical, laboratory 
or tissue studies, radiology studies, procedure results
Research Visit and Research Test records
Testing for or infection with diseases reportable to the Public Health department, 
including but not limited to: Human Immunodeficiency Virus 
(HIV), hepatitis (all 
forms) tuberculosis, or other sexually transmitted diseases.
Tissue samples and the data with the samples. 
Billing or financial information
What happens to  Data, Tissue, Blood and Specimens that are collected in this 
study? 
Scientists at the University of Colorado Denver and the hospitals involved in this study 
work to find the causes and cures of disease.  The data, tissue, blood and specimens 
collected from you during this study are important to this study.  If you join this study:
The data, tissue, blood, or other specimens given by you to the investigators for 
this research no longer belong to you.  
Both 
the investigators and any sponsor of this research may study your data, 
tissue, blood, or other specimens collected
 from you.
If data, tissue, blood, or other specimens are in a form that identifies you, UCD or 
the hospitals
 involved in this study may use them for future research only with 
your consent or Institutional Review Board (IRB) approval.
Any product or idea created by the researchers working on this study will not 
belong to you.
There is no plan for you to receive any financial benefit from the creation, use or 
sale of such a
 product or idea. 
If you wish to no longer participate in the study and have your specimens used 
for this 
research, please contact the PI in writing at the address included in this 
form. The PI will destroy any remaining specimens. However, the PI may 
continue to use the data generated from the specimens already collected. 
C O MI R B # 1 7- 0 4 6 6 
PI:  C hri st o p h er H. Li e u, M D 
V er si o n D at e:  0 4/ 1 5/ 2 0 2 1 
P a g e 2 3 of 2 3 A gr e e m e nt t o b e i n t hi s st u d y a n d u s e m y  d at a 
T h e r e s e ar c h pr oj e ct a n d t h e pr o c e d ur e s a s s o ci at e d wit h it h a v e b e e n e x pl ai n e d t o m e.  
T h e e x p eri m e nt al pr o c e d ur e s h a v e b e e n i d e ntifi e d a n d n o g u ar a nt e e h a s b e e n gi v e n 
a b o ut t h e p o s si bl e r e s ult s. I will r e c ei v e a si g n e d c o p y of t hi s c o n s e nt f or m f or m y 
r e c or d s. 
I a gr e e t o p arti ci p at e i n t hi s st u d y.  M y p arti ci p ati o n i s v ol u nt ar y a n d I d o n ot h a v e t o 
si g n t hi s f or m if I d o n ot w a nt t o b e p art of t hi s r e s e ar c h st u d y. 
Si g n at ur e: D at e: 
Pri nt N a m e: 
C o n s e nt f or m e x pl ai n e d b y: D at e: 
Pri nt N a m e: 
Wit n e s s Si g n at ur e: _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _   D at e: 
Wit n e s s Pri nt N a m e: _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ 
Wit n e s s of Si g n at ur e 
Wit n e s s of c o n s e nt pr o c e s s 